

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
7 September 2001 (07.09.2001)

PCT

(16) International Publication Number  
**WO 01/64879 A2**(51) International Patent Classification<sup>7</sup>: **C12N 15/12**,  
C07K 14/705, 16/28, C12N 1/21, 5/10, G01N 33/68,  
C12Q 1/68, A61K 38/17, 31/70, 39/395

(21) International Application Number: PCT/US01/06474

(22) International Filing Date: 28 February 2001 (28.02.2001)

(25) Filing Language: English

(26) Publication Language: English

## (30) Priority Data:

60/185,674	28 February 2000 (28.02.2000)	US
60/185,535	28 February 2000 (28.02.2000)	US
60/186,585	3 March 2000 (03.03.2000)	US
60/186,604	3 March 2000 (03.03.2000)	US
60/186,606	3 March 2000 (03.03.2000)	US
60/186,715	3 March 2000 (03.03.2000)	US
60/186,716	3 March 2000 (03.03.2000)	US
60/186,717	3 March 2000 (03.03.2000)	US
60/186,719	3 March 2000 (03.03.2000)	US
60/186,827	3 March 2000 (03.03.2000)	US
60/218,323	14 July 2000 (14.07.2000)	US
60/218,435	14 July 2000 (14.07.2000)	US
60/220,517	24 July 2000 (24.07.2000)	US
60/223,897	9 August 2000 (09.08.2000)	US
60/260,020	5 January 2001 (05.01.2001)	US
60/264,849	26 January 2001 (26.01.2001)	US
09/795,271	27 February 2001 (27.02.2001)	US

## (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/185,674 (CIP)
Filed on	28 February 2000 (28.02.2000)
US	60/185,535 (CIP)
Filed on	28 February 2000 (28.02.2000)
US	60/186,585 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/186,604 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/186,606 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/186,715 (CIP)
Filed on	3 March 2000 (03.03.2000)

US	60/186,716 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/186,717 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/186,719 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/186,827 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/218,323 (CIP)
Filed on	14 July 2000 (14.07.2000)
US	60/218,435 (CIP)
Filed on	14 July 2000 (14.07.2000)
US	60/220,517 (CIP)
Filed on	24 July 2000 (24.07.2000)
US	60/223,897 (CIP)
Filed on	9 August 2000 (09.08.2000)
US	60/260,020 (CIP)
Filed on	5 January 2001 (05.01.2001)
US	60/264,849 (CIP)
Filed on	26 January 2001 (26.01.2001)
US	Not furnished (CIP)
Filed on	27 February 2001 (27.02.2001)

(71) Applicant (for all designated States except US): **CURAGEN CORPORATION** [US/US]; 555 Long Wharf Drive, 11th floor, New Haven, CT 06511 (US).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **PADIGARU, Muralidhara** [IN/US]; 1579 Rhinelander Avenue, Apartment 6E, Bronx, NY 10561 (US). **MAJUMDER, Kumud** [IN/US]; 140 Silver Hill Lane, Stamford, CT 06905 (US). **BURGESS, Catherine, E.** [US/US]; 90 Carriage Hill Drive, Wethersfield, CT 06109 (US). **VERNET, Corine, A., M.** [FR/US]; 4830 N.W. 43rd Street P#253, Gainesville, FL 32060 (US). **FERNANDES, Elma** [IN/US]; 77 Florence Road, #2, Branford, CT 06405 (US). **SHIMKETS, Richard, A.** [US/US]; 191 Leete Street, West Haven, CT 06516 (US). **TCHERNEV, Velizar, T.** [BG/US]; 1216 S.W. 2nd Avenue, Apt. 156, Gainesville, FL 32601 (US). **MISHRA, Vishnu** [IN/US]; 309 East Main Street, #306, Branford, CT 06405 (US). **CASMAN, Stacie** [US/US]; 155 Knollwood Drive, Wallingford, CT 06492 (US). **SPYTEK, Kimberly, A.** [US/US]; 28 Court Street #1, New Haven, CT 06511 (US). **ZERHUSEN, Bryan** [US/US]; 45 Jefferson Road, Apartment #2-10, Branford, CT 06405 (US).

[Continued on next page]

(54) Title: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME

(57) Abstract: Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, of fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.



(74) Agent: ELRIFI, Ivor, R.: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C, One Financial Center, Boston, MA 02111 (US).

(81) Designated States (*national*): AF, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

# NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME

## BACKGROUND OF THE INVENTION

The invention generally relates to nucleic acids and polypeptides. More particularly, the invention relates to nucleic acids encoding novel G-protein coupled receptor (GPCR) polypeptides, as well as vectors, host cells, antibodies, and recombinant methods for producing these nucleic acids and polypeptides.

## SUMMARY OF THE INVENTION

The invention is based in part upon the discovery of nucleic acid sequences encoding novel polypeptides. The novel nucleic acids and polypeptides are referred to herein as GPCR<sub>X</sub>, or GPCR1, GPCR2, GPCR3, GPCR4, GPCR5, GPCR6, GPCR7, GPCR8, GPCR9, and GPCR10 nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as "GPCR<sub>X</sub>" nucleic acid or polypeptide sequences.

In one aspect, the invention provides an isolated GPCR<sub>X</sub> nucleic acid molecule encoding a GPCR<sub>X</sub> polypeptide that includes a nucleic acid sequence that has identity to the nucleic acids disclosed in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38. In some embodiments, the GPCR<sub>X</sub> nucleic acid molecule will hybridize under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule that includes a protein-coding sequence of a GPCR<sub>X</sub> nucleic acid sequence. The invention also includes an isolated nucleic acid that encodes a GPCR<sub>X</sub> polypeptide, or a fragment, homolog, analog or derivative thereof. For example, the nucleic acid can encode a polypeptide at least 80% identical to a polypeptide comprising the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83. The nucleic acid can be, for example, a genomic DNA fragment or a cDNA molecule that includes the nucleic acid sequence of any of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38.

Also included in the invention is an oligonucleotide, *e.g.*, an oligonucleotide which includes at least 6 contiguous nucleotides of a GPCR<sub>X</sub> nucleic acid (*e.g.*, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38) or a complement of said oligonucleotide.

Also included in the invention are substantially purified GPCR<sub>X</sub> polypeptides (SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83). In certain embodiments,

the GPCR<sub>X</sub> polypeptides include an amino acid sequence that is substantially identical to the amino acid sequence of a human GPCR<sub>X</sub> polypeptide.

The invention also features antibodies that immunoselectively bind to GPCR<sub>X</sub> polypeptides, or fragments, homologs, analogs or derivatives thereof.

5 In another aspect, the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically-acceptable carrier. The therapeutic can be, *e.g.*, a GPCR<sub>X</sub> nucleic acid, a GPCR<sub>X</sub> polypeptide, or an antibody specific for a GPCR<sub>X</sub> polypeptide. In a further aspect, the invention includes, in one or more containers, a therapeutically- or prophylactically-effective  
10 amount of this pharmaceutical composition.

In a further aspect, the invention includes a method of producing a polypeptide by culturing a cell that includes a GPCR<sub>X</sub> nucleic acid, under conditions allowing for expression of the GPCR<sub>X</sub> polypeptide encoded by the DNA. If desired, the GPCR<sub>X</sub> polypeptide can then be recovered.

15 In another aspect, the invention includes a method of detecting the presence of a GPCR<sub>X</sub> polypeptide in a sample. In the method, a sample is contacted with a compound that selectively binds to the polypeptide under conditions allowing for formation of a complex between the polypeptide and the compound. The complex is detected, if present, thereby identifying the GPCR<sub>X</sub> polypeptide within the sample.

20 The invention also includes methods to identify specific cell or tissue types based on their expression of a GPCR<sub>X</sub>.

Also included in the invention is a method of detecting the presence of a GPCR<sub>X</sub> nucleic acid molecule in a sample by contacting the sample with a GPCR<sub>X</sub> nucleic acid probe or primer, and detecting whether the nucleic acid probe or primer bound to a GPCR<sub>X</sub> nucleic  
25 acid molecule in the sample.

In a further aspect, the invention provides a method for modulating the activity of a GPCR<sub>X</sub> polypeptide by contacting a cell sample that includes the GPCR<sub>X</sub> polypeptide with a compound that binds to the GPCR<sub>X</sub> polypeptide in an amount sufficient to modulate the activity of said polypeptide. The compound can be, *e.g.*, a small molecule, such as a nucleic  
30 acid, peptide, polypeptide, peptidomimetic, carbohydrate, lipid or other organic (carbon containing) or inorganic molecule, as further described herein.

Also within the scope of the invention is the use of a therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, *e.g.*, diabetes, metabolic disturbances associated with obesity, the metabolic syndrome X, anorexia, wasting



disorders associated with chronic diseases, metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, or other disorders related to cell signal processing and metabolic pathway modulation. The therapeutic can be, *e.g.*, a GPCR<sub>X</sub> nucleic acid, a GPCR<sub>X</sub> polypeptide, or a GPCR<sub>X</sub>-specific antibody, or biologically-active derivatives or fragments thereof.

For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: developmental diseases, MHCII and III diseases (immune diseases), taste and scent detectability Disorders, Burkitt's lymphoma, corticoneurogenic disease, signal transduction pathway disorders, Retinal diseases including those involving photoreception, Cell growth rate disorders; cell shape disorders, feeding disorders; control of feeding; potential obesity due to over-eating; potential disorders due to starvation (lack of appetite), noninsulin-dependent diabetes mellitus (NIDDM1), bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation. Dentatorubro-pallidoluysian atrophy (DRPLA) Hypophosphatemic rickets, autosomal dominant (2) Acrocallosal syndrome and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders of the like.

The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding GPCR<sub>X</sub> may be useful in gene therapy, and GPCR<sub>X</sub> may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and Treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign

prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders.

5           The invention further includes a method for screening for a modulator of disorders or syndromes including, *e.g.*, diabetes, metabolic disturbances associated with obesity, the metabolic syndrome X, anorexia, wasting disorders associated with chronic diseases, metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder,  
10       immune disorders, and hematopoietic disorders or other disorders related to cell signal processing and metabolic pathway modulation. The method includes contacting a test compound with a GPCR<sub>X</sub> polypeptide and determining if the test compound binds to said GPCR<sub>X</sub> polypeptide. Binding of the test compound to the GPCR<sub>X</sub> polypeptide indicates the test compound is a modulator of activity, or of latency or predisposition to the aforementioned  
15       disorders or syndromes.

          Also within the scope of the invention is a method for screening for a modulator of activity, or of latency or predisposition to an disorders or syndromes including, *e.g.*, diabetes, metabolic disturbances associated with obesity, the metabolic syndrome X, anorexia, wasting disorders associated with chronic diseases, metabolic disorders, diabetes, obesity, infectious  
20       disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders or other disorders related to cell signal processing and metabolic pathway modulation by administering a test compound to a test animal at increased risk for the aforementioned disorders or syndromes. The test animal expresses a recombinant polypeptide encoded by a  
25       GPCR<sub>X</sub> nucleic acid. Expression or activity of GPCR<sub>X</sub> polypeptide is then measured in the test animal, as is expression or activity of the protein in a control animal which recombinantly-expresses GPCR<sub>X</sub> polypeptide and is not at increased risk for the disorder or syndrome. Next, the expression of GPCR<sub>X</sub> polypeptide in both the test animal and the control animal is compared. A change in the activity of GPCR<sub>X</sub> polypeptide in the test animal relative to the  
30       control animal indicates the test compound is a modulator of latency of the disorder or syndrome.

          In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a GPCR<sub>X</sub> polypeptide, a GPCR<sub>X</sub> nucleic acid, or both, in a subject (*e.g.*, a human subject). The method includes

measuring the amount of the GPCR<sub>X</sub> polypeptide in a test sample from the subject and comparing the amount of the polypeptide in the test sample to the amount of the GPCR<sub>X</sub> polypeptide present in a control sample. An alteration in the level of the GPCR<sub>X</sub> polypeptide in the test sample as compared to the control sample indicates the presence of or predisposition to a disease in the subject. Preferably, the predisposition includes, *e.g.*, diabetes, metabolic disturbances associated with obesity, the metabolic syndrome X, anorexia, wasting disorders associated with chronic diseases, metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders. Also, the expression levels of the new polypeptides of the invention can be used in a method to screen for various cancers as well as to determine the stage of cancers.

In a further aspect, the invention includes a method of treating or preventing a pathological condition associated with a disorder in a mammal by administering to the subject a GPCR<sub>X</sub> polypeptide, a GPCR<sub>X</sub> nucleic acid, or a GPCR<sub>X</sub>-specific antibody to a subject (*e.g.*, a human subject), in an amount sufficient to alleviate or prevent the pathological condition. In preferred embodiments, the disorder, includes, *e.g.*, diabetes, metabolic disturbances associated with obesity, the metabolic syndrome X, anorexia, wasting disorders associated with chronic diseases, metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders.

In yet another aspect, the invention can be used in a method to identify the cellular receptors and downstream effectors of the invention by any one of a number of techniques commonly employed in the art. These include but are not limited to the two-hybrid system, affinity purification, co-precipitation with antibodies or other specific-interacting molecules.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

## DETAILED DESCRIPTION OF THE INVENTION

The invention is based, in part, upon the discovery of novel nucleic acid sequences that encode novel polypeptides. The novel nucleic acids and their encoded polypeptides are referred to individually as GPCR1, GPCR2, GPCR3, GPCR4, GPCR5, GPCR6, GPCR7, GPCR8, GPCR9, and GPCR10. The nucleic acids, and their encoded polypeptides, are collectively designated herein as "GPCRX".

The novel GPCRX nucleic acids of the invention include the nucleic acids whose sequences are provided in Tables 1A, 1D, 1G, 2A, 3A, 4A, 4C, 4G, 5A, 5C, 5G, 6A, 7A, 8A, 9A, 10A, 10C and 10F, inclusive ("Tables 1A - 10F"), or a fragment, derivative, analog or homolog thereof. The novel GPCRX proteins of the invention include the protein fragments whose sequences are provided in Tables 1B, 1E, 1H, 2B, 3B, 4B, 4H, 5B, 5D, 5H, 6B, 7B, 8B, 9B, 10B, 10D, and 10G, inclusive ("Tables 1B - 10G"). The individual GPCRX nucleic acids and proteins are described below. Within the scope of this invention is a method of using these nucleic acids and peptides in the treatment or prevention of a disorder related to cell signaling or metabolic pathway modulation.

G-Protein Coupled Receptor proteins (GPCRs) have been identified as a large family of G protein-coupled receptors in a number of species. These receptors share a seven transmembrane domain structure with many neurotransmitter and hormone receptors, and are likely to underlie the recognition and G-protein-mediated transduction of various signals. Human GPCR generally do not contain introns and belong to four different gene subfamilies, displaying great sequence variability. These genes are dominantly expressed in olfactory epithelium. See, *e.g.*, Ben-Arie et al., Hum. Mol. Genet. 1994 3:229-235; and, Online Mendelian Inheritance in Man (OMIM) entry # 164342 (<http://www.ncbi.nlm.nih.gov/entrez/dispmim.cgi?>).

The olfactory receptor (OR) gene family constitutes one of the largest GPCR multigene families and is distributed among many chromosomal sites in the human genome. See Rouquier et al., Hum. Mol. Genet. 7(9):1337-45 (1998); Malnic et al., Cell 96:713-23 (1999). Olfactory receptors constitute the largest family among G protein-coupled receptors, with up to 1000 members expected. See Vanderhaeghen et al., Genomics 39(3):239-46 (1997); Xie et al., Mamm. Genome 11(12):1070-78 (2000); Issel-Tarver et al., Proc. Natl. Acad. Sci. USA 93(20):10897-902 (1996). The recognition of odorants by olfactory receptors is the first stage in odor discrimination. See Krautwurst et al., Cell 95(7):917-26 (1998); Buck et al., Cell 65(1):175-87 (1991). Many ORs share some characteristic sequence motifs and

have a central variable region corresponding to a putative ligand binding site. See Issel-Tarver et al., Proc. Natl. Acad. Sci. USA 93:10897-902 (1996).

Other examples of seven membrane spanning proteins that are related to GPCRs are chemoreceptors. See Thomas et al., Gene 178(1-2):1-5 (1996). Chemoreceptors have been identified in taste, olfactory, and male reproductive tissues. See *id.*; Walensky et al., J. Biol. Chem. 273(16):9378-87 (1998); Parmentier et al., Nature 355(6359):453-55 (1992); Asai et al., Biochem. Biophys. Res. Commun. 221(2):240-47 (1996).

## GPCR1

GPCR1 includes a family of three novel G-protein coupled receptor ("GPCR") proteins disclosed below. The disclosed proteins have been named GPCR1a, GPCR1b, and GPCR1c and are related to olfactory receptors.

### GPCR1a

A disclosed GPCR1a nucleic acid of 1019 nucleotides is shown in Table 1A. The disclosed GPCR1a open reading frame ("ORF") begins at the ATG initiation codon at nucleotides 27-29, shown in bold in Table 1A. The encoded polypeptide is alternatively referred to herein as GPCR1a or as ba113a10\_B. The disclosed GPCR1a ORF terminates at a TAG codon at nucleotides 984-986. As shown in Table 1A, putative untranslated regions 5' to the start codon and 3' to the stop codon are underlined, and the start and stop codons are in bold letters.

**Table 1A. GPCR1a nucleotide sequence (SEQ ID NO:1).**

```

CCTTCAGTTGACAGAGGAGATACACTATGGTAAAGTGCCAATCAGACAGCCTCTGTGACCGAGTTTATTC
TCCTGGGCCTCTCTGCCCACCCAAAGCTGGAGAAAACGTTCTTTGTGCTCATCCTGCTGATGTACCTGG
TGATCCTACTGGGCAATGGGGTCCTCATCCTGATGACTGTGTCCAACCTCCACCTGCACATGCCCCATGT
ACTTCTTCCTGGGGAACCTCTCCTTCTGACATCTGCTATACAACATCCTCAGTCCCCCTCATCCTTG
ACAGCTTCTTGACCCCCAGGAAAACCATCTCCTTCTCAGCCTGTGCAGTGCAGATGTTCTCTCCTTTG
CCATGGGAGCCACAGAGTGTGTTCTCTGAGCATGATGGCGTTTGATCGCTACGTGGCCATCTGCAACC
CCCTTAGGTACCCTGTGGTCATGAGCAAGGCTGCCTACATGCCCCATAAGGCTGCCGGCTCCTGGGTAG
CTGGAAGCACTGCTTCCATGGTGCAGACATCCCTTGCAATGAGGCTGCCCTTCTGTGGAGACAACATCA
TCAACCACTTCACCTGTGAGATTCTGGCTGTCTGAAGTTGGCCTGTGCTGATATCTCTGTCAATGTGA
TCAGTATGGGAGTGACCAATGTGATCTTCTGGGGGTCCCGTTCTGTTTCATCTCTTTCTCCTATGTCT
TCATCATTGCCACCATCCTGAGGATCCCCCTCAGCTGAGGGGAGGAAAAGGCCTTCTCCACCTGCTCTG
CCCACCTCACAGTCGTGGTCATCTTCTATGGGACCATCCTCTTCATGTATGGGAAGCCCAAGTCTAAGG
ACCCGCTGGGGGAGACAAGCAAGACCTTGCAGACAACTCATTTCCCTTTTCTATGGGGTGGTGACCC
CCATGCTCAACCCCATCATCTACAGCCTGAGGAACAAGGATGTAAAGGCTGCTGTGAGGACTTGATAT
TTCAGAAATGCTTTGCCTAGTGATGTTTGGGGGAACAGATGTCTCATAGCTC

```

A disclosed encoded GPCR1a protein has 319 amino acid residues, referred to as the GPCR1a protein. The GPCR1a protein was analyzed for signal peptide prediction and cellular localization. SignalP results predict that GPCR1a is cleaved between position 44 and 55 of

SEQ ID NO:2, *i.e.*, at the slash in the amino acid sequence GNG-VL. Psort and Hydropathy profiles also predict that GPCR1 contains a signal peptide and is likely to be localized at the plasma membrane (certainty of 0.6000). The disclosed GPCR1 polypeptide sequence is presented in Table 1B using the one-letter amino acid code.

5

Table 1B. Encoded GPCR1a protein sequence (SEQ ID NO:2).	
MV	SA
NT	AS
VS	TE
FI	LL
GL	SA
HP	KL
ET	FF
VL	LL
MY	VL
LL	GN
GN	/V
LI	LM
TV	SN
SH	LM
PM	YF
FL	GN
LS	
FL	DI
CY	TT
SS	VP
LI	DS
FL	TP
PK	TI
SF	SA
CA	VQ
MF	LS
FA	MG
AT	EC
VL	LS
SM	MA
AF	DR
YV	AI
CN	PL
RY	PV
VM	
SK	AA
YMP	HK
KA	AG
SW	AG
ST	AS
TM	VQ
SL	AM
RL	PF
CG	DN
II	NH
FT	CE
IL	AV
LK	LA
CA	DI
SV	NV
IS	MG
VT	NV
I	FL
GV	PV
LF	IS
FS	YV
FI	AT
IL	RI
PS	AE
GR	KA
FS	TC
SA	HL
TV	VV
VI	FY
GT	IL
FM	YG
PK	PK
SK	DP
LG	AD
KQ	
DL	AD
KL	IS
LF	YG
VT	PM
LN	PI
II	YS
LR	NK
DV	KA
AV	RD
LI	FO
QC	FA

GPCR1a was initially identified on chromosome 9 with a TblastN analysis of a proprietary sequence file for a G-protein coupled receptor probe or homolog, which was run against the Genomic Daily Files made available by GenBank. A proprietary software program (GenScan™) was used to further predict the nucleic acid sequence and the selection of exons. The resulting sequences were further modified by means of similarities using BLAST searches. The sequences were then manually corrected for apparent inconsistencies, thereby obtaining the sequences encoding the full-length protein.

A region of the GPCR1a nucleic acid sequence has 873 of 1016 bases (85%) identical to a sequence coding for a partial *Mus musculus* olfactory receptor mRNA (1731 bp), with an E-value of  $3.6e^{-160}$  (GENBANK-ID: Aj133427). In all BLAST alignments herein, the "E-value" or "Expect" value is a numeric indication of the probability that the aligned sequences could have achieved their similarity to the BLAST query sequence by chance alone, within the database that was searched. For example, the probability that the subject ("Sbjct") retrieved from the GPCR1a BLAST analysis, *e.g.*, the *Mus musculus* olfactory receptor, matched the Query GPCR1a sequence purely by chance is  $3.6 \times 10^{-160}$ .

A BLASTX search was performed against public protein databases. The full amino acid sequence of the protein of the invention was found to have 274 of 316 amino acid residues (86%) identical to, and 295 of 316 residues (93%) positive with, the 319 amino acid olfactory receptor protein from *Mus musculus* (ptnr:TREMBLNEW-ACC:CAB55592, E= 1.8 e-142). The disclosed GPCR1a protein (SEQ ID NO:2) has good identity with a number of olfactory receptor proteins. For example, GPCR1a has 256/316 (81%) amino acids identical with the 319 amino acid *Mus musculus* olfactory receptor 37a protein, and 376/316 (87%) amino acids identical, to (Expect = e-128, gi|11276075|ref|NP\_062346.1|) olfactory receptor

37a from *Mus musculus*. The disclosed protein is also similar to the olfactory proteins disclosed in Table 1C.

Table 1C. BLAST results for GPCR1a

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 11464981 ref NP_062349.1	Olfactory Receptor (OR) 37e <i>Mus musculus</i>	319	255/318 (80%)	275/318 (86%)	e-127
gi 11276077 ref NP_062347.1	OR 37b <i>Mus musculus</i>	318	248/317 (78%)	276/317 (86%)	e-127
gi 11276079 ref NP_062348.1	OR 37c <i>Mus musculus</i>	318	251/314 (79%)	274/314 (86%)	e-127
gi 10092669 ref NP_063950.1	OR Family 2, Subfamily S, member 2 <i>Homo sapiens</i>	309	238/306 (77%)	261/306 (84%)	e-118
gi 3769624 gb AAC64568.1  (AF091565)	OR <i>Rattus norvegicus</i>	227	206/227 (90%)	217/227 (94%)	e-102

### GPCR1b

A disclosed GPCR1b (also referred to as ba32713\_A) nucleic acid of 1015 nucleotides is shown in Table 1D. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 17-19 and ending with a TAG codon at nucleotides 971-973. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 1D, and the start and stop codons are in bold letters.

Table 1D. GPCR1b Nucleic acid sequence (SEQ ID NO:3).

ACAGAGGAGATACACTATGGTAAGTGCCAATCAGACAGCCTCTGTGACCGAGTTTATTCTCCTGGGCCTC  
TCTGCCCAACCAAGCTGGAGAAAACGTTCTTTGTGCTCATCTGCTGATGTACCTGGTGATCCTACTGG  
GCAATGGGGTCTCATCTGATGACTGTGTCCAACCTCCACCTGCACATGCCCATGTACTTCTTCCTGGG  
GAACCTCTCCTTCCTGGACATCTGCTATACAACATCCTCAGTCCCCCTCATCCTTGACAGCTTCTTGACC  
CCCAGGAAAACCATCTCCTTCTCAGCCTGTGCAGTGCAGATGTTCTCTCCTTTGCCATGGGAGCCACAG  
AGTGTGTTCTCCTGAGCATGATGGCGTTTGATCGCTACGTGGCCATCTGCAACCCCTTAGGTACCCTGT  
GGTCATGAGCAAGGCTGCCTACATGCCCATAGCTGCCGGCTCCTGGGTAGCTGGAAGCACTGCTTCCATG  
GTGCAGACATCCCTTGCAATGAGGCTGCCCTTCTGTGGAGACAACATCATCAACCACTTACCTGTGAGA  
TTCTGGCTGTCTGAAGTTGGCCTGTGCTGATATCTGTGCAATGTGATCAGTATGGGAGTGACCAATGT  
GATCTTCTGGGGTCCCGGTTCTGTTTCATCTCTTTCTCCTATGTCTTCATCATTGCCACCATCCTGAGG  
ATCCCTCAGCTGAGGGGAGGAAAAAGGCCTTCTCCACCTGCTCTGCCACCTCACAGTCGTGGTCATCT  
TCTATGGGACCATCCTCTTCATGTATGGGAAGCCCAAGTCTAAGGACCCGCTGGGGGCAGACAAGCAAGA  
CCTTGACAGACAACTCATTCCCTTTCTATGGGGTGGTGACCCCATGCTCAACCCCATCATCTACAGC  
CTGAGGAACAAGGATGTAAAGGCTGCTGTGAGGGACTTGATATTTAGAAATGCTTTGCCTAGTGATGTT  
TGGGGGAACAGATGTCCCTCATAGCTCTTTGCCTCT

In a search of sequence databases, it was found, for example, that the nucleic acid sequence has 869 of 1015 bases (85%) identical to a 1731 bp *Mus musculus* OR 37d pseudogene (GENBANK-ID: MMU133427|acc:AJ133427, E = 5.5 e-161). It was also found

that the nucleic acid has 505 of 791 bases identical (63%) to a partial human mRNA for olfactory receptor protein (GENBANK-ID:HSOLFMF|acc:Y14442, E= 9.5 e-49).

The encoded protein having 318 amino acid residues is presented using the one-letter code in Table 1E. The full amino acid sequence of the protein of the invention was found to have 274 of 315 amino acid residues (86%) identical to, and 296 of 315 residues (93%) positive with, a 319 amino acid residue olfactory receptor protein from *Mus musculus* (ptnr: TREMBLNEW-ACC:CAB55592, E= 6.3 e-144).

The disclosed GPCR1b protein differs from the disclosed GPCR1a protein at only two positions. At positions 145 and 146, GPCR1a has HK, while GPCR1b has a deletion ( $\Delta$ ) and an I.

**Table 1E. Encoded GPCR1b protein sequence (SEQ ID NO:4).**

MVSANQTASVTEFILLGLSAHPKLEKTFVLLILLMYLVILLGNG/VLILMTVSNSHLHMPMYFFLGNLSFL  
DICYTTSSVPLILDSFLTTPRKTISFSACAVQMFLSFAMGATECVLLSMMAFDYVAICNPLRYPVVMMSKA  
AYMPIAAGSWVAGSTASMVQTSIAMRLPFCGDNIINHFTCEILAVLKLACADISVNVISMGTNVIPLGV  
PVLFIISFSYVFI IATILRIPSAEGRKKAFSTCSAHLTVVVI FYGTILFMYGKPKSKDPLGADKQDLADKL  
ISLFYGVVTPMLNP I IYSLRNKDVKA A VRDLIFQKCF A

A PSORT analysis predicts that the ba32713\_A protein (GPCR1b) is localized in the plasma membrane with a certainty of 0.6000, or with lower certainty in the mitochondrial inner membrane, the mitochondrial intermembrane space or the Golgi body. It is also predicted that the protein has a signal peptide with the most likely cleavage site between residues 44 and 45: GNG-VL, indicated by a slash in Table 1E.

A BLASTX search was performed against public protein databases. The full amino acid sequence of the protein of the invention was found to have 274 of 315 amino acid residues (86%) identical to, and 296 of 315 residues (93%) positive with, the 319 amino acid olfactory receptor protein from *Mus musculus* (ptnr:TREMBLNEW-ACC:CAB55592, E= 6.3 e-144). The disclosed GPCR1b protein (SEQ ID NO:4) has good identity with a number of olfactory receptor proteins, as shown in Table 1F.

**Table 1F. BLAST results for GPCR1b**

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 11276075 ref NP_062346.1	OR 37a <i>Mus musculus</i>	319	256/315 (81%)	277/315 (87%)	e-129
gi 11464981 ref NP_062349.1	(OR) 37 <i>Mus musculus</i>	319	255/317 (80%)	276/317 (86%)	e-128



gi 11276077 ref NP_062347.1	OR 37b <i>Mus musculus</i>	318	248/316 (78%)	277/316 (87%)	e-128
gi 11276079 ref NP_062348.1	OR 37c <i>Mus musculus</i>	318	251/313 (80%)	275/313 (87%)	e-128
gi 10092669 ref NP_063950.1	OR Family 2, Subfamily S, member 2 <i>Homo sapiens</i>	309	238/305 (78%)	262/305 (85%)	e-119

### GPCR1c

A disclosed GPCR1c (also referred to as ba113a10\_C) nucleic acid of 1003

nucleotides is shown in Table 1G. An open reading frame was identified beginning with an

- 5 ATG initiation codon at nucleotides 26-28 and ending with a TGA codon at nucleotides 974-976. Putative untranslated regions 5' to the start codon and 3' to the stop codon are underlined in Table 1G and the start and stop codons are in bold letters.

In a search of sequence databases, it was found, for example, that the nucleic acid sequence has 719 of 899 bases (79%) identical to a *Mus musculus* GPCR mRNA

- 10 (GENBANK-ID: AJ133428, E = 1.9e-120).

**Table 1G. GPCR1c Nucleic acid sequence (SEQ ID NO:5).**

```

TTTGTACAAGTGACATAGAAACACCATGGTCAGTTCC
AATCAGACCTCCCTGTGCTGGGGTTCCTTCTCCTGGGGCTCTCTGCCCATCCAAAGCTGGAGAAGACAT
TCTTCGTGCTCATCTGCTGATGTACCTGGTGATCCTACTGGGCAATGGGGTCTCATCTGGTGACCAT
CCTTGACTCCCGCTGGACACACCCATGTACTTCTTCTGCGGGAACCTCTCCTTCCTGGACATCTGCTAT
ACAACCTCCTCATCTTGACAGCTTCCCTGACCCCCAGGAAAACCATCTCCTTCTCAGCCTGTGCAGTAC
AGATGTTCTCTCCCTTGCCATGGGAGCCACAGAGTGTGTTCTCCTGAGCATGATGGCGTTTGATCGCTA
CGTGGCCATCTGCAACCCCTTTGGTACCCTGAAGTCATGAACAAAGCTACTTATGTGCCCATGGCTGCT
GGCTCCTGGGTAGCTGGAAGCCTCACTGCCATGGTGCAGACACCCCTTGCAATTGAGGCTGCCCTTCTGTG
GAGACAACATCATCAATCACTTACCTGTGAGATTCTGGCTGTCCTGAAGTTGGCCTGTGCTGATATCTC
TGTCAATGTGATCAGTATGGGAGTGGCCAATGTGATCTTCTGCGGGTCCCTGTCTGTTTCATCTCTTTC
TCCTATGTCTTCATCATTGCCACCATCCTGAGGATCCCTCAGCTGAGGGGAGGAAAAAGGCCTTCTCCA
CCTGCTCTGCCACCTCACTGTGCTGATCGTCTTCTACGGGACCATCCTCTTCATGTACGGGAAGCCCAA
GTCTAAGGACCCACTGGGAGCAGACAAACAGGACCTTGCAGACAACTCATTTCCCTTTTCTATGGGGTG
GTGACCCCATGCTCAACCCCATCATCTACAGCCTGAGGAACAAGGAAGTGAAGGCTGCTGTGAGGAACC
TGGTATTTAGAAACGCTTCTGTCAGTATGGTGGAGGGTCTGATGGCTCTGTG

```

The disclosed GPCR1c protein having 316 amino acid residues is presented using the one-letter code in Table 1H. An analysis using the PSORT program predicts that the

- 15 ba113a10\_C protein localizes in the plasma membrane with a certainty=0.6400; it may also be localized in the Golgi body with a moderate certainty. It is also predicted that protein has a signal peptide whose most likely cleavage site is between residues 44 and 45: GNG-VL, indicated by a slash in Table 1H.

**Table 1H. Encoded GPCR1c protein sequence (SEQ ID NO:6).**

MVSSNQTSPLGLLGLSAHPKLEKTFVLIILLMYLVILLGNG/VLILVTILDSRLDTPMYFFLGN  
 LSFLDICYTSSSLTASLTPRKTI SFSAVQMFSLAMGATECVLLSMMAFDTRYVAICNPLWYPEVMNK  
 ATYVPMAGSWVAGSLTAMVQTPALRLPFCGDNIINHFTCEILAVLKLACADISVNVISMGVANVIFLG  
 VPVLFISFSYVFIIATILRIPSAEGRKKAFTCSAHLTVVIVFYGTILFMYGPKPSKDPLGADKQDLADK  
 LISLFYGVVTPMLNPPIIYSLRNKEVKA AVRNLV FQKRFLQ

A BLASTX search was performed against public protein databases. The full amino acid sequence of the protein of the invention was found to have 270 of 317 amino acid residues (85%) identical to, and 287 of 317 residues (90%) positive with, a 319 amino acid residue OR from *Mus musculus* (ptnr:TREMBLNEW-ACC:CAB55596, E= 5.2 e-138). The disclosed GPCR1b protein (SEQ ID NO:6) has good identity with a number of olfactory receptor proteins, as shown in Table 1I.

**Table 1I. BLAST results for GPCR1c**

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 11464981 ref NP_062349.1	OR 37e <i>Mus musculus</i>	319	242/317 (76%)	257/317 (80%)	e-120
gi 11276075 ref NP_062346.1	OR 37a <i>Mus musculus</i>	319	241/319 (75%)	256/319 (87%)	e-119
gi 11276077 ref NP_062347.1	OR 37b <i>Mus musculus</i>	318	236/319 (78%)	255/319 (87%)	e-116
gi 11276079 ref NP_062348.1	OR 37c <i>Mus musculus</i>	318	235/308 (76%)	250/308 (80%)	e-116
gi 10092669 ref NP_063950.1	OR Family 2, Subfamily S, member 2 <i>Homo sapiens</i>	309	220/309 (71%)	242/309 (78%)	e-108

The amino acids differences between the three GPCR1 proteins are shown in Table 1J. Deletions are marked by a delta ( $\Delta$ ). The differences between the three proteins appear to be localized to a few distinct regions. Thus, these proteins may have similar functions, such as serving as olfactory or chemokine receptors (see below).

Table 1J. Differences for GPCR1 Proteins													
Position	4	8	9	11	12	14	49	51	52	53	55	57	58
GPCR1a	A	A	S	T	E	I	M	V	S	N	H	H	M
GPCR1b	A	A	S	T	E	I	M	V	S	N	H	H	M
GPCR1c	S	S	P	L	G	L	V	I	L	D	R	D	T
Position	79	80	81	82	84	85	86	106	132	135	138	141	143
GPCR1a	V	P	L	I	D	S	F	F	R	V	S	A	M
GPCR1b	V	P	L	I	D	S	F	F	R	V	S	A	M
GPCR1c	S	Δ	Δ	Δ	T	A	S	L	W	E	N	T	V
Position	145	146	156	157	158	163	166	204	251	252	304	311	313
GPCR1a	H	K	T	A	S	S	M	T	V	I	D	D	I
GPCR1b	Δ	I	T	A	S	S	M	T	V	I	D	D	I
GPCR1c	Δ	M	L	T	A	P	L	A	I	V	E	N	V
Position	317	319	320										
GPCR1a	C	A	Δ										
GPCR1b	C	A	Δ										
GPCR1c	R	L	Q										

A ClustalW analysis comparing disclosed proteins of the invention with related OR protein sequences is given in Table 1K, with GPCR1a shown on line 1, and GPCR1c on line 2.

In the ClustalW alignment of the GPCR1a protein, as well as all other ClustalW analyses herein, the black outlined amino acid residues indicate regions of conserved sequence (*i.e.*, regions that may be required to preserve structural or functional properties), whereas non-highlighted amino acid residues are less conserved and can potentially be mutated to a much broader extent without altering protein structure or function. Unless specifically addressed as GPCR1a GPCR1b, or GPCR1c, any reference to GPCR1 is assumed to encompass all variants. Residue differences between any GPCRX variant sequences herein are written to show the residue in the "a" variant and the residue position with respect to the "a" variant. GPCR residues in all following sequence alignments that differ between the individual GPCR variants are highlighted with a box and marked with the (o) symbol above the variant residue in all alignments herein. For example, the protein shown in line 1 of Table 1K depicts the sequence for GPCR1a, and the positions where GPCR1b differs are marked with a (o) symbol and are highlighted with a box. All GPCR1 proteins have significant homology to olfactory receptor (OR) proteins: 37a, 37b, 37e, and 37c from *Mus musculus* and to a human OR protein member 2 from family 2, subfamily S (see also Tables 1C, 1F, and 1I).

Table 1K. ClustalW Analysis of GPCR1

- 1) Novel GPCR1a (SEQ ID NO:2)  
 2) Novel GPCR1c (SEQ ID NO: 6)  
 3) gi|11276075|ref|NP\_062346.1| olfactory receptor 37a *Mus musculus* (SEQ ID NO:39)  
 4) gi|11276077|ref|NP\_062347.1| olfactory receptor 37b *Mus musculus* (SEQ ID NO:40)  
 5) gi|11464981|ref|NP\_062349.1| olfactory receptor 37c *Mus musculus* (SEQ ID NO:41)  
 6) gi|11276079|ref|NP\_062348.1| olfactory receptor 37c *Mus musculus* (SEQ ID NO:42)  
 7) gi|10092669|ref|NP\_063950.1| OR, fam. 2, subfam. S, mem. 2 *H. sapiens* (SEQ ID NO:43)

	10	20	30	40	50	60
GPCR1a	MVS	QNTASVTE	LLGLSAHPKLEK	TFVLI	LLMYLVILLGNGV	LILVLS
GPCR1c	MVS	QNTSPVLG	LLGLSAHPKLEK	TFVLI	LLMYLVILLGNGV	LILVLS
gi 11276075	MVS	QNTASVTE	LLGLSAHPKLEK	TFVLI	LLMYLVILLGNGV	LILVLS
gi 11276077	MEGAN	QSTVAE	LLGLSAHPKLEK	TFVLI	LLMYLVILLGNGV	LILVLS
gi 11464981	MERS	NKTPVSS	LLGLSAHPKLEK	TFVLI	LLMYLVILLGNGV	LILVLS
gi 11276079	GDVSH	QTTVTE	LLGLSAHPKLEK	TFVLI	LLMYLVILLGNGV	LILVLS
gi 10092669	---	MGFVLL	RLSAHPKLEK	TFVLI	LLMYLVILLGNGV	LILVLS
	70	80	90	100	110	120
GPCR1a	YFFLGNLS	FLDIC	YTTSSVPL	LD	SFLTPRK	TISFS
GPCR1c	YFFLGNLS	FLDIC	YTTSSVPL	LD	SFLTPRK	TISFS
gi 11276075	YFFLGNLS	FLDIC	YTTSSVPL	LD	SFLTPRK	TISFS
gi 11276077	YFFLGNLS	FLDIC	YTTSSVPL	LD	SFLTPRK	TISFS
gi 11464981	YFFLGNLS	FLDIC	YTTSSVPL	LD	SFLTPRK	TISFS
gi 11276079	YFFLGNLS	FLDIC	YTTSSVPL	LD	SFLTPRK	TISFS
gi 10092669	YFFLGNLS	FLDIC	YTTSSVPL	LD	SFLTPRK	TISFS
	130	140	150	160	170	180
GPCR1a	FDRYVAIC	NPLRY	PVVMS	SKAAYM	PHKAAG	SWVAG
GPCR1c	FDRYVAIC	NPLRY	PVVMS	SKAAYM	PHKAAG	SWVAG
gi 11276075	FDRYVAIC	NPLRY	PVVMS	SKAAYM	PHKAAG	SWVAG
gi 11276077	FDRYVAIC	NPLRY	PVVMS	SKAAYM	PHKAAG	SWVAG
gi 11464981	FDRYVAIC	NPLRY	PVVMS	SKAAYM	PHKAAG	SWVAG
gi 11276079	FDRYVAIC	NPLRY	PVVMS	SKAAYM	PHKAAG	SWVAG
gi 10092669	FDRYVAIC	NPLRY	PVVMS	SKAAYM	PHKAAG	SWVAG
	190	200	210	220	230	240
GPCR1a	CEILAVL	KLACADIS	INVISMG	VANVIF	LGVPVLF	IFVS
GPCR1c	CEILAVL	KLACADIS	INVISMG	VANVIF	LGVPVLF	IFVS
gi 11276075	CEILAVL	KLACADIS	INVISMG	VANVIF	LGVPVLF	IFVS
gi 11276077	CEILAVL	KLACADIS	INVISMG	VANVIF	LGVPVLF	IFVS
gi 11464981	CEILAVL	KLACADIS	INVISMG	VANVIF	LGVPVLF	IFVS
gi 11276079	CEILAVL	KLACADIS	INVISMG	VANVIF	LGVPVLF	IFVS
gi 10092669	CEILAVL	KLACADIS	INVISMG	VANVIF	LGVPVLF	IFVS
	250	260	270	280	290	300
GPCR1a	STCSAHL	TVVV	VFYGTIL	FMYGKPKS	KDPLGADK	QDLADKLIS
GPCR1c	STCSAHL	TVVV	VFYGTIL	FMYGKPKS	KDPLGADK	QDLADKLIS
gi 11276075	STCSAHL	TVVV	VFYGTIL	FMYGKPKS	KDPLGADK	QDLADKLIS
gi 11276077	STCSAHL	TVVV	VFYGTIL	FMYGKPKS	KDPLGADK	QDLADKLIS
gi 11464981	STCSAHL	TVVV	VFYGTIL	FMYGKPKS	KDPLGADK	QDLADKLIS
gi 11276079	STCSAHL	TVVV	VFYGTIL	FMYGKPKS	KDPLGADK	QDLADKLIS
gi 10092669	STCSAHL	TVVV	VFYGTIL	FMYGKPKS	KDPLGADK	QDLADKLIS
	310	320				
GPCR1a	RNKDV	KAAVRN	LG	QHLTE		
GPCR1c	RNKDV	KAAVRN	LG	QHLTE		
gi 11276075	RNKDV	KAAVRN	LG	QHLTE		
gi 11276077	RNKDV	KAAVRN	LG	QHLTE		
gi 11464981	RNKDV	KAAVRN	LG	QHLTE		
gi 11276079	RNKDV	KAAVRN	LG	QHLTE		
gi 10092669	RNKDV	KAAVRN	LG	QHLTE		

The GPCR1 proteins also have regions of identity with a 321 amino acid human transmembrane receptor (gi|6691937|emb|CAB65797.1| bA150A6.2, novel 7 transmembrane

receptor (rhodopsin family), olfactory receptor-like protein (hs6M1-21)), as shown in line 3 of in Table 1L (SEQ ID NO: 44).

Table 1L. Alignment of GPCR1a & c with SEQ ID NO:44																												
	10	20	30	40	50	60																						
GPCR1a	MVSA	NOTAS	VTEF	ILLGL	SAHP	LEKTF	FEVL	ILLMY	VILLG	NGV	LIL	MT	VNS	SHL	MPM													
GPCR1c	MVSS	NOTSP	VLGF	ILLGL	SAHP	LEKTF	FEVL	ILLMY	VILLG	NGV	LIL	MT	ILDS	RLD	TPM													
gi 6691937	MERR	NOTA	ITEFI	ILLGF	SNLNE	LQFL	ETFE	LTY	FCT	EGCN	HL	ILTT	VTD	PHL	TPN													
	70	80	90	100	110	120																						
GPCR1a	YFFL	GNLS	FEL	DICY	TSSV	PLIL	DS	FEL	TPRK	TIS	SFSA	CAV	QMF	LS	AMG	ATE	CVLL	SMA										
GPCR1c	YFFL	GNLS	FEL	DICY	TSSS	---	LT	ASLT	PRKT	TIS	SFSA	CAV	QMF	LS	AMG	ATE	CVLL	SMA										
gi 6691937	YFFL	GNLS	FEL	DICY	TSSV	PLIL	DS	FEL	TPRK	TIS	SFSA	CAV	QMF	LS	AMG	ATE	CVLL	SMA										
	130	140	150	160	170	180																						
GPCR1a	FDRY	VAIC	NPL	RY	PV	MSK	AA	Y	PH	KA	AG	SW	VAG	ST	AS	MV	QTS	LA	RL	PF	CG	DN	I	NH	ET			
GPCR1c	FDRY	VAIC	NPL	RY	PV	MSK	AA	Y	PH	KA	AG	SW	VAG	ST	AS	MV	QTS	LA	RL	PF	CG	DN	I	NH	ET			
gi 6691937	FDRY	VAIC	NPL	RY	PV	MSK	AA	Y	PH	KA	AG	SW	VAG	ST	AS	MV	QTS	LA	RL	PF	CG	DN	I	NH	ET			
	190	200	210	220	230	240																						
GPCR1a	CEIL	AVL	KL	AC	AD	IS	VN	VI	SM	GV	TV	NI	FL	GV	PV	LF	IS	FS	YV	FI	AT	IL	RI	PS	AE	GR	KK	AF
GPCR1c	CEIL	AVL	KL	AC	AD	IS	VN	VI	SM	GV	TV	NI	FL	GV	PV	LF	IS	FS	YV	FI	AT	IL	RI	PS	AE	GR	KK	AF
gi 6691937	CE	PP	EL	IL	SC	NT	SV	NE	EH	LS	TV	GV	FI	GT	EL	LC	VL	SY	TC	TI	ST	IL	RI	PS	AE	GR	KK	AF
	250	260	270	280	290	300																						
GPCR1a	STCS	AHL	TV	VV	NI	YF	GT	IL	FM	Y	GK	PK	SK	DP	LG	AD	KD	LD	AK	LIS	LF	Y	GV	VT	PML	NP	II	YS
GPCR1c	STCS	AHL	TV	VV	NI	YF	GT	IL	FM	Y	GK	PK	SK	DP	LG	AD	KD	LD	AK	LIS	LF	Y	GV	VT	PML	NP	II	YS
gi 6691937	STC	ASH	IA	LV	FE	YF	GS	AL	TV	VR	PI	ST	YS	IK	KE	---	---	---	---	---	---	---	---	---	---	---	---	---
	310	320																										
GPCR1a	RNKD	VKA	AV	FD	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---
GPCR1c	RNKD	VKA	AV	FN	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---
gi 6691937	RNKD	VKA	AV	FN	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---

- 5 The presence of identifiable domains in GPCR1, as well as all other GPCR<sub>X</sub> proteins, was determined by searches using software algorithms such as PROSITE, DOMAIN, Blocks, Pfam, ProDomain, and Prints, and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro>). DOMAIN results, e.g., for GPCR1a as disclosed in Table 1M, were collected from the
- 10 Conserved Domain Database (CDD) with Reverse Position Specific BLAST analyses. This BLAST analysis software samples domains found in the Smart and Pfam collections. For Table 1M and all successive DOMAIN sequence alignments, fully conserved single residues are indicated by black shading and "strong" semi-conserved residues are indicated by grey shading. The "strong" group of conserved amino acid residues may be any one of the
- 15 following groups of amino acids: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW.

Table 1M lists the domain description from DOMAIN analysis results against GPCR1a. The region from amino acid residue 53 through 239 (SEQ ID NO:2) most probably (E = 2e<sup>-19</sup>) contains a "seven transmembrane receptor (rhodopsin family) fragment" domain, aligned here with residues 12-180 of the 7tm\_1 entry (TM7, SEQ ID NO:45, see Table 1N for the complete sequence) of the Pfam database. This indicates that the GPCR1 sequence has properties similar to those of other proteins known to contain this domain as well as to the 377 amino acid 7tm domain itself. GPCR1a also has identity to another region of the TM7 protein. The region from amino acid residue 226 through 298 (of SEQ ID NO:2) aligns with amino acid residues 310-377 of TM7 (E = 3e<sup>-4</sup>). GPCR1b and GPCR1c also align to this domain: residues 53-238 of GPCR1b align with residues 12-180 of TM7 (E = 6e<sup>-19</sup>) and residues 225-297 of GPCR1b align with residues 310-377 of TM7 (E = 3e<sup>-4</sup>); residues 55-235 of GPCR1c align with residues 14-180 of TM7 (E = 2e<sup>-12</sup>) and residues 222-294 of GPCR1c align with residues 310-377 of TM7 (E = 2e<sup>-4</sup>).

Table 1M. Domain Analysis of GPCR1a	
Sbjct: 7 transmembrane receptor (rhodopsin family) fragment	
Gnl Pfam pfam00001; Length = 377	
Score = 89.7 bits (221), Expect = 2e-19	
GPCR1a	.....NSH.....HMPMY.....F.....G.....FL.....CYTTSS.....DSF.....TPRKTI.....SFA.....AQ
TM7	GNVLVCMASREKALQTTTNELVSLVADELVAFLVMPW.....YLELVGEWKFRIRHDDF
GPCR1a	MF.....SFANGATEC.....LSMRAFDRYVEICN.....R.....PVVM.....KAAAY.....PHKAAGS.....VAGS.....IA.....MVQ
TM7	MTDVMCTASININCAFSIDRYTEVAMEILNTRYISKRRITVMIIVVVLSEFIISCPM
GPCR1a	.....TSLAMRLPFCGDNIIINHFT.....ETLAVLRLACADISVM.....ISMGVINVF.....FLGVVEVFISFS.....
TM7	LFGLNNTDQNE.....GILANP.....EFVNYSSIVSY.....PFVTLTV.....
GPCR1a	.....FTIATLE.....--IPSAEC.....KKA.....
TM7	KYIVVERRRKRKRVNTKSSRAFRANLKAFLKGNCTHPEDMKLCTVIMKSNGSFPVNRVRV

The representative member of the 7 transmembrane receptor family is the D2 dopamine receptor from *Bos taurus* (SWISSPROT: locus D2DR\_BOVIN, accession P20288; gene index 118205). The D2 receptor is an integral membrane protein and belongs to Family 1 of G-protein coupled receptors. The activity of the D2 receptor is mediated by G proteins which inhibit adenylyl cyclase. Chio *et al.*, Nature 343:255-269 (1990). Residues 51-427 of this 444 amino acid protein are considered to be the representative TM7 domain, shown in Table 1N.

**Table 1N Amin Acid sequence f r TM7 (SEQ ID NO:45)**

GNVLVCMASREKALQTTTNYLIVSLAVADLLVATLVMPWVVYLEVVGWKFSSRIHCDIF VTLDVMMCTASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMIAIVWVLSFTISCPM LFGLNNTDQNECIIANPAFVVYSSIVSFYVPFIVTLLVYIKIYIVLRRRRKRVTNKRSSR AFRANLKAPLKGNCTHPEDMKLCTVIMKSNGSFPVNRVRVEAARRAQELEMELSSSTSP ERTRYSPIPPSSHQTLTLPDPSHHGLHSTPDSPAKPEKNGHAKTVNPKIAKIFEIQSMPNG KTRTSLKTSRRKLSQQKEKKATQMLAIVLGVFIIICWLPFFITHILNIHDCNIPVLYS AFTWLGYN SAVNPIIY
--

The 7 transmembrane receptor family includes a number of different proteins, including, for example, serotonin receptors, dopamine receptors, histamine receptors, andrenergic receptors, cannabinoid receptors, angiotensin II receptors, chemokine receptors, opioid receptors, G-protein coupled receptor (GPCR) proteins, olfactory receptors (OR), and the like. Some proteins and the Protein Data Base Ids/gene indexes include, for example: rhodopsin (129209); 5-hydroxytryptamine receptors; (112821, 8488960, 112805, 231454, 1168221, 398971, 112806); G protein-coupled receptors (119130, 543823, 1730143, 132206, 137159, 6136153, 416926, 1169881, 136882, 134079); gustatory receptors (544463, 462208); c-x-c chemokine receptors (416718, 128999, 416802, 548703, 1352335); opsins (129193, 129197, 129203); and olfactory receptor-like proteins (129091, 1171893, 400672, 548417);

Expression information for GPCR<sub>X</sub> RNA was derived using tissue sources including, but not limited to, proprietary database sources, public EST sources, literature sources, and/or RACE sources, as described in the Examples.

The nucleic acids and proteins of GPCR<sub>1</sub> are useful in potential therapeutic applications implicated in various GPCR- or olfactory receptor (OR)-related pathologies and/or disorders. For example, a cDNA encoding the G-protein coupled receptor-like protein may be useful in gene therapy, and the G-protein coupled receptor-like protein may be useful when administered to a subject in need thereof. The novel nucleic acid encoding GPCR<sub>1</sub> protein, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. The GPCR<sub>X</sub> nucleic acids and proteins are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis,

scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, bronchial asthma, and other diseases, disorders and conditions of the like. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from neoplasm, adenocarcinoma, lymphoma, prostate cancer, uterus cancer, immune response, AIDS, asthma, Crohn's disease, multiple sclerosis, and Albright Hereditary Osteodystrophy. Additional GPCR-related diseases and disorders are mentioned throughout the Specification.

Further, the protein similarity information, expression pattern, and map location for GPCR1 suggests that GPCR1 may have important structural and/or physiological functions characteristic of the GPCR family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration *in vitro* and *in vivo* (vi) biological defense weapon.

These materials are further useful in the generation of antibodies that bind immunospecifically to the novel GPCR1 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-GPCR Antibodies" section below.

## GPCR2

An additional GPCR-like protein of the invention, referred to herein as GPCR2, is an Olfactory Receptor ("OR")-like protein. The novel nucleic acid of 1254 nucleotides (11612531\_1, SEQ ID NO:7) encoding a novel G-protein coupled receptor-like protein is shown in Table 2A. SeqCalling fragments for GPCR2 came from placenta, indicating that it may be expressed in tissues important for female health.



**Table 2A. GPCR2 Nucleotide Sequence (SEQ ID NO:7)**

```

ACGCGCTTCGACATACTATTCCTGGTGGGCTCTTCCTACATATCAGGTCGTTAAATAAGCTGCCAGATTCTGCCTTTACAGCCCAA
GGAGCTTGTTCATGGACCATGGGCATGGAGGGTCTTCTCCAGAACTCCACTAACTTCGTCCTCAGAGGCTCATCACCCTATCTGCCT
TCCCCGGGCTTCTTTTGAATAGTCTTCTCCATCTTTGTGGTGGCTATAACAGCCAACTTGGTCATGATTCTGCTCATCCACATGG
ACTCCCGCTCCACACACCCATGTACTTCTTGCTCAGCCAGCTCTCCATCATGGATACCATCTACATCTGTATCACTGTCCCAAGA
TGCTCCAGGACCTCCTGTCCAAGGACAAGACCATTTCTTCATGGGCTGTGCAGTTCAGATCTTCTCTACCTGACCCTGATTGGAG
GGGAATTCTTCTGCTGGGTCTCATGGCCTATGACCGCTATGTGGCTGTGTGCAACCCTCTACGGTACCCTCTCCTCATGAACCGCA
GGGTTTGGCTTATTCATGGTGGTGGGCTCCTGGGTTGGTGGTTCCTTGGATGGGTTTCATGCTGACTCCTGTCACTATGAGTTTCCCT
TCTGTAGATCCCAGAGATCAATCACTTTTTCTGTGAGATCCCAGCGGTGCTGAAGTTGTCTTGACACAGACAGTCACTCTATGAGA
CCCTGATGATGCCTGCTGCTGCTGATTATCCCTCTATCTGTCTCTGTGCTTACACGCACATCTCCTGACTGTCCACAGGA
TGAACCTCTGCTGAGGGCCGGCCAAAGCCTTTGCTACGTGTTCTCCACATTATGGTGGTGGAGCGTTTCTACGGGGCAGCTTTCT
ACACCAACGTGCAGCCCACTCTACACACTCCAGAGAAAGATAAAGTGGTGTCTGCCTTCTACACCATCTCACCCTCATGCTCA
ACCCACTCATCTACAGCTTGAGGAATAAAGATGTGGCTGCAGCTCTGAGGAAAGTACTAGGGAGATGTGGCTCCTCCAGAGCATCA
GGGTGATGACTGTGTGATCAGGAAGGACTAGCAGGGACTCCAGAGATCAGCGTGGTGACTATGATCAGGAAGGACTAGTGGGGAC
TCCTAGAGCATCAGGTTGGCGACTGTGATCAGGAAGGACTAGCAAGGACTAGCGCAACATCTGCGGTGCTGCGGCAATAACGCAG
CTATTACAGAAAATATGTTATTGGTTCTGAAGAAGT

```

An open reading frame (ORF) for GPCR2 was identified from nucleotides 105 to 1058. The disclosed GPCR2 polypeptide (SEQ ID NO:8) encoded by SEQ ID NO:7 is 318 amino acid residues and is presented using the one-letter code in Table 2B. The GPCR2 protein was analyzed for signal peptide prediction and cellular localization. SignalPep results predict that GPCR2 is cleaved between position 42 and 43 of SEQ ID NO:8, *i.e.*, at the slash in the amino acid sequence ITA-NL. Psort and Hydropathy profiles also predict that GPCR2 contains a signal peptide and is likely to be localized at the plasma membrane (certainty of 0.6400).

**Table 2B. Encoded GPCR2 protein sequence (SEQ ID NO:8).**

```

MGMEGLLQNSTNFVLTGLITHPAFPGLLEFAIVFSIFVVAITA/NLVMILLIHMSRLHTPMYFLLSQLS
IMDTIYICITVPKMLQDLLSKDKTISFMGCAVQIFLYLTIGGEFFLLGLMAYDRYVAVCNPLRYPLLM
NRRVCLFMVVGWSVGGSLDGFMLTPVTMSFPFCRSREINHFFCEIPAVLKLSCDTDSL YETLMYACCVL
IIPLSVISVSYTHILLTVHRMNSAEGRRKAFATCSSHIMVVSVFYGAIFYTNVQPHSYHTPEKDKVVA
FYTILTPMLNPLIYSLRNKDVAALRKVLGRGSSQSIRVMTV

```

The full amino acid sequence of the protein of the invention was found to have 151 of 216 amino acid residues (69%) identical to, and 177 of 216 residues (81%) positive with, a 216 amino acid residue olfactory receptor from *Homo sapiens* (ptnr:SPTREMBL-ACC: O43869) ( $E = 2.2 \times 10^{-61}$ ). The protein encoded by GPCR2 (SEQ ID NO:7) has significant homology to olfactory, odorant, and taste chemoreceptors and belongs to the family of G-Protein coupled receptors (GPCRs). This family of genes has been used as a target for small molecule drugs and GPCRs are expressed on the plasma membrane and are also a suitable target for protein drugs like therapeutic antibodies, cytotoxic antibodies and diagnostic antibodies.

As shown in Table 2C, BLAST analysis shows that GPCR2 has significant homology with a number of olfactory receptors.

Table 2C. GPCR2 BLAST results

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob. P(N)
Ptnr:SPTREMBL-ACC:O43869 OLFACTORY RECEPTOR - HOMO SAPIENS...	827	1.8e-82	1
Ptnr:SWISSPROT-ACC:P23275 OLFACTORY RECEPTOR 15 (OR3) - M...	712	2.7e-70	1
Ptnr:SPTREMBL-ACC:Q90808 OLFACTORY RECEPTOR 4 - GALLUS GALLUS...	708	7.3e-70	1
Ptnr:TREMBLNEW-ACC:CAB55593 OLFACTORY RECEPTOR - Mus musculus...	706	1.2e-69	1
Ptnr:TREMBLNEW-ACC:CAB55594 OLFACTORY RECEPTOR - Mus musculus...	704	1.9e-69	1
Ptnr:SPTREMBL-ACC:Q63394 OL1 RECEPTOR - RATTUS NORVEGICUS...	702	3.1e-69	1
Ptnr:TREMBLNEW-ACC:CAB55592 OLFACTORY RECEPTOR - Mus musculus...	698	8.3e-69	1
Ptnr:TREMBLNEW-ACC:CAB55596 OLFACTORY RECEPTOR - Mus musculus...	697	1.1e-68	1
Ptnr:SWISSPROT-ACC:Q95156 OLFACTORY RECEPTOR-LIKE PROTEIN...	695	1.7e-68	1
Ptnr:SWISSPROT-ACC:Q13606 OLFACTORY RECEPTOR-LIKE PROTEIN...	694	2.2e-68	1
Ptnr:SWISSPROT-ACC:Q13607 OLFACTORY RECEPTOR-LIKE PROTEIN...	689	7.5e-68	1
Ptnr:TREMBLNEW-ACC:AAC64376 OLFACTORY RECEPTOR-LIKE PROTEIN...	685	2.0e-67	1

Other BLAST results including the sequences used for ClustalW analysis is presented in Table 2D.

5

Table 2D. BLAST results for GPCR2

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 3983382 gb AAD13319.1  (AF102527)	OR E3 <i>Mus musculus</i>	223	156/223 (69%)	184/223 (81%)	2e-78
gi 2921628 gb AAC39611.1  (U86215)	OR <i>Homo sapiens</i>	216	151/216 (69%)	177/216 (81%)	5e-75
gi 12007423 gb AAG45196.1  (AF321234)	T2 OR <i>Mus musculus</i>	316	155/298 (52%)	205/298 (68%)	2e-72
gi 12007424 gb AAG45197.1  (AF321234)	T3 OR <i>Mus musculus</i>	315	156/304 (51%)	209/304 (68%)	2e-72
gi 12007425 gb AAG45198.1  (AF321234)	T4 OR <i>Mus musculus</i>	319	152/304 (50%)	207/304 (68%)	9e-72
gi 12007422 gb AAG45195.1  (AF321234)	T1 OR <i>Mus musculus</i>	316	156/305 (51%)	207/305 (67%)	2e-67

This information is presented graphically in the multiple sequence alignment given in Table 2E (with GPCR2 being shown on line 1) as a ClustalW analysis comparing GPCR2 with related protein sequences.

10

Table 2E. Information for the ClustalW proteins:

- 1) Novel GPCR2 (SEQ ID NO:8)
- 2) gi|3983382|gb|AAD13319.1| olfactory receptor E3 *Mus musculus* (SEQ ID NO:46)
- 3) gi|2921628|gb|AAC39611.1| olfactory receptor *Homo sapiens* (SEQ ID NO:47)
- 4) gi|12007423|gb|AAG45196.1| T2 olfactory receptor *Mus musculus* (SEQ ID NO:48)
- 5) gi|12007424|gb|AAG45197.1| T3 olfactory receptor *Mus musculus* (SEQ ID NO:49)
- 6) gi|12007425|gb|AAG45198.1| T4 olfactory receptor *Mus musculus* (SEQ ID NO:50)
- 7) gi|12007422|gb|AAG45195.1| T1 olfactory receptor *Mus musculus* (SEQ ID NO:51)

	10	20	30	40	50	60
GPCR2	MMEGLLQNSTN	SVTSTTHPAF	EGTTF	IVFSSSWAT	PAFLVMT	PIHMSRIHTPE
gi 3983382						
gi 2921628						
gi 12007423	-MEFWNSTLGT	DNVVEEDDSGS	PELLCATFT	AEYMLAHIS	NGCHITV	ITCARHVP
gi 12007424	-MEVCNSTLRSG	ILMGLDDND	DFPELLCATIT	AEYMLAHIS	NGCHITV	ITCARHVP
gi 12007425	-MEFRNSTMGNG	ILVVEEDDSG	ADLLCATIT	AEYMLAHIS	NGCHITV	ITCARHVP
gi 12007422	-MELWNSTLES	GSILVVEEDDS	GSPELLCATIV	AEYMLAHIS	NGCHITV	ITCARHVP
	70	80	90	100	110	120
GPCR2	YFLLSOLSLMD	DEETSVATPKA	VIDELLKONT	ISEGGCA	YOMFLALT	LGGAEDLLLA
gi 3983382	YFLLSOLSLMD	DEETSVATPKA	VIDELLKONT	ISEGGCA	YOMFLALT	LGGAEDLLLA
gi 2921628	YFLLSOLSLMD	DEETSVATPKA	VIDELLKONT	ISEGGCA	YOMFLALT	LGGAEDLLLA
gi 12007423	YFLLSOLSLMD	DEETSVATPKA	VIDELLKONT	ISEGGCA	YOMFLALT	LGGAEDLLLA
gi 12007424	YFLLSOLSLMD	DEETSVATPKA	VIDELLKONT	ISEGGCA	YOMFLALT	LGGAEDLLLA
gi 12007425	YFLLSOLSLMD	DEETSVATPKA	VIDELLKONT	ISEGGCA	YOMFLALT	LGGAEDLLLA
gi 12007422	YFLLSOLSLMD	DEETSVATPKA	VIDELLKONT	ISEGGCA	YOMFLALT	LGGAEDLLLA
	130	140	150	160	170	180
GPCR2	YDRYVAICNPL	RYPLNRRVCL	FAVGSIVGG	SDGFM	LTPVTMS	PFCCSSEIN
gi 3983382	YDRYVAICNPL	RYPLNRRVCL	FAVGSIVGG	SDGFM	LTPVTMS	PFCCSSEIN
gi 2921628	YDRYVAICNPL	RYPLNRRVCL	FAVGSIVGG	SDGFM	LTPVTMS	PFCCSSEIN
gi 12007423	YDRYVAICNPL	RYPLNRRVCL	FAVGSIVGG	SDGFM	LTPVTMS	PFCCSSEIN
gi 12007424	YDRYVAICNPL	RYPLNRRVCL	FAVGSIVGG	SDGFM	LTPVTMS	PFCCSSEIN
gi 12007425	YDRYVAICNPL	RYPLNRRVCL	FAVGSIVGG	SDGFM	LTPVTMS	PFCCSSEIN
gi 12007422	YDRYVAICNPL	RYPLNRRVCL	FAVGSIVGG	SDGFM	LTPVTMS	PFCCSSEIN
	190	200	210	220	230	240
GPCR2	EIPAVLKLSCT	DTSLYETEM	YACCV	LAIPLSV	SVSYTHI	LTVHRRNSA
gi 3983382	EIPAVLKLSCT	DTSLYETEM	YACCV	LAIPLSV	SVSYTHI	LTVHRRNSA
gi 2921628	EIPAVLKLSCT	DTSLYETEM	YACCV	LAIPLSV	SVSYTHI	LTVHRRNSA
gi 12007423	EIPAVLKLSCT	DTSLYETEM	YACCV	LAIPLSV	SVSYTHI	LTVHRRNSA
gi 12007424	EIPAVLKLSCT	DTSLYETEM	YACCV	LAIPLSV	SVSYTHI	LTVHRRNSA
gi 12007425	EIPAVLKLSCT	DTSLYETEM	YACCV	LAIPLSV	SVSYTHI	LTVHRRNSA
gi 12007422	EIPAVLKLSCT	DTSLYETEM	YACCV	LAIPLSV	SVSYTHI	LTVHRRNSA
	250	260	270	280	290	300
GPCR2	TCSSHMTVVS	IFYGAAT	ETNVCSHS	YETPERCK	AVSAFYTI	ETPMNPLI
gi 3983382	TCSSHMTVVS	IFYGAAT	ETNVCSHS	YETPERCK	AVSAFYTI	ETPMNPLI
gi 2921628	TCSSHMTVVS	IFYGAAT	ETNVCSHS	YETPERCK	AVSAFYTI	ETPMNPLI
gi 12007423	TCSSHMTVVS	IFYGAAT	ETNVCSHS	YETPERCK	AVSAFYTI	ETPMNPLI
gi 12007424	TCSSHMTVVS	IFYGAAT	ETNVCSHS	YETPERCK	AVSAFYTI	ETPMNPLI
gi 12007425	TCSSHMTVVS	IFYGAAT	ETNVCSHS	YETPERCK	AVSAFYTI	ETPMNPLI
gi 12007422	TCSSHMTVVS	IFYGAAT	ETNVCSHS	YETPERCK	AVSAFYTI	ETPMNPLI
	310	320				
GPCR2	ALRRVLD	CGSSQSIR	VMTV			
gi 3983382	ALRRVLD	CGSSQSIR	VMTV			
gi 2921628	ALRRVLD	CGSSQSIR	VMTV			
gi 12007423	ALRRVLD	CGSSQSIR	VMTV			
gi 12007424	ALRRVLD	CGSSQSIR	VMTV			
gi 12007425	ALRRVLD	CGSSQSIR	VMTV			
gi 12007422	ALRRVLD	CGSSQSIR	VMTV			

DOMAIN results for GPCR2 were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST. This BLAST samples domains found in the

Smart and Pfam collections. The 7tm\_1, a seven transmembrane receptor (rhodopsin family), was shown to have two segments with homology to GPCR2. The region from amino acid residue 43 through 238 aligns with amino acids 2 through 181 of the "seven transmembrane receptor (rhodopsin family) fragment" domain (SEQ ID NO:45, E= 2e-22), and GPCR2 amino acids 226-289 aligned with residues 313-377 of the 7tm\_1 entry (SEQ ID NO:45, E= .008) of the Pfam database. This indicates that the GPCR2 sequence has properties similar to those of other proteins known to contain this domain as well as to the 7tm\_1 domain itself.

The disclosed GPCR2 is expressed in tissues that are important in female reproductive health and hence GPCR2 may serve as a drug target for, e.g., premature labor, endometriosis, and *in vitro* fertilization. The homology to the olfactory receptors suggests that an endogenous small molecule ligand regulates this gene and hence drugs structurally similar to the endogenous ligand could serve as agonists and antagonists to regulate the biological effects of GPCR2.

The nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various GPCR-related pathological disorders and/or OR-related pathological disorders, described further below. For example, a cDNA encoding the olfactory receptor -like protein may be useful in gene therapy, and the olfactory receptor -like protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from neoplasm, adenocarcinoma, lymphoma, uterus cancer, immune response, AIDS, asthma, Crohn's disease, multiple sclerosis, and Albright Hereditary Osteodystrophy. Other GPCR-related diseases and disorders are contemplated.

The novel nucleic acid encoding the GPCR-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-GPCR3 Antibodies" section below. In one embodiment, a contemplated GPCR3 epitope is from about amino acids 105 to 140. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.

**GPCR3**

An additional GPCR-like protein of the invention, referred to herein as GPCR3, is an Olfactory Receptor ("OR")-like protein. The novel nucleic acid was identified on chromosome 6 by TblastN using CuraGen Corporation's sequence file for GPCR probe or homolog, run against the Genomic Daily Files made available by GenBank. The nucleic acid was further predicted by the program GenScan™, including selection of exons. These were further modified by means of similarities using BLAST searches. The sequences were then manually corrected for apparent inconsistencies, thereby obtaining the sequences encoding the full-length protein. The novel nucleic acid of 957 nucleotides (ba145122\_B, SEQ ID NO:9) encoding a novel olfactory receptor-like protein is shown in Table 3A. An open reading frame (ORF) was identified beginning with an ATG initiation codon at nucleotides 10-12 and ending with a TGA codon at nucleotides 955-957. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 3A, and the start and stop codons are in bold letters.

**Table 3A. GPCR3 Nucleotide Sequence (SEQ ID NO:9)**

```

AGATTAGTCATGAAGGCCAACTACAGCGCAGAGGAGCGCTTCTCCTGCTGGGTTTCTCCGACTGGCCTT
CCCTGCAGCCGGTCTCTTCGCCCTTGCTCCTGTGCTACCTCCTGACCTTGACGGGCAACTCGGCGCT
GGTGCTGCTGGCGGTGCGCGACCCGCGCCTGCACACGCCCATGTACTACTTCTTCTGCCACCTGGCCTTG
GTAGACGCGGGCTTCACTACTAGCGTGGTGCCGCGCTGCTGGCCAACTGCGCGGACCAGCGCTCTGGC
TGCCGCGCAGCCACTGCACGGCGCAGCTGTGCGCATCGCTGGCTCTGGGTTCTGGCCGAATGCGTCTCCT
GGCGGTGATGGCTCTGGACCGCGCGCGCCGAGTGTGCCGCCGCTGCGCTATGCGGGGCTCGTCTCCCCG
CGCCTATGTCGCACGCTGGCCAGCGCCTCCTGGCTAAGCGGCCTCACCAACTCGGTTGCGCAAACCGCGC
TCCTGGCTGAGCGGCCGCTGTGCGCGCCCCGCTGCTGGGCCACTTCATCTGTGAGCTGCCGGCGTTGCT
CAAGCTGGCCCGGAGGCGACGGAGACACTACCGAGAACCAGATGTTGCCGCCCGCGTGGTTCATCCTG
CTGCTGCCGTTTGCCGTCATCCTGGCCTCCTACGGTGCCGTGGCCCGAGCTGTCTGTTGTATGCGGTTCA
GCGGAGGCCGAGGAGGGCGGTGGGCACGTGTGGGTCCACCTGACAGCCGTCTGCCTGTTCTACGGCTC
GGCCATCTACACCTACCTGCAGCCGCGCAGCGCTACAACAGGCACGGGGCAAGTTCGTATCGCTCTTC
TACACCGTGGTCACACCTGCTCTCAACCGCTCATCTACACCCTCAGGAATAAGAAAGTGAAGGGGCGAG
CGAGGAGGCTGCTGCGGAGTCTGGGGAGAGGCCAGGCTGGGCAGTGA

```

A putative splice site is located between nucleotides 15 and 16 in SEQ ID NO:9. In one embodiment, nucleotides 1-15 come from exon 1 and nucleotides 16-957 are from exon 2.

The disclosed ba145122\_B nucleic acid sequence has 592 of 934 bases (63%) identical to a GPCR mRNA (GENBANK-ID: HUMORLMHC| acc: L35475) from *Homo sapiens* ( $E=2.4 \times 10^{-51}$ ).

The disclosed GPCR3 polypeptide (SEQ ID NO:10) encoded by SEQ ID NO:9 is 315 amino acid residues and is presented using the one-letter code in Table 3B. The first 70 amino acids of the disclosed GPCR3 protein were analyzed for signal peptide prediction and cellular localization. SignalP results predict that GPCR3 is cleaved between position 46 and 47 of

SEQ ID NO:10, *i.e.*, at the slash in the amino acid sequence NSA-LV. Psort and Hydropathy profiles also predict that GPCR3 contains a signal peptide and is likely to be localized at the plasma membrane (certainty of 0.6000).

**Table 3B. Encoded GPCR3 protein sequence (SEQ ID NO:10).**

MKANYSAEERFLLGFSWPSLQPVLFALVLLCYLLTLTGNSA/LVLLAVRDPRLHTPMYYFLCHLALVDA  
GFTTSVVPPLLNLRGPAWLPFRSHCTAQLCASLALGSAECVLLAVMALDRAAAVCRPLRYAGLVSPRLC  
RTLASASWLSGLTNSVAQTALLAERPLCAPRLLGHFICELPALLKLARGGDDTTENQMFARVVILLP  
FAVILASYGAVARAVCCMRFSGGRRRAVGTCGSHLTAVCLFYGSAIYTYLQPAQRYNQARGKFVSLFYTV  
VTPALNPLIYTLRNKKVKGAARRLLRSLGRGQAGQ

5

A BLASTX search was performed against public protein databases. The full amino acid sequence of the protein of the invention was found to have 253 of 308 amino acid residues (82%) identical to, and 264 of 308 residues (85%) positive with, the 309 amino acid residue MM17M1-6, 7 transmembrane receptor (OR-like protein) from *Mus musculus* (ptnr:SPTREMBL-ACC:Q9WV09, SEQ ID NO:52) ( $E = 1.5 \times 10^{-128}$ ). The alignment of these proteins is shown in Table 3C.

10

**Table 3C. Alignment of GPCR3 with QpWV09 (SEQ ID NO:52).**

	10	20	30	40	50	60	
GPCR3	.....	.....	.....	.....	.....	.....	
Q9WV09	.....	.....	.....	.....	.....	.....	
GPCR3	MKANYSAEERFLLGFSWPSLQPVLFALVLLCYLLTLTGNSA	LVLLAVRDPRLHTPMYY	FLCHLALVDA				60
Q9WV09	--ANHSASAEERFLLGFSWPSLQPVLFALVLLCYLLTLTGNSA	LVLLAVRDPRLHTPMYY	FLCHLALVDA				58
	70	80	90	100	110	120	
GPCR3	FLCHLALVDAGFTTSVVPPLLNLRGPAWLPFRSHCTAQLCASLALGSAECVLLAVMALD						120
Q9WV09	FLCHLALVDVGFSTTSVVPPLLNLRGPAWLPFRSHCTAQLCASLALGSAECVLLAVMALD						118
	130	140	150	160	170	180	
GPCR3	RAAAVCRPLRYAGLVSPRLCRTLASASWLSGLTNSVAQTALLAERPLCAPRLLGHFICEL						180
Q9WV09	RAAAVGNPLRYTSLASPLLCRTLAGVSWLGGCLNSAAQTALLAERPLCAPRLLDHFICEL						178
	190	200	210	220	230	240	
GPCR3	PALLKLARGGDDTTENQMFARVVILLFPAVILASYGAVARAVCCMRFSGGRRRAVGTC						240
Q9WV09	PALLQLACRGRSATERQMFARVVILLFPAVILASYGAVARAVCCMRFSGGRRRAVGTC						238
	250	260	270	280	290	300	
GPCR3	CGSHLTAVCLFYGSAIYTYLQPAQRYNQARGKFVSLFYTVVTPALNPLIYTLRNKKVKGA						300
Q9WV09	CGSHLTAVCLFYGSAIYTYLQPAQRYNQARGKFVSLFYTVVTPALNPLIYTLRNKKVKGA						298
	310						
GPCR3	ARRLLRSLGRGQAGQ						315
Q9WV09	ARRLLRSLGRP----						309

The disclosed GPCR3 protein (SEQ ID NO:10) also has good identity with a number of olfactory receptor proteins, as shown in Table 3D.

15

Table 3D. BLAST results for GPCR3

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Exp ct
gi 5051404 emb CA B45012.1  (AL078630)	573K1.15 - mm17M1-6 (novel 7 transmembrane receptor) <i>Mus musculus</i>	309	229/296 (77%)	240/296 (80%)	e-108
gi 12054359 emb C AC20487.1  (AJ302567) (AJ02568)	OR <i>Homo sapiens</i>	312	145/298 (48%)	191/298 (63%)	2e-69
gi 12054355 emb C AC20485.1  (AJ302565) (AJ302566) (AJ3025 69) (AJ302570)	OR <i>Homo sapiens</i>	312	144/298 (48%)	191/298 (63%)	3e-69
gi 12231029 sp Q1 5062 O2H3 HUMAN	OR 2H3 <i>Homo sapiens</i>	316	143/294 (48%)	185/294 (62%)	3e-68
gi 9798920 gb AAF 98752.1 AF211940_ 1 (AF211940)	OR <i>Homo sapiens</i>	303	142/287 (49%)	183/287 (63%)	5e-68

This information is presented graphically in the multiple sequence alignment given in Table 3E (with GPCR3 being shown on line 1) as a ClustalW analysis comparing GPCR3 with related protein sequences.

5

Table 3E. Information for the ClustalW proteins:

- 1) Novel GPCR3 (SEQ ID NO:10)
- 2) gi|5051404|emb|CAB45012.1| 573K1.15 (mm17M1-6 (novel 7 transmembrane receptor (rhodopsin family) (olfactory receptor LIKE) protein)) *Mus musculus* (SEQ ID NO:53)
- 3) gi|12054359|emb|CAC20487.1| olfactory receptor *Homo sapiens* (SEQ ID NO:54)
- 4) gi|12054355|emb|CAC20485.1| olfactory receptor *Homo sapiens* (SEQ ID NO:55)
- 5) gi|12231029|sp|Q15062|O2H3\_HUMAN OLFACTORY RECEPTOR 2H3 (OLFACTORY RECEPTOR-LIKE PROTEIN FAT11) (SEQ ID NO:56)
- 6) gi|9798920|gb|AAF98752.1|AF211940\_1 olfactory receptor *Homo sapiens* (SEQ ID NO:57)

10

	10	20	30	40	50	60
GPCR3	----	----	----	----	----	----
Gi 5051404	--MKANYSAEERFLLLGFS	WPSLQPVLEAVL	ECYLLTITGNSA	AVLL	EVDRDPELH	TPM
Gi 12054359	---ANHSSAEERFLLLGFS	WPSLQPVLEAVL	ECYLLTITGNSA	AVLL	EVDRDPELH	TPM
Gi 12054355	MLMKKNASFEERFLLLGFS	NWPHLEVVLFVVV	LEFYLTFLGKLF	ITLSYLD	SHLHTPM	
Gi 12231029	MLMKKNASFEERFLLLGFS	NWPHLEVVLFVVV	LEFYLTFLGKLF	ITLSYLD	SHLHTPM	
Gi 9798920	---MDNCSSTPGFLLLGFS	HPGLERTLFVVV	FETSYLLTLVGNTL	ITLLSGALDPK	ELHSPM	
	----	----	----	----	----	----
	70	80	90	100	110	120
GPCR3	YFELCHLNLV	DAGFTTSVVP	PLIANLRGP	ALWPREHC	QAOLCAS	LALGSAECVLLAVNA
Gi 5051404	YFELCHLNLV	DAGFTTSVVP	PLIASIRGSM	LORPRAGMA	QALCSSL	ALGSAECVLLAVNA
Gi 12054359	YFELCHLNLV	DAGFTTSVVP	PLIASIRGSM	LORPRAGMA	QALCSSL	ALGSAECVLLAVNA
Gi 12054355	YFELCHLNLV	DAGFTTSVVP	PLIASIRGSM	LORPRAGMA	QALCSSL	ALGSAECVLLAVNA
Gi 12231029	YFELCHLNLV	DAGFTTSVVP	PLIASIRGSM	LORPRAGMA	QALCSSL	ALGSAECVLLAVNA
Gi 9798920	YFELCHLNLV	DAGFTTSVVP	PLIASIRGSM	LORPRAGMA	QALCSSL	ALGSAECVLLAVNA

	130	140	150	160	170	180
GPCR3	LDRAAVCRPLRYAGVMSPLRCPTLASASWLSCLTNSVAQTLAERPLCAPPLCPSV					
gi 5051404	LDRAAVCNPLRYTSASPLLCRTLAGVSWLGGIANSAAQTLLAARPLCAPPCDHF					
gi 12054359	LDRYAAVCRPLHYTVLMHPFECRLAASWVSFTTSADHSSFTFWHPLCRHPLVDHF					
gi 12054355	LDRYAAVCRPLHYTVLMHPFECRLAASWVSFTTSADHSSFTFWHPLCRHPLVDHF					
gi 12231029	LDRYAVCCPLHYATLHPRLCNOLASVLEVI GLVESVVOPTSLHHEFCDFDQVDCSVC					
gi 9798920	LDRYAVCCPLHYATLHPRLCNOLASVLEVI GLVESVVOPTSLHHEFCDFDQVDCSVC					
	190	200	210	220	230	240
GPCR3	EVPALELRGGDGDTEENQFAARVVILLLEFAYILASYGAVARAVCCREFSGGRFV					
gi 5051404	EVPALELRGGGSRATERQFAARVVILLVPSVILASYIANGRAVMCHSSCWKFA					
gi 12054359	EVPALELRSCVDI-QANSETLMVMSSHFLLPLILILTSYGATARAVLSQSETCLDFVL					
gi 12054355	EVPALELRSCVDI-QANSETLMVMSSHFLLPLILILTSYGATARAVLSQSETCLDFVL					
gi 12231029	EVPALELRSCEDT-SYNEEDVAVASVFTLVPLSLIIVSYGATTWAVLRINSEKGRFAF					
gi 9798920	EVPALELRSCEDT-SYNEEDVAVASVFTLVPLSLIIVSYGATTWAVLRINSEKGRFAF					
	250	260	270	280	290	300
GPCR3	GTCGSHLTAVCLFYGSATYTYLQPAQRVNCARGKEVSLFYTVVTPLNPLIYTLRNH					
gi 5051404	GTCGSHLTAVCLFYGSATYTYLQPTHSVNCRGKKEVSLFYTVVTPLNPLIYTLRNH					
gi 12054359	RTCGAHLMVVSLFPIPVCMYLQPPSENEODCGKFFALFYTVVTPLNPLIYTLRNH					
gi 12054355	RTCGAHLMVVSLFPIPVCMYLQPPSENEODCGKFFALFYTVVTPLNPLIYTLRNH					
gi 12231029	GTCSSHLTVVILFYSSVAVVYLQKPNVPCRGRKFFGLFYAVGTPSLNPLIYTLRNH					
gi 9798920	GTCSSHLTVVILFYSSVAVVYLQKPNVPCRGRKFFGLFYAVGTPSLNPLIYTLRNH					
	310	320				
GPCR3	GAARLLRLSLGRGQAGQ----					
gi 5051404	GAARLLRLSLGRP-----					
gi 12054359	GAARLLRLSLGRM-----					
gi 12054355	GAARLLRLSLGRM-----					
gi 12231029	RAFRLLLGKGRDSRESWRAA					
gi 9798920	RAFRLLLGKEMGLTQS----					

DOMAIN results for GPCR3 were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST. This BLAST samples domains found in the Smart and Pfam collections. The 7tm\_1, a seven transmembrane receptor (rhodopsin family), was shown to have two segments with significant homology to GPCR3. The region from amino acid residue 40 through 226 aligns with amino acids 1 through 167 of the "seven transmembrane receptor (rhodopsin family) fragment" domain (SEQ ID NO:45, E=1e-15), and GPCR3 amino acids 219-290 aligned with residues 305-377 of the 7tm\_1 entry of the Pfam database (E=.004). This indicates that the GPCR3 sequence has properties similar to those of other proteins known to contain this domain as well as to the 7tm\_1 domain itself.

The nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various GPCR-related pathological disorders and/or OR-related pathological disorders, described further below. For example, a cDNA encoding the olfactory receptor-like protein may be useful in gene therapy, and the olfactory receptor-like protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from neoplasm, adenocarcinoma, lymphoma, prostate cancer, uterus cancer, immune response, AIDS, asthma, Crohn's disease, multiple sclerosis, and Albright Hereditary Osteodystrophy. Other GPCR-related diseases and disorders are contemplated.



The novel nucleic acid encoding the GPCR-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-GPCR<sub>X</sub> Antibodies" section below. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.

## 10 GPCR4

GPCR4 includes a family of three nucleic acids disclosed below. The disclosed nucleic acids encode a GPCR-like protein.

### GPCR4a

The disclosed GPCR4a is encoded by three different nucleic acids, GPCR4a1 (dj408b20\_C) GPCR4a2 (dj408b20\_C\_da1), and GPCR4a3 (CG55358-03). A first nucleic acid, dj408b20\_C (GPCR4a1), is 947 nucleotides long (SEQ ID NO:11). An open reading frame was identified beginning with an ATG initiation codon at nucleotides 3-5 and ending with a TGA codon at nucleotides 939-941. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 4A, and the start and stop codons are in bold letters. The encoded protein having 312 amino acid residues is presented using the one-letter code in Table 4B (SEQ ID NO:12).

**Table 4A. GPCR4a1 Nucleotide Sequence (SEQ ID NO:11).**

```

GTATGGAAAACGATAATACAAGTTCTTTGGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCT
AGAGCTGATCGTCTTTGTGGTTGTCCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTC
TTGCTTTTCAGCTCTGGATTCCCGGCTGCACACCAATGTATTCTTTTGGCAAACCTCTCATTCCCTGG
ACATGTGTTTTACCCACAGGTTCCATCCCTCAGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAG
CTATGTGGGTTGTGCCATCCAGCTGTACTTTGTCTGGCCCTGGGAGGGGTGGAGTGTGTCTCTGGCT
GTCATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACACCATCATCATGCACCCACGTC
TCTGTGGACAGCTGGCTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCACAGAC
ATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTCTCTGTGAGATGCCAGCACTAATTGGT
ATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTTGCCCTGGCAATCTTTATCATCCTGGCAC
CACTCATCCTCATTCTCATTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGG
GCCAAAGAAAGCCTTCAACACTTGCAGCTCGCATCTAATTGTTGTCTCTCTCTCTATGGTACAATCATA
TACATGTACCTCCAGCCAGCAAATACTTATCCCAGGACCAAGGGCAAGTTTCTTACCCTTTTCTACACAA
TTGTCACTCCCAGTGTAAACCCCTGATCTATACATAAGAAACAAAGATGTTAAAGAGGCCATGAAGAA
GGTGCTAGGGAAGGGGAGTGCAGAAATATAGTAAGGG

```

The disclosed nucleic acid GPCR4a1 sequence has 624 of 931 bases (67%) identical (with 624/931 positives, 67%) to a 939 bp *Homo sapiens* olfactory receptor-like protein

(OR2C1) gene (GENBANK-ID: AF098664) ( $E = 3.8e^{-72}$ ). In a search of sequence databases, partial matches were also identified, e.g., the minus strand of nucleotides 719-947 had 229 of 229 bases (100%) identical to a 1320 bp *synthetic* GPCR mRNA (PATENT-ID: T72050), the sequence around marker 2B8 in HH region of chromosome 6p2.1, and the same region of GPCR4a1 had 229 of 229 bases (100%) identical to a *synthetic* GPCR mRNA (PATENT-ID: T72050), also sequence around marker 2B8 in HH region of chromosome 6p2.1 ( $E$  value in both cases is  $9.6e^{-47}$ ).

The GPCR4a polypeptide (SEQ ID NO:12) encoded by SEQ ID NO:11 is presented using the one-letter amino acid code in Table 4B. The Psort profile for GPCR4a predicts that this sequence has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. The most likely cleavage site for a GPCR4a peptide is between amino acids 41 and 42, i.e., at the slash in the amino acid sequence LLG-NM, based on the SignalP result.

**Table 4B. GPCR4a protein sequence (SEQ ID NO:12)**

MENDNTSSFEGFILVGFSRPHLELIVFVVVLI FYLLTLLG/NMTIVLLSALDSRLHTPMYFFLANLSF LDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAAVCKPLHYTIIMH PRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALIGMACVDMMLEALAFALAFI ILAPLILILISYGYGGTVLRIKSAAGRKKAFNTCSSHLIVVSLFYGTIIYMYLQFANTYSQDQGKFLT LFYTIIVTPSVNPLIYTLRNKDVKEAMKKVLGKGS AEI
--

The predicted GPCR4a1 sequence, above, was subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such suitable sequences were then used as the forward and reverse primers in a PCR amplification based on a wide range of cDNA libraries. The resulting amplicon was gel purified, cloned and sequenced to high redundancy, as described in the Examples.

The cloned sequence is disclosed as an alternative embodiment of GPCR4a2 (SEQ ID NO:13), referred to herein as the GPCR4a2 and reported in Table 4C. This 945 nucleotide sequence (GPCR4a2) is alternatively referred to herein as dj408b20\_C\_da1. This nucleic acid is two nucleotides shorter than GPCR4a1 at the 5' UTR. However, GPCR4a2 encodes the same 312 amino acid protein (GPCR4a, SEQ ID NO:12).

**Table 4C. GPCR4a2 Nucleotide Sequence (SEQ ID NO:13)**

```

GTATGGAAAACGATAATACAAGTTCTTTTGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGCTGATC
GTCTTTGTGGTGTCTCATCTTTTATCTGCTGACTCTTCTTGGCAACATGACCATTGTCTTGCTTTCAGCTCTGGATTTC
CCGGCTGCACACACCAATGTATTTCTTTTGGCAAACCTCTCATTCTGGACATGTGTTTCACCACAGGTTCCATCCCTC
AGATGCTCTACAACCTTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTGTGCCATCCAGCTGTACTTTGTCCCTGGCC
CTGGGAGGGGTGGAGTGTGTCTCTCTGGCTGTCTATGGCATATGACCGCTATGCTGCAGTCTGCAAACCCCTGCACTACAC
CATCATCATGACCCACGTCTCTGTGGACAGCTGGCTTCACTGGCATGGCTGAGTGGCTTGGCAATTCTCTCATAATGG
CACCCAGACATTGATGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTTCTCTGTGAGATGCCAGCACTAATTGGT
ATGGCCTGTGTAGACACCATGATGCTTGAGGCACCTGGCTTTTGGCCTGGCAATCTTTATCATCCTGGCACCACTCATCCT
CATTCTCATTCTTATGGTTACGTTGGAGGAACAGTGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACA
CTTGACGCTCGCATCTAATTGTTGTCTCTCTCTTCTATGGTACAATCATATACATGTACCTCCAGCCAGCAAATACTTAT
TCCAGGACCAGGGCAAGTTTCTTACCCTTTCTACACAATTGTCACTCCAGTGTTAACCCCTGATCTATACACTAAG

```

The full amino acid sequence of the disclosed GPCR4a polypeptide has 197 of 305 amino acid residues (64%) identical to, and 242 of 305 residues (79%) positive with, the 320 amino acid residue protein from *Homo sapiens* novel 7 transmembrane receptor (rhodopsin family, olfactory receptor-like protein HS6M1-15, ptnr:SPTREMBL-ACC:Q9Y3N9 DJ88J8.1, E = 5.0e<sup>-108</sup>).

BLASTP (Non-Redundant Composite database) analysis of the best hits for alignments with GPCR4a are listed in Table 4D.

**Table 4D. BLASTP results for GPCR4a**

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
ACC:Q9Y3N9 DJ88J8.1	Novel 7 Transmembrane Receptor (Rhodopsin Family, OR-Like) Hs6m1-15 <i>Homo Sapiens</i>	320	197/305 (64%)	242/305 (79%)	9.4e- 109
ACC:P23275	OLFACTORY RECEPTOR 15 (OR3) <i>Mus musculus</i>	312	190/308 (61%)	241/308 (78%)	5.5e- 104
ACC:O76001 DJ80I19.7	OR-LIKE PROTEIN (HS6M1-3) <i>Homo sapiens</i>	311	193/302 (63%)	244/302 (80%)	1.5e- 103

A BLASTX was also performed to determine the proteins that have significant identity with GPCR4a. The BLASTX results are shown in Table 4E.

**Table 4E. BLASTX results for GPCR4a**

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)	N
Ptnr:SPTREMBL-ACC:Q9Y3N9 DJ88J8.1 (NOVEL 7 TRANSMEMBRA...	+3	1076	5.6e-108	1
Ptnr:SWISSPROT-ACC:P23275 OLFACTORY RECEPTOR 15 (OR3) ...	+3	1031	3.3e-103	1
Ptnr:SPTREMBL-ACC:O76001 DJ80I19.7 (OLFACTORY RECEPTOR...	+3	1027	8.7e-103	1
Ptnr:SPTREMBL-ACC:O95371 OLFACTORY RECEPTOR-LIKE PROTE...	+3	992	4.5e-99	1
Ptnr:SPTREMBL-ACC:O95918 DJ271M21.2 (HS6M1-12 (7 TRANS...	+3	988	1.2e-98	1
Ptnr:SPTREMBL-ACC:Q9WV11 573K1.8 (MM17M1-2 (NOVEL 7 TR...	+3	984	3.2e-98	1
Ptnr:SPTREMBL-ACC:Q9WV14 573K1.2 (MM17M1-3 (NOVEL 7 TR...	+3	981	6.6e-98	1

Possible SNPs found for GPCR4a2 are listed in Table4F.

Table 4F: SNPs		
Base Position	Base Before	Base After
44	T	C(20)
147	T	C(2)
220	T	C(2)
271	T	C(3)
432	A	G(2)
452	C	T(2)
493	A	G(2)
771	T	C(3)

## 5 GPCR4b

The target sequence identified as dj408b20\_C (GPCR4a1) was again subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. The cDNA coding for the sequence was cloned by

10 polymerase chain reaction (PCR) using the following primers:

ATACAAGTTCTTTCGAAGGCTTCATCC (SEQ ID NO:14) and

CCCTTACTATATTTCTGCACTCCCCTT (SEQ ID NO:15) on pool 1 of human cDNAs

containing the following: Adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal  
15 kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus.

Primers were designed based on in silico predictions for the full length or part (one or more exons) of the DNA/protein sequence of the invention or by translated homology of the  
20 predicted exons to closely related human sequences or to sequences from other species.

Usually multiple clones were sequenced to derive the sequence which was then assembled similar to the SeqCalling process. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. The PCR product derived by exon linking was cloned into the pCR2.1 vector from Invitrogen. The bacterial clone

25 115843::DJ408B20\_C.698322.D10 has an insert covering the entire open reading frame cloned into the pCR2.1 vector from Invitrogen.

In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on *in silico* predictions for the full length cDNA, part (one or  
5 more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. Typically, the resulting amplicons were gel purified, cloned and sequenced to high redundancy as described in the examples. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs.  
10 Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate.

These procedures provided a third nucleic acid encoding a GPCR4 protein. The nucleic acid is referred to as GPCR4a3 or CG55358-03. This nucleic acid is 932 nucleotides  
15 long (SEQ ID NO:16, Table 4G) and is 16 nucleotides shorter in the 5' UTR than GPCR2a1. An open reading frame of the mature protein was identified beginning with an ACA codon which codes for the amino acid threonine at nucleotides 3-5 and ending with a TAG codon at nucleotides 924-926. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon. One silent base substitution is  
20 present: C767 is T752 in GPCR4a3. GPCR4b, the protein encoded by GPCR4a3 is identical to GPCR4a, except for the 5 amino acid deletion at the N terminus, as shown in Table 4H (SEQ ID NO:17).

The GPCR Olfactory Receptor disclosed herein is expressed in at least the following tissues: Apical microvilli of the retinal pigment epithelium, arterial (aortic), basal forebrain,  
25 brain, Burkitt lymphoma cell lines, corpus callosum, cardiac (atria and ventricle), caudate nucleus, CNS and peripheral tissue, cerebellum, cerebral cortex, colon, cortical neurogenic cells, endothelial (coronary artery and umbilical vein) cells, palate epithelia, eye, neonatal eye, frontal cortex, fetal hematopoietic cells, heart, hippocampus, hypothalamus, leukocytes, liver, fetal liver, lung, lung lymphoma cell lines, fetal lymphoid tissue, adult lymphoid tissue, Those  
30 that express MHC II and III nervous, medulla, subthalamic nucleus, ovary, pancreas, pituitary, placenta, pons, prostate, putamen, serum, skeletal muscle, small intestine, smooth muscle (coronary artery in aortic) spinal cord, spleen, stomach, taste receptor cells of the tongue, testis, thalamus, and thymus tissue. This information was derived by determining the tissue

sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.

In a search of sequence databases, it was found, for example, that the disclosed GPCR4a3 nucleic acid sequence has 614 of 913 bases (67%) identical to a gb:GENBANK-  
 5 ID:AF098664|acc:AF098664.1 mRNA from Homo sapiens (Homo sapiens olfactory receptor-like protein (OR2C1) gene, complete cds, E= 2.1e-71).

**Table 4G. GPCR4a3 Nucleotide Sequence (SEQ ID NO:16)**

ATACAAGTTCTTTGGAAGGCTTCATCCTGGTGGGCTTCTCTGATCGTCCCCACCTAGAGC	60
TGATCGTCTTTGTGGTTGTCTCATCTTTATCTGCTGACTCTTCTTGGCAACATGACCA	120
TTGTCTTGCTTTGAGCTCTGGATTCCCGGCTGCACACACCAATGTATTTCTTTTGGCAA	180
ACCTCTCATTCTGGACATGTGTTTCACACAGGTTCATCCCTCAGATGCTCTACAACC	240
TTTGGGGTCCAGATAAGACCATCAGCTATGTGGGTGTGCCATCCAGCTGTACTTTGTCC	300
TGGCCCTGGGAGGGGTGGAGTGTGTCTCCTGGCTGTCATGGCATATGACCGCTATGCTG	360
CAGTCTGCAAACCCCTGCACTACACCATCATATGCACCCACGTCTCTGTGGACAGCTGG	420
CTTCAGTGGCATGGCTGAGTGGCTTTGGCAATTCTCTCATAATGGCACCCAGACATTGA	480
TGCTACCCCGCTGTGGGCACAGACGAGTTGACCACTTCTCTGTGAGATGCCAGCACTAA	540
TTGGTATGGCCTGTGTAGACACCATGATGCTTGAGGCACTGGCTTTGCCCTGGCAATCT	600
TTATCATCCTGGCACCCTCATCCTCATTCTCATTCTTATGGTTACGTTGGAGGAACAG	660
TGCTTAGGATCAAGTCAGCTGCTGGGCGAAAGAAAGCCTTCAACACTTGCAGCTCGCATC	720
TAATTGTTGTCTCTCTCTTCTATGGTACAATTATATACATGTACCTCCAGCCAGCAAATA	780
CTTATTTCCAGGACAGGGCAAGTTTCTTACCCTTTCTACACAATTGTCACTCCAGTG	840
TTAACCCCTGATCTATACACTAAGAAACAAAGATGTTAAAGAGGCCATGAAGAAGGTGC	900
TAGGGAAGGGGAGTGCAGAAATATAGTAAGGG	932

The SignalP, Psort and/or Hydropathy profile for the disclosed GPCR4b Olfactory  
 10 Receptor-like protein predicts that this sequence has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. The SignalP shows a signal sequence is coded for in the first 36 amino acids with a cleavage site at between amino acids 36 and 37, as indicated by a slash between LLG/NM in Table 4H. This is typical of this type of membrane protein.

**Table 4H. GPCR4b Amino Acid Sequence (SEQ ID NO:17)**

TSSFEGFILVGFSRPHLELIVFVVLIFYLLTLG/NMTIVLLSALDSRLHTPMYFFLAN	60
LSFLDMCFTTGSIPQMLYNLWGPDKTISYVGCAIQLYFVLALGGVECVLLAVMAYDRYAA	120
VCKPLHYTIIMHPRLCGQLASVAWLSGFGNSLIMAPQTLMLPRCGHRRVDHFLCEMPALI	180
GMACVDTMMLEALAFALAFIILAPLILILISYGYVGGTVLRKSAAGRKKAFNTCSSHL	240
IVVSLFYGTIIMYLQPANTYSQDQGKFLTFYITVTPSVNPLIYTLRNKDVKEAMKKVL	300
GKGS AEI	307

The full amino acid sequence of the disclosed GPCR4b protein of the invention was found to have 195 of 299 amino acid residues (65%) identical to, and 239 of 299 amino acid residues (79%) similar to, the 320 amino acid residue ptrn:SPTREMBL-ACC:Q9Y3N9  
 20 protein from Homo sapiens (DJ88J8.1, NOVEL 7 TRANSMEMBRANE RECEPTOR

(RHODOPSIN FAMILY) (OLFACTORY RECEPTOR LIKE) PROTEIN) (HS6M1-15), E= 1.6e-107).

In following positions, one or more consensus positions (Cons. Pos.) of the GPCR4a3 nucleotide sequence have been identified as SNPs. "Depth" represents the number of clones covering the region of the SNP. The Putative Allele Frequency (Putative Allele Freq.) is the fraction of all the clones containing the SNP. A dash ("-"), when shown, means that a base is not present. The sign ">" means "is changed to": Cons. Pos.: 422 Depth: 18 Change: T > C, Putative Allele Freq.: 0.333; Cons. Pos.: 546 Depth: 15 Change: T > C, Putative Allele Freq.: 0.133; Cons. Pos.: 753 Depth: 8 Change: C > T, Putative Allele Freq.: 0.250.

Unless specifically addressed as GPCR4a or GPCR4b, any reference to GPCR4 is assumed to encompass all variants. Residue differences between any GPCRX variant sequences herein are written to show the residue in the "a" variant and the residue position with respect to the "a" variant. In all following sequence alignments, the GPCR4a protein sequence was used.

The disclosed GPCR4 protein (SEQ ID NO:12) also has good identity with a number of olfactory receptor proteins. The identity information used for ClustalW analysis is presented in Table 4I.

**Table 4I. BLAST results for GPCR4**

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
Gi 6679170 ref NP_032788.1	OR 15 (OR3) <i>Mus musculus</i>	312	174/308 (56%)	216/308 (69%)	1e-93
Gi 4826521 emb CAC42853.1  (AL035402, dJ88J8.1) (AJ302594-99) (AJ302600-01)	novel 7 tm receptor protein (rhodopsin fam., OR-like) (hs6M1-15) <i>Homo sapiens</i>	320	174/305 (57%)	213/305 (69%)	2e-93
Gi 12054431 emb CAC20523.1  (AJ302603)	OR <i>Homo sapiens</i>	320	173/305 (56%)	213/305 (69%)	3e-93
Gi 12054429 emb CAC20522.1  (AJ302602)	OR <i>Homo sapiens</i>	320	173/305 (56%)	213/305 (69%)	7e-93
Gi 12054347 emb CAC20478.1  (AJ302558)	OR <i>Homo sapiens</i>	311	170/302 (56%)	211/302 (69%)	6e-90

This information is presented graphically in the multiple sequence alignment given in Table 4J (with GPCR4 being shown on line 1) as a ClustalW analysis comparing GPCR4 with related OR sequences.

Table 4J Information for the ClustalW proteins:

- 1) GPCR4 (SEQ ID NO:12)
- 2) gi|6679170|ref|NP\_032788.1| olfactory receptor 15 *Mus musculus* (SEQ ID NO:58)
- 3) gi|4826521|emb|CAB42853.1| dJ88J8.1 (novel 7 transmembrane receptor (rhodopsin family) (OR like) protein) (*hs6M1-15*) *Homo sapiens* (SEQ ID NO:59)
- 4) gi|12054431|emb|CAC20523.1| olfactory receptor *Homo sapiens* (SEQ ID NO:60)
- 5) gi|12054429|emb|CAC20522.1| olfactory receptor *Homo sapiens* (SEQ ID NO:61)
- 6) gi|12054347|emb|CAC20478.1| olfactory receptor *Homo sapiens* (SEQ ID NO:62)

	10	20	30	40	50	60
GPCR4	.....	.....	.....	.....	.....	.....
Gi 6679170	.....	.....	.....	.....	.....	.....
Gi 4826521	.....	.....	.....	.....	.....	.....
Gi 12054431	.....	.....	.....	.....	.....	.....
Gi 12054429	.....	.....	.....	.....	.....	.....
Gi 12054347	.....	.....	.....	.....	.....	.....
	70	80	90	100	110	120
GPCR4	.....	.....	.....	.....	.....	.....
Gi 6679170	.....	.....	.....	.....	.....	.....
Gi 4826521	.....	.....	.....	.....	.....	.....
Gi 12054431	.....	.....	.....	.....	.....	.....
Gi 12054429	.....	.....	.....	.....	.....	.....
Gi 12054347	.....	.....	.....	.....	.....	.....
	130	140	150	160	170	180
GPCR4	.....	.....	.....	.....	.....	.....
Gi 6679170	.....	.....	.....	.....	.....	.....
Gi 4826521	.....	.....	.....	.....	.....	.....
Gi 12054431	.....	.....	.....	.....	.....	.....
Gi 12054429	.....	.....	.....	.....	.....	.....
Gi 12054347	.....	.....	.....	.....	.....	.....
	190	200	210	220	230	240
GPCR4	.....	.....	.....	.....	.....	.....
Gi 6679170	.....	.....	.....	.....	.....	.....
Gi 4826521	.....	.....	.....	.....	.....	.....
Gi 12054431	.....	.....	.....	.....	.....	.....
Gi 12054429	.....	.....	.....	.....	.....	.....
Gi 12054347	.....	.....	.....	.....	.....	.....
	250	260	270	280	290	300
GPCR4	.....	.....	.....	.....	.....	.....
Gi 6679170	.....	.....	.....	.....	.....	.....
Gi 4826521	.....	.....	.....	.....	.....	.....
Gi 12054431	.....	.....	.....	.....	.....	.....
Gi 12054429	.....	.....	.....	.....	.....	.....
Gi 12054347	.....	.....	.....	.....	.....	.....
	310	320				
GPCR4	.....	.....				
Gi 6679170	.....	.....				
Gi 4826521	.....	.....				
Gi 12054431	.....	.....				
Gi 12054429	.....	.....				
Gi 12054347	.....	.....				

DOMAIN results for GPCR4 were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST. This BLAST samples domains found in the Smart and Pfam collections. Two regions of GPCR4 have identity to the 377 amino acid 7TM



domain, as described above. The 7tm\_1, a seven transmembrane receptor (rhodopsin family), SEQ ID NO:45, above, was shown to have homology to GPCR4. Residues 1-120 of 7TM align with residues 41-159 of GPCR4 (E= 7e-22, shown in Table 2K) and residues 224-290 of GPCR4 have identity with residues 310-377 of 7TM (E=2e-04).

5

Table 4K: Domain Alignment between GPCR4 and 7TM.	
GPCR4	GNYTIVLSALESRDHTPMYFFANISFLDYCFITGSEFQMEINLWGPDKTISYSGCAIQ
TM7	GNVLYCMAVSRKALQTTNMLVLSLEVANLLVATLVMEWYANLEVVGKWKFSREHDF
GPCR	RYFVTAAGGVECLLAVMYDRYPAVCKEHTTIIM-HPFLCGQASVANTSGFGNLI
TM7	VTLDMMCTASINLCAISIDRYTAVAMEMLNTRYSSKPRVTVMIRIVVLSFTISCP

The nucleic acids and proteins of GPCR4 are useful in potential therapeutic applications implicated in various GPCR-related pathological disorders and/or OR-related pathological disorders, described further below. For example, a cDNA encoding the olfactory receptor-like protein may be useful in gene therapy, and the olfactory receptor-like protein may be useful when administered to a subject in need thereof. The protein similarity information, expression pattern, and map location for the Olfactory Receptor-like protein and nucleic acid disclosed herein suggest that this Olfactory Receptor may have important structural and/or physiological functions characteristic of the Olfactory Receptor family.

Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

The nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: developmental diseases, MHCII and III diseases (immune diseases), taste and scent detectability Disorders, Burkitt's lymphoma, corticoneurogenic disease, signal transduction pathway disorders, retinal diseases including those involving photoreception, cell growth rate disorders; cell shape disorders, feeding disorders; control of feeding; potential obesity due to over-eating; potential disorders due to

starvation (lack of appetite), noninsulin-dependent diabetes mellitus (NIDDM1), bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation, dentatorubro-pallidolusian atrophy (DRPLA) hypophosphatemic rickets, autosomal dominant (2) acrocallosal syndrome and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders of the like. The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding the OR-like protein may be useful in gene therapy, and the OR-like protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome. Other GPCR-4 diseases and disorders are contemplated.

The novel nucleic acid encoding OR-like protein, and the OR-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immuno-specifically to the novel substances of the invention for use in therapeutic or diagnostic methods and other diseases, disorders and conditions of the like. These materials are further useful in the generation of antibodies that bind immuno-specifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods

known in the art, using prediction from hydrophobicity charts, as described in the "Anti-  
GPCRX Antibodies" section below. In one embodiment, a contemplated GPCR<sup>4</sup> epitope is  
from about amino acids 65 to 85. In another embodiment, a GPCR<sup>4</sup> epitope is from about  
amino acids 115 to 130. In additional embodiments, GPCR<sup>4</sup> epitopes are from amino acids  
5 155 to 175, from 215 to 240, from 250 to 275 and from amino acids 280 to 310. These novel  
proteins can also be used to develop assay system for functional analysis.

### GPCR5

GPCR5 includes a family of three similar nucleic acids and three similar proteins  
disclosed below. The disclosed nucleic acids encode GPCR, OR-like proteins.

#### GPCR5a

The disclosed novel GPCR5a nucleic acid of 1003 nucleotides (also referred to as 115-  
p-12-A) is shown in Table 5A. An ORF begins with an ATG initiation codon at nucleotides 6-  
8 and ends with a TAA codon at nucleotides 999-1001. A putative untranslated region  
upstream from the initiation codon and downstream from the termination codon is underlined  
15 in Table 5A, and the start and stop codons are in bold letters.

**Table 5A. GPCR5a Nucleotide Sequence (SEQ ID NO:18)**

```

AGACAATGAGTCTCTGATGGGAACACAGTAGTGATCCAACAGAGTTCGTCTGGCAGGGCTCCCAAATCT
CAACAGCGCAAGAGTGGAAATATTTTCTGTGTTCTTCTTGCTATCTCCTGAATCTGACAGGCAATGTG
TTGATTGTGGGGGTGGTAAGGGCTGATACTCGACTACAGACCCCTATGTAATTCTTTCTGGGTAACCTGT
CCTGCCCTAGAGATACTGCTCACTTCTGTGCATCATCCAAAGATGCTGAGCAATTCCTCTCAAGGCAACA
CACTATTTCTTTGCTGCATGTATCACCAATTCTATTTCTACTTTCTCGGGGCTCCGAGTTCTTA
CTGTTGGCTGTGCATGTCTGCGGATCGCTACCTGGCCATCTGTCATCCTCTGCGCTACCCCTTGCTCATGA
GTGGGGCTGTGTGCTTTCTGTGGCCTTGGCCTGCTGGGTGGGGGGACTCGTCCCTGTGCTGGTCCAC
AGTGGCTGTGGCCTTGCTTCCTTTCTGTAAGCAGGGTGTGTGGTACAGCACTTCTTCTGCGACAGTGGC
CCACTGCTCCGCTGGCTTGACCAACACCAAGAAGCTGGAGGAGACTGACTTTGTCTGGCCTCCCTCG
TCATTGTATCTTCTTGCTGATCACTGCTGTGCTACGGCCTCATTTGTGCTGGCAGTCTGAGCATCCC
CTCTGCTTCAGGCCGTCAGAAGGCCTTCTCTACCTGTACCTCCCACTTGATAGTGGTGACCCTCTTCTAT
GGAAGTGCCATTTTCTCTATGTGCGGCCATCGCAGAGTGGTTCTGTGGACACTAACTGGGCAGTGACAG
TAATAACGACATTTGTGACACCACTGTTGAATCCATTATCTATGCCTTACGTAATGAGCAAGTCAAGGA
AGCTTTGAAGGACATGTTAGGAAGGTAGTGGCAGGCGTTTTAGGGAATCTTTTACTTGATAAATGTCTC
AGTGAGAAAGCAGTAAAGTAAAA

```

The GPCR5a protein encoded by SEQ ID NO:18 has 331 amino acid residues and is  
presented using the one-letter code in Table 5B. The Psort profile for GPCR5a predicts that  
20 this sequence has a signal peptide and is likely to be localized at the plasma membrane with a  
certainty of 0.6000, it may also localize to the Golgi body. The most likely cleavage site for a  
peptide is between amino acids 54 and 55, i.e., at the slash in the amino acid sequence VRA-  
DT (shown as a slash in Table5B) based on the SignalP result.

**Table 5B. Encoded GPCR5a protein sequence (SEQ ID NO:19)**

MSPDGNHSSDPTEFVLAGLPNLNSARVELFSVFLVYLLNLTGNVLIVGVVRA/DTRLQTPMYFF LGNLSCLEILLTSV IIPKMLSNFLSRQHTISFAACITQFYFYFFLGASEFLLLAVMSADRYLAIC HPLRYPLMSGAVCFRVALACWVGGLVPVLGPTVAVALLPFCCKQGAVVQHFFCDSGPLLRLACTN TKKLEETDFVLASLVIVSSLLITAVSYGLIVLAVLSIPSASGRQKAFSTCTSHLIVVTLFYGSAI FLYVRPSQSGSVDTNWAVTVITTFVTPLLNPFITYALRNEQVKEALKDMFRKVVAGVLGNLLLDKC LSEKAVK
---

The disclosed nucleic acid sequence for GPCR5 has 604 of 934 bases (64%) identical to and 604 of 934 bases (64%) positive with *Rattus norvegicus* olfactory receptor protein mRNA (936 bp) (GENBANK-ID: RATOLFPDROD| acc:M64378) ( $E=1.1e^{-45}$ ).

5 The full GPCR5 amino acid sequence has 149 of 304 amino acid residues (49 %) identical to, and 201 of 304 residues (66%) positive with, the 313 amino acid residue olfactory receptor from *Mus musculus* (ptnr: SPTREMBL-ACC: Q9Z1V0) ( $E=2.6e^{-74}$ ).

### GPCR5b

10 GPCR5a (115-a-12-A) was subjected to an exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was  
15 encountered, or, in the case of the reverse primer, until the stop codon was reached. Such suitable sequences were then employed as the forward and reverse primers in a PCR amplification based on a wide range of cDNA libraries. The resulting amplicon was gel purified, cloned and sequenced to high redundancy to provide GPCR5b, which is also referred to as 115-a-12-B.

20 The nucleotide sequence for GPCR5b (1004 bp, SEQ ID NO:20) is presented in Table 5C. The nucleotide sequence differs from GPCR5a by the addition of a T between A5 and A6, and by 6 nucleotide changes (numbered with respect to GPCR5a) C131>T; T186>C; G472>A; T579>A; A687>T; C799>T.

**Table 5C. GPCR5b Nucleotide Sequence (SEQ ID NO:20)**

AGACATATGAGTCCTGATGGGAACCACAGTAGTGATCCAACAGAGTTCGTCCTGGCAGGGCTCCCAA  
 ATCTCAACAGCGCAAGAGTGGAAATTATTTTCTGTGTTTCTTCTGTCTATCTCCTGAATCTGATAGG  
 CAATGTGTTGATTGTGGGGGTGGTAAGGGCTGATACTCGACTACAGACCCCATGTACTTCTTTCTG  
 GGTAACCTGTCTGCCTAGAGATACTGCTCACTTCTGTCACTTCCAAAGATGCTGAGCAATTTCC  
 TCTCAAGGCAACACACTATTTCCCTTTGCTGCATGTATCACCCAATTCTATTTCTACTTCTTTCTCGG  
 GGCTCCGAGTTCTTACTGTTGGCTGTCACTGTGCGGATCGCTACCTGGCCATCTGTATCCTCTG  
 CGCTACCCCTTGCTCATGAGTGGGGCTGTGTGCTTTCGTGTGGCCTTGGCCTGCTGGGTGGGGGAC  
 TCATCCCTGTGCTTGGTCCCACAGTGGCTGTGGCCTTGCTTCCTTTCTGTAAGCAGGGTGCTGTGGT  
 ACAGCACTTCTTCTGCGACAGTGGCCCACTGCTCCGCTGGCATGCACCAACACCAAGAAGCTGGAG  
 GAGACTGACTTTGTCTGGCCTCCCTCGTCATTGTATCTTCCTTGCTGATCACTGCTGTGTCCTACG  
 GCCTCATTGTGCTGGCTGTCCTGAGCATCCCCCTGCTTCAGGCCGTGAGAAGGCCTTCTCTACCTG  
 TACCTCCCACTTGATAGTGGTGACCCTCTTCTATGGAAGTGCCATTTTTCTCTATGTGCGGTATCG  
 CAGAGTGGTTCTGTGGACACTAACTGGGCAGTGACAGTAATAACGACATTTGTGACACCACTGTTGA  
 ATCCATTCATCTATGCCTTACGTAATGAGCAAGTCAAGGAAGCTTTGAAGGACATGTTTAGGAAGGT  
 AGTGGCAGGCGTTTTAGGGAATCTTTACTTGATAATGTCTCAGTGAGAAAGCAGTAAAGTAAAA

The encoded GPCR5b protein is presented in Table 5D. The disclosed protein is 331 amino acids long and is denoted by SEQ ID NO:21. GPCR5b differs from GPCR5a by 3 amino acid residues: T42>I; V151>I; P265>S. Like GPCR5a, the Psort profile for GPCR5b predicts that this sequence has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. The most likely cleavage site for a peptide is between amino acids 54 and 55, *i.e.*, at the slash in the amino acid sequence VRA-DT (shown as a slash in Table 5D) based on the SignalP result.

**Table 5D. Encoded GPCR5b protein sequence (SEQ ID NO:21)**

MSPDGNHSSDPTEFVLAGLPNLNSARVELFSVFLVYLLNLIGNVLIVGVVRA/DTRLQTPMYFFLGN  
 LSCLEILLTSVII PKMLSNFLSRQHTISFAACITQFYFFFLGASEFLLAVMSADRYLAICHPLRYP  
 LLMSGAVCFRVALACWVGGLIPVLGPTVAVALLPFCQKQGAHVQHFFCDSGPLRLACTNKKLEETDF  
 VLASLIVIVSSLLITAVSYGLIVLAVLSIPSASGRQKAFSTCTSHLIVVTLFYGSAIFLYVRSSQSGSV  
 DTNWAVTVITTFVTPLLNPFIIYALRNEQVKEALKDMFRKVVAGVLGNLLLDKCLSEKAVK

BLASTP (Non-Redundant Composite database) analysis of the best hits for alignments with GPCR5b are listed in Table 5E.

**Table 5E. BLASTP results for GPCR5b**

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
SPTREMBL- ACC:Q921V0	OLFACTORY RECEPTOR C6 <i>Mus musculus</i>	313	150/304 (49%)	203/304 (66%)	9.4e-76
SWISSPROT- ACC:P23267	OLFACTORY RECEPTOR- LIKE PROTEIN F6 <i>Rattus norvegicus</i>	311	152/301 (50%)	199/301 (66%)	5.2e-75
SPTREMBL- ACC:Q9Y3P5 DJ994E9.5	HS6M1-17 (NOVEL 7 TM (RHODOPSIN FAMILY) (OR LIKE PROTEIN) <i>Homo sapiens</i>	306	145/301 (48%)	197/301 (65%)	1.1e-67

A BLASTX was also performed to determine the proteins that have significant identity with GPCR4a. The BLASTX results are shown in Table 5F.

**Table 5F. BLASTX results for GPCR5b**

Sequences producing High-scoring Segment Pairs:	Reading Frame	High Score	Smallest Sum Prob P(N)	N
Ptnr:SP TREMBL-ACC:Q9Z1V0 OLFACTORY RECEPTOR C6 - Mus m...	+1	764	5.6e-75	1
ptnr:SWISSPROT-ACC:P23267 OLFACTORY RECEPTOR-LIKE PROT...	+1	757	3.1e-74	1
ptnr:SWISSPROT-ACC:P23270 OLFACTORY RECEPTOR-LIKE PROT...	+1	701	2.7e-68	1
ptnr:SP TREMBL-ACC:Q9Y3P5 DJ994E9.5 (HS6M1-17 (NOVEL 7 ...	+1	688	6.3e-67	1
ptnr:SP TREMBL-ACC:O70271 OLFACTORY RECEPTOR-LIKE PROTE...	+1	688	6.3e-67	1
ptnr:SP TREMBL-ACC:O95007 WUGSC:H DJ0669B10.3 PROTEIN -...	+1	680	4.5e-66	1
ptnr:SP TREMBL-ACC:O13036 CHICK OLFACTORY RECEPTOR 7 - ...	+1	675	1.5e-65	1
ptnr:SP TREMBL-ACC:O95222 OLFACTORY RECEPTOR - Homo sap...	+1	672	3.1e-65	1
ptnr:SP TREMBL-ACC:O70269 OLFACTORY RECEPTOR-LIKE PROTE...	+1	670	5.1e-65	1
ptnr:SP TREMBL-ACC:O57597 CHICK OLFACTORY RECEPTOR 7 - ...	+1	669	6.5e-65	1
ptnr:SP TREMBL-ACC:O70270 OLFACTORY RECEPTOR-LIKE PROTE...	+1	668	8.4e-65	1
ptnr:TREMBLNEW-ACC:AAF65461 OLFACTORY RECEPTOR P2 - Mu...	+1	666	1.4e-64	1
ptnr:SP TREMBL-ACC:Q9WU86 ODORANT RECEPTOR S1 - Mus mus...	+1	665	1.7e-64	1
ptnr:SP TREMBL-ACC:Q90808 OLFACTORY RECEPTOR 4 - Gallus...	+1	665	1.7e-64	1
ptnr:SWISSPROT-ACC:P37071 OLFACTORY RECEPTOR-LIKE PROT...	+1	646	1.8e-62	1

### GPCR5c

Another nucleotide sequence resulted when GPCR5a (115-a-12-A) was subjected to an exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such suitable sequences were then employed as the forward and reverse primers in a PCR amplification based on a wide range of cDNA libraries. The resulting amplicon was gel purified, cloned and sequenced to high redundancy to provide the sequence reported below, which is designated as Accession Number 115\_A\_12\_A\_dal, or GPCR5c.

Human tissues providing SeqCalling Fragments of the clone include Pool One: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain - whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. The tissue origin of the clone is RACE(asm:126603384).

The nucleotide sequence for GPCR5c (1005 bp, SEQ ID NO:22) is presented in Table 5G. The GPCR5c nucleotide sequence differs from GPCR5a by having an extra T at the 5' end, an A at the 3' end, and 6 nucleotide changes: (numbered with respect to GPCR5a) T123>C; C131>T; T186>C; G472>A; T579>A; A687>T.

5

Table 5G. GPCR5c Nucleotide Sequence (SEQ ID NO:22)
TAGACAATGAGTCCTGATGGGAACCACAGTAGTGATCCAACAGAGTTCGTCCTGGCAGGGCTCCCAAATC TCAACAGCGCAAGAGTGGAATTATTTCTGTGTTCTTCTTGTCTATCTCCGAATCTGATAGGCAATGT GTTGATTGTGGGGGTGGTAAGGGCTGATACTCGACTACAGACCCCATGTACTTCTTTCTGGGTAACTTG TCCTGCCTAGAGATACTGCTCACTTCTGTCACTATTCCAAAGATGCTGAGCAATTTCTCTCAAGGCAAC ACACTATTTCTTTGCTGCATGTATCAACCAATTCTATTTCTACTTCTTTCTCGGGGCTCCGAGTTCTT ACTGTTGGCTGTCACTGTCTGCGGATCGCTACCTGGCCATCTGTCACTCTGCGCTACCCCTTGCTCATG AGTGGGGCTGTGTGCTTTCTGTGCGCTTGGCCTGTGCGGTGGGGGACTCATCCCTGTGCTTGGTCCCA CAGTGGCTGTGGCCTTGCTTCTTTCTGTAAGCAGGGTGCTGTGGTACAGCACTTCTTGTGCGACAGTGG CCCACTGCTCCGCTGGCATGCACCAACACCAAGAAGCTGGAGGAGACTGACTTTGTCCTGGCCTCCCTC GTCATTGTATCTTCTTGTGCTGATCACTGCTGTGCTACGGCCTCATTGTGCTGGCTGTCTGAGCATCC CCTCTGCTTCAGGCCGTCAGAAGGCCCTTCTCTACCTGTACCTCCCACTTGATAGTGGTGACCCCTCTTA TGGGAAGTGCCATTTTCTCTATGTGCGGCCATCGCAGAGTGGTTCTGTGGACACTAACTGGGCAGTGACA GTAATAACGACATTTGTGACACCACTGTTGAATCCATTCACTATGCCTTACGTAATGAGCAAGTCAAGG AAGCTTTGAAGGACATGTTAGGAAGGTAGTGGCAGGCGTTTATAGGAATCTTTACTTGATAAATGTCT CAGTGAGAAAGCAGTAAGTAAAAA

The coding region of GPCR5c is from nucleotide 7 to 1000, giving the encoded GPCR5c protein, as presented in Table 5H. The disclosed protein is 331 amino acids long and is denoted by SEQ ID NO: 23. GPCR5c differs from GPCR5a by 3 amino acid residues: L39>P; T42>I; and V151>I. Like GPCR5a, the Psort profile for GPCR5c predicts that this sequence has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. The most likely cleavage site for a peptide is between amino acids 54 and 55, i.e., at the slash in the amino acid sequence VRA-DT (shown as a slash in Table 5H) based on the SignalP result.

15

Table 5H. Encoded GPCR5b protein sequence (SEQ ID NO:23)
MSPDGNHSSDPTEFVLGLPNLNSARVELFSVFLLVLPNLIGNVLIVGVVRA/DTRLQTPMYFFLGNLSC LEILLTSV IIPKMLSNFLSRQHTISFAACITQFYFFFLGASEFLLAVMSADRYLAICHPLRYPLMSG

that differ between the individual GPCR variants are highlighted with a box and marked with the (o) symbol above the variant residue in all alignments herein. For example, the protein shown in line 1 of Table 5J depicts the sequence for GPCR5a, and the positions where GPCR5b or GPCR5c differs are marked with a (o) symbol and are highlighted with a box. All GPCR5 proteins have significant homology to olfactory receptor (OR) proteins:

Table 5I. BLAST results for GPCR5					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
Gi 129091 sp P23267 OLF6_RAT	OR 15 (OR3) <i>Rattus norvegicus</i>	311	144/301 (47%)	189/301 (61%)	7e-67
Gi 6754932 ref NP_035121.1  (AF102523)	OR 49, ORC6 <i>Mus musculus</i>	313	145/305 (47%)	192/305 (62%)	3e-66
Gi 7242165 ref NP_035113.1  (AF106007) (AF321233)	OR 41, OR17 <i>Mus musculus</i>	234	136/304 (44%)	181/304 (58%)	9e-61
Gi 7363437 ref NP_039229.1	OR, family 10, subfamily C, member 1 <i>Homo sapiens</i>	306	139/301 (46%)	186/301 (61%)	2e-59
Gi 12007431 gb AAG45202.1 AF321236_1 (AF321236)	M50 OR <i>Mus musculus</i>	316	129/303 (42%)	181/303 (59%)	4e-59

This information is presented graphically in the multiple sequence alignment given in Table 5J (with GPCR5 being shown on line 1) as a ClustalW analysis comparing GPCR5 with related protein sequences.

Table 5J Information for the ClustalW proteins:

- 1) GPCR5 (SEQ ID NO:19)
- 2) gi|129091|sp|P23267|OLF6\_RAT OLFACTORY RECEPTOR-LIKE PROTEIN F6 (SEQ ID NO:63)
- 3) gi|6754932|ref|NP\_035121.1| olfactory receptor 49 *Mus musculus* (SEQ ID NO:64)
- 4) gi|7242165|ref|NP\_035113.1| olfactory receptor 41 *Mus musculus* (SEQ ID NO:65)
- 5) gi|7363437|ref|NP\_039229.1| olfactory receptor, family 10, subfamily C, member 1 *Homo sapiens* (SEQ ID NO:66)
- 6) gi|12007431|gb|AAG45202.1|AF321236\_1 m50 olfactory receptor *Mus musculus* (SEQ ID NO:67)

	10	20	30	40	50	60
GPCR5	.....	.....	.....	.....	.....	.....
Gi 129091	.....	.....	.....	.....	.....	.....
Gi 6754932	.....	.....	.....	.....	.....	.....
Gi 7242165	.....	.....	.....	.....	.....	.....
Gi 7363437	.....	.....	.....	.....	.....	.....
Gi 12007431	.....	.....	.....	.....	.....	.....
	70	80	90	100	110	120
GPCR5	.....	.....	.....	.....	.....	.....
Gi 129091	.....	.....	.....	.....	.....	.....



Gi 6754932	PMYFLRNFMLEIWTSTVIFPKMLTNIETGHR-----TISLLGCFLCASIMFFLCTTEFF
Gi 7242165	PMYFFLANMSFLEIWTSTVIFPKMLTNIETGHR-----TISLLGCFLCASIMFFLCTTEFF
Gi 7363437	PMYFFLRTSALEICSTSTVIFPKMLTNIETGHR-----TISLLGCFLCASIMFFLCTTEFF
Gi 12007431	PMYFFLSTMSFLEIWTSTVIFPKMLTNIETGHR-----TISLLGCFLCASIMFFLCTTEFF
	130 140 150 160 170 180
GPCR5	LLAVMSADRYAICHPLRYEITMSGAVCFRVALACVGGVLPVVGPTVANDLPFCCKQA
Gi 129091	LLAVMSADRYAICHPLRYEITMSGAVCFRVALACVGGVLPVVGPTVANDLPFCCKQA
Gi 6754932	LLAVMSADRYAICHPLRYEITMSGAVCFRVALACVGGVLPVVGPTVANDLPFCCKQA
Gi 7242165	LLAVMSADRYAICHPLRYEITMSGAVCFRVALACVGGVLPVVGPTVANDLPFCCKQA
Gi 7363437	LLAVMSADRYAICHPLRYEITMSGAVCFRVALACVGGVLPVVGPTVANDLPFCCKQA
Gi 12007431	LLAVMSADRYAICHPLRYEITMSGAVCFRVALACVGGVLPVVGPTVANDLPFCCKQA
	190 200 210 220 230 240
GPCR5	LVNHFFCDNSGSHLIRACTNITKKLEETDVIISLWSSLLTAVSYGLINLANSIPSA
Gi 129091	LVNHFFCDNSGSHLIRACTNITKKLEETDVIISLWSSLLTAVSYGLINLANSIPSA
Gi 6754932	LVNHFFCDNSGSHLIRACTNITKKLEETDVIISLWSSLLTAVSYGLINLANSIPSA
Gi 7242165	LVNHFFCDNSGSHLIRACTNITKKLEETDVIISLWSSLLTAVSYGLINLANSIPSA
Gi 7363437	LVNHFFCDNSGSHLIRACTNITKKLEETDVIISLWSSLLTAVSYGLINLANSIPSA
Gi 12007431	LVNHFFCDNSGSHLIRACTNITKKLEETDVIISLWSSLLTAVSYGLINLANSIPSA
	250 260 270 280 290 300
GPCR5	GRKAFSTCSHLIVVTFYGSATFFVVRP-SQSGVDNFWAVTATTTETVTPILNPFILYA
Gi 129091	GRKAFSTCSHLIVVTFYGSATFFVVRP-SQSGVDNFWAVTATTTETVTPILNPFILYA
Gi 6754932	GRKAFSTCSHLIVVTFYGSATFFVVRP-SQSGVDNFWAVTATTTETVTPILNPFILYA
Gi 7242165	GRKAFSTCSHLIVVTFYGSATFFVVRP-SQSGVDNFWAVTATTTETVTPILNPFILYA
Gi 7363437	GRKAFSTCSHLIVVTFYGSATFFVVRP-SQSGVDNFWAVTATTTETVTPILNPFILYA
Gi 12007431	GRKAFSTCSHLIVVTFYGSATFFVVRP-SQSGVDNFWAVTATTTETVTPILNPFILYA
	310 320 330
GPCR5	LRNKGVKDALRRTTCKGK-----
Gi 129091	LRNKGVKDALRRTTCKGK-----
Gi 6754932	LRNKGVKDALRRTTCKGK-----
Gi 7242165	LRNKGVKDALRRTTCKGK-----
Gi 7363437	LRNKGVKDALRRTTCKGK-----
Gi 12007431	LRNKGVKDALRRTTCKGK-----

DOMAIN results for GPCR5 were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST. This BLAST samples domains found in the Smart and Pfam collections. The results are listed in Table 5K with the statistics and domain description.

Residues 1-115 of 7tm\_1 (SEQ ID NO:45) are aligned with GPCR5 43-156 ( $E = 1e-20$ ), in Table 5K. Residues 314-377 of 7tm\_1 also have identity with residues 231-293 ( $E=2e-05$ ) of GPCR5.

**Table 5K. DOMAIN results for GPCR5**

gnl Pfam pfam00001, 7tm_1, 7 transmembrane receptor (rhodopsin family) (SEQ ID NO: 45) Length = 377	
Statistics for GPCR5: Score = 93.6 bits (231), Expect = 1e-20	
GPCR5	GNVLEIVGVVRAETRLQTPMYEFGNLSCELELITSEVETKMTSNFISRGHTISFAACITQ
TM7	GNVLACMAVSREKALOTTNNLELVSLVAVLELMAVMTWVWYLEIVGVWKFRIHCDIF
GPCR5	FYFYFFFGASEFLLAVMSADRYLAICHPLRYEITMSGAVCFRVALACVGGVLPVVGPTVANDLPFCCKQA
TM7	VTLDVMMCTASINLCAESIDRYLAICHPLRYEITMSGAVCFRVALACVGGVLPVVGPTVANDLPFCCKQA

The nucleic acids and proteins of GPCR5 are useful in potential therapeutic applications implicated in various GPCR-related pathological disorders and/or OR-related pathological disorders, described further below. For example, a cDNA encoding the GPCR (or olfactory-receptor) like protein may be useful in gene therapy, and the receptor-like protein may be useful when administered to a subject in need thereof. The nucleic acids and proteins of the invention are also useful in potential therapeutic applications used in the treatment of infections such as bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders. Other GPCR-related diseases and disorders are contemplated.

The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding the GPCR-like protein may be useful in gene therapy, and the GPCR-like protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders. The novel nucleic acid encoding GPCR-like protein, and the GPCR-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind

immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-GPCRX Antibodies" section below. This novel protein also has value in development of powerful assay system for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.

## GPCR6

The disclosed novel GPCR6 nucleic acid of 948 nucleotides (also referred to as 6-L-19-C) is shown in Table 6A. An open reading begins with an ATG initiation codon at nucleotides 7-9 and ends with a TAG codon at nucleotides 940-942. A putative untranslated region upstream from the initiation codon and downstream from the termination codon are underlined in Table 6A, and the start and stop codons are in bold letters.

**Table 6A. GPCR6 Nucleotide Sequence (SEQ ID NO:24)**

```

GGAGACATGGGCAAGGAAAAGTGCACCACTGTGGCTGAGTTCATTCTCCTTGGACTATCAGATGTCCCTG
AGTTGAGAGTCTGCCTCTTCTCTGCTGTTCTTCTCATCTATGGAGTCACGTTGTTAGCCAACCTGGGCAT
GATTGCACTGATTCAGGTCAGCTCTCGGCTCCACACCCCATGTACTTTTCCCTCAGCCACTTGTCCCTCT
GTAGATTTCTGCTACTCCTCAATAATTGTGCCAAAAATGTTGGCTAATATCTTTAACAAGGACAAAGCCA
TCTCCTTCCCTAGGGTGCATGGTGCAATTCTACTTGTTTTGCACTTGTGTGGTCACTGAGGTCTTCTGCT
GGCGGTGATGGCCTATGACCGCTTTGTGGCCATCTGTAACCCCTTTGCTATACACAGTCACCATGTCTTGG
AAGGTGCGTGTGGAGCTGGCTTCTTCTGCTACTTCTGTGGGACGGTGTGTTCTCTGATTTCATTTGTGCT
TAGCTCTTAGGATCCCTTCTATAGATCTAATGTGATTAACCACTTTTCTGTGATCTACCTCCTGTCTT
AAGTCTTGCTTGCTCTGATATCACTGTGAATGAGACACTGCTGTTCCCTGGTGGCCACTTTGAATGAGAGT
GTTACCATCATGATCATCCTCACCTCCTACCTGCTAATTCTCACCACCATCCTGAAGATGGGCTCTGCAG
AGGGCAGGCACAAAGCCTTCTCCACCTGTGCTTCCCACCTCACAGCTATCACTGTCTTCCATGGAACAGT
CCTTTCCATTTATTGCAGGCCAGTTCAGGCAATAGTGGAGATGCTGACAAAGTGGCCACCGTGTCTTAC
ACAGTCGTGATTCCTATGCTGAACCTCTGTGATCTACAGCCTGAGAAATAAAGATGTGAAAGAAGCTCTCA
GAAAGTGATGGGCTCCAAAATTCACCTCTAGGGAAGA

```

The disclosed nucleic acid sequence has 617 of 915 bases (67%) identical to a *G. gallus* cor4 olfactory receptor 4 DNA (GENBANK-ID: GGCOR4GEN|acc:X94744) (E value =  $8.7e^{-65}$ ).

The GPCR6 protein encoded by SEQ ID NO:24 has 318 amino acid residues, and is presented using the one-letter code in Table 6B (SEQ ID NO:25). The SignalP, Psort and/or Hydropathy profile for GPCR6 predict that GPCR6 has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. The SignalP shows a signal sequence is coded for in the first 41 amino acids, i.e., with a cleavage site at the slash in the sequence TLL-AN, between amino acids 40 and 41. This is typical of this type of membrane protein.

**Table 6B. Encoded GPCR6 protein sequence (SEQ ID NO:25).**

MGKENCTTVAEFILLGLSDVPELRVCLFLLFLLIYGVTL/ANLGMIALIQVSSRLHTPMYFFLSHLSSVD FCYSSIIVPKMLANIFNKDKAISFLGCMVQFYLFCTCVVTEVFLAVMAYDRFVAICNPLLYTVTMSWKV RVELASCCYFCGTVCSLIHLCLALRIPFYRSNVINHFFCDLPPVLSLACSDITVNETLLFLVATLNESVT IMIILTSYLLILTTILKMGSAGEGRHKAFSTCASHLTAITVFHGTVLSIYCRPSSGNSGADAKVATVFYTV VI PMLNSVIYSLRNKOVKEALRKVMGSKIHS
--

The full amino acid sequence of the protein of the invention was found to have 166 of 307 amino acid residues (54%) identical to, and 217 of 307 residues (70%) positive with, the 314 amino acid residue human olfactory receptor-like protein OLF1 (ptnr:SWISSPROT-ACC:Q13606) (E value =  $5.8e^{-86}$ ).

The GPCR6 target sequence identified previously (6\_L\_19\_C) was subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached.

The cDNA coding for the sequence was cloned by polymerase chain reaction (PCR) using the following primers: CACTGTGGCTGAGTTCATTCTCCTT (SEQ ID NO:26) and TCTTCCCTAGGAGTGAATTTTGGAGC (SEQ ID NO:27) on the following pool of human cDNAs: Pool 1 - Adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain - whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Primers were designed based on in silico predictions for the full length or part (one or more exons) of the DNA/protein sequence of the invention or by translated homology of the predicted exons to closely related human sequences or to sequences from other species. Usually multiple clones were sequenced to derive the sequence which was then assembled similar to the SeqCalling process. In addition, sequence traces were evaluated manually and edited for corrections if appropriate.

The PCR product derived by exon linking was cloned into the pCR2.1 vector from Invitrogen. The bacterial clone 55446::6\_L\_19\_C.698018.M1 has an insert covering the entire open reading frame cloned into the pCR2.1 vector from Invitrogen.

Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and

ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported below, which is designated Accession Number CG50383\_01 which does not differ from GPCR6 (6\_L\_19\_C) in amino acid or nucleotide sequence.

The disclosed GPCR6-Olfactory Receptor-like protein is expressed in at least the following tissues: Apical microvilli of the retinal pigment epithelium, arterial (aortic), basal forebrain, brain, Burkitt lymphoma cell lines, corpus callosum, cardiac (atria and ventricle), caudate nucleus, CNS and peripheral tissue, cerebellum, cerebral cortex, colon, cortical neurogenic cells, endothelial (coronary artery and umbilical vein) cells, palate epithelia, eye, neonatal eye, frontal cortex, fetal hematopoietic cells, heart, hippocampus, hypothalamus, leukocytes, liver, fetal liver, lung, lung lymphoma cell lines, fetal lymphoid tissue, adult lymphoid tissue, tissues that express MHC II and III, nervous tissue, medulla, subthalamic nucleus, ovary, pancreas, pituitary, placenta, pons, prostate, putamen, serum, skeletal muscle, small intestine, smooth muscle (coronary artery in aortic) spinal cord, spleen, stomach, taste receptor cells of the tongue, testis, thalamus, and thymus tissue. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.

The disclosed GPCR6 protein (SEQ ID NO:25) has good identity with a number of olfactory receptor proteins. The identity information used for ClustalW analysis is presented in Table 6C. The GPCR6 protein has significant identity to olfactory receptor (OR) proteins:

Table 6C. BLAST results for GPCR6					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
Gi 5729960 ref NP_006628.1	OR fam. 5, subfam. I, mem 1 <i>Homo sapiens</i>	314	154/307 (50%)	200/307 (64%)	2e-72
Gi 2495054 sp Q95155 OLF2 CANFA	OR-like prt OLF2 <i>Canis familiaris</i>	311	152/308 (49%)	207/308 (66%)	8e-70
Gi 11692519 gb AAG39856.1 AF282271_1 (AF282271)	OR 41, K11 <i>Mus musculus</i>	314	150/308 (48%)	199/308 (63%)	8e-69
Gi 3746443 gb AAC63969.1  (AF045577)	OR, OR93ch <i>Pan troglodytes</i>	314	151/306 (49%)	199/306 (64%)	1e-68
Gi 3746448 gb AAC63971.1  (AF045580)	OR OR93Gib <i>Hylobates lar</i>	313	149/305 (48%)	198/305 (64%)	3e-68

This information is presented graphically in the multiple sequence alignment given in Table 6D (with GPCR6 being shown on line 1) as a ClustalW analysis comparing GPCR6 with related protein sequences.

Table 6D Information for the ClustalW proteins:

- 1) GPCR6 (SEQ ID NO:25)
- 2) gi|5729960|ref|NP\_006628.1| OR, family 5, subfamily 1, member 1 Homo sapiens (SEQ ID NO:25)
- 3) gi|2495054|sp|Q95155|OLF2\_CANFA OR-LIKE PROTEIN OLF2 (SEQ ID NO:25)
- 4) gi|11692519|gb|AAG39856.1|AF282271\_1 odorant receptor K11 Mus musculus (SEQ ID NO:25)
- 5) gi|3746443|gb|AAC63969.1| olfactory receptor OR93Ch [Pan troglodytes] (SEQ ID NO:25)
- 6) gi|3746448|gb|AAC63971.1| olfactory receptor OR93Gib [Hylobates lar] (SEQ ID NO:25)

	10	20	30	40	50	60
GPCR6	---	MGKNC	CTVPA	ETILG	ISDV	PEIRV
gi 5729960	---	MEFTD	RNYTL	VTEF	ILLG	FPTR
gi 2495054	---	MDGNC	ESVNE	ELVGS	NKEG	CVTL
gi 11692519	---	MND	TS	SGNY	CTVTE	FFLAG
gi 3746443	---	MAN	ENYTK	VTEF	IFTGL	NYNE
gi 3746448	---	MAN	ENYTK	VTEF	IFTGL	NYNE
	70	80	90	100	110	120
GPCR6	TPMY	FFLS	HLSS	VDF	CYSS	ELV
gi 5729960	TPMY	FFLS	HLSS	VDF	CYSS	ELV
gi 2495054	TPMY	FFLS	HLSS	VDF	CYSS	ELV
gi 11692519	TPMY	FFLS	HLSS	VDF	CYSS	ELV
gi 3746443	TPMY	FFLS	HLSS	VDF	CYSS	ELV
gi 3746448	TPMY	FFLS	HLSS	VDF	CYSS	ELV
	130	140	150	160	170	180
GPCR6	VMAY	DRV	VAIC	NPLLY	VTMS	WKR
gi 5729960	VMAY	DRV	VAIC	NPLLY	VTMS	WKR
gi 2495054	VMAY	DRV	VAIC	NPLLY	VTMS	WKR
gi 11692519	VMAY	DRV	VAIC	NPLLY	VTMS	WKR
gi 3746443	VMAY	DRV	VAIC	NPLLY	VTMS	WKR
gi 3746448	VMAY	DRV	VAIC	NPLLY	VTMS	WKR
	190	200	210	220	230	240
GPCR6	FFCD	PLP	LLK	AC	SN	TY
gi 5729960	FFCD	PLP	LLK	AC	SN	TY
gi 2495054	FFCD	PLP	LLK	AC	SN	TY
gi 11692519	FFCD	PLP	LLK	AC	SN	TY
gi 3746443	FFCD	PLP	LLK	AC	SN	TY
gi 3746448	FFCD	PLP	LLK	AC	SN	TY
	250	260	270	280	290	300
GPCR6	AFST	CS	SHLT	AV	ILY	GT
gi 5729960	AFST	CS	SHLT	AV	ILY	GT
gi 2495054	AFST	CS	SHLT	AV	ILY	GT
gi 11692519	AFST	CS	SHLT	AV	ILY	GT
gi 3746443	AFST	CS	SHLT	AV	ILY	GT
gi 3746448	AFST	CS	SHLT	AV	ILY	GT
	310					
GPCR6	VND	AH	HT	TE	ER	KCKA
gi 5729960	VND	AH	HT	TE	ER	KCKA
gi 2495054	VND	AH	HT	TE	ER	KCKA
gi 11692519	VND	AH	HT	TE	ER	KCKA
gi 3746443	VND	AH	HT	TE	ER	KCKA
gi 3746448	VND	AH	HT	TE	ER	KCKA

The presence of identifiable domains in GPCR6 was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>).

DOMAIN results for GPCR6 were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST. This BLAST samples domains found in the Smart and Pfam collections. The results are listed in Table 6E with the statistics and domain description. The results indicate that this protein contains the 7tm\_1 (InterPro) 7 transmembrane receptor (rhodopsin family) (as defined by Interpro) at residues 42-203, which align with residues 2-158 of the 7TM domain. This indicates that the sequence of GPCR6 has properties similar to those of other proteins known to contain this/these domain(s) and similar to the properties of these domains.

**Table 6E. DOMAIN results for GPCR6**

gnl|Pfam|pfam00001, 7tm\_1, 7 transmembrane receptor (rhodopsin family) Length = 377 (SEQ ID NO:45).  
Score = 86.3 bits (212), Expect = 2e-18

GPCR6 - N E G I A L I Q V S S R I H T P M Y E F F S H L S S V D F C Y S S I N V P K M L A N I F N K D K A I S F E G C M V Q  
TM7 G N E L L C M A S R E K A L C I T T N L E V S L A V A D L L V I R A M P W A Y L E V V G W K F S R H C D I F

GPCR6 F Y L C T C V V T E F L I A V I Y D R E V L C N P E L Y T V T M S W K V R V E A S - C C F C G T V C S L I H  
TM7 V T D V M M C T A S I L N C A S I D R Y T A W A M P M L Y N T R Y S S K R R V T M I A I V A V L S F T I S C P M

GPCR6 ECL-ALRIPFYR-----SNVINHFFCDLPPV--LSLACSDITVNETLLFVA--  
TM7 LFGLNNTDNE-----CIIANP-----AFVYSSIVSEYV---PFIITLLVYI

The similarity information for the GPCR6 protein and nucleic acid disclosed herein suggest that GPCR6 may have important structural and/or physiological functions characteristic of the Olfactory Receptor family and the GPCR family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon. The novel nucleic acid

encoding GPCR6, and the GPCR6 protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

The nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: developmental diseases, MHCII and III diseases (immune diseases), taste and scent detectability disorders, Burkitt's lymphoma, corticoneurogenic disease, signal transduction pathway disorders, retinal diseases including those involving photoreception, cell growth rate disorders; cell shape disorders, feeding disorders; control of feeding; potential obesity due to over-eating; potential disorders due to starvation (lack of appetite), noninsulin-dependent diabetes mellitus (NIDDM1), bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and treatment of Albright hereditary osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation dentatorubro-pallidoluysian atrophy(DRPLA) hypophosphatemic rickets, autosomal dominant (2) acrocallosal syndrome and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders of the like.

The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding the OR -like protein may be useful in gene therapy, and the OR-like protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and treatment of Albright hereditary osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety,



schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders.

The novel nucleic acid encoding OR-like protein, and the OR-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

These materials are further useful in the generation of antibodies that bind immuno-specifically to the novel GPCR6 substances for use in therapeutic or diagnostic methods.

These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-PCR6 Antibodies" section below. In one embodiment, a contemplated GPCR6 epitope is from about aa 225 to 240. In another embodiment, a GPCR6 epitope is from about aa 255 to 275. In additional embodiments, GPCR6 epitopes are from aa 280 to 310.

#### GPCR7

A novel GPCR nucleic acid was identified by TblastN using CuraGen Corporation's sequence file for GPCR probes or homologs, and run against the Genomic Daily Files made available by GenBank. The nucleic acid was further predicted by the program GenScan™, including selection of exons. These were further modified by means of similarities using BLAST searches. The sequences were then manually corrected for apparent inconsistencies, thereby obtaining the sequences encoding the full-length protein. The disclosed novel GPCR7 nucleic acid of 1013 nucleotides (also referred to as dj313i6\_D) is shown in Table 7A. An open reading begins with an ATG initiation codon at nucleotides 5-7 and ends with a TAG codon at nucleotides 997-999. A putative untranslated region upstream from the initiation codon and downstream from the termination codon are underlined in Table 7A, and the start and stop codons are in bold letters.

**Table 7A. GPCR7 Nucleotide Sequence (SEQ ID NO:28)**

```

TACAATGGAAAGAGCTAACGACAGCACCTTCTCTGGATTATCTCTGCTGGGCTTCTCCAACAGGCCTCAGCTGGAAAC
AGCTCTCTTTGTGGTCATCTTGATCATCTACTTTCTGAGCTTTCTGGGCAATGGCACCATTATACTTTTATCCATTGT
AGATCCTCGCTCCATACCCCTATGTATTTCTTCTCTCCAATCTCTCTTTATGGATCTTTGTTGACCACTTGATAC
TGTCCTCAGACACTGGTCAACTTTAAGGGGAAGGACAAGACCATCACCTATGGTGGCTGCGTGACCCAGCTATTTCAT
TGCTTTGGGACTCGGGGGGGAGTGGAGTGTGTCTTATTGTCTGCCATGGCCTATGACCGCTATGCAGCCGTCTGCCG
CCCACTCCACTACATGGTGAGCATGCATCCCCAACTTTGCTTGCAGTTGGTTGTAACCACTTGGCTCACAGGGTTTGG
CAATTCTGTGATACAGACAGCATTGACCATGACTCTCCCCCTCTGTGATAAAAACCAAGTGGATCATTTCTCTGTGA
AGTTCCAGTGATGCTGAACTGTCTGCACCAACACCTCCATCAACGAGGCTGAAATCTTTGCTGTCAGTGTCTTCTT
CTTGGTGGTGCCTCTCTCACTCATCTTAGCATCCTATGGTCACATTACTCATGCAGTCCTGAAGATAAAGTCAGCTCA
AGGGAGGCAGAAAGGCTTTTGAACCTGTGGTTCTCACCTCCTGGTAGTGATCATTTCTTTGGGACACTCATCTCCAT
GTACCTCCAGCTCCCTCCAGTTATTCACAGGATGTGAACAAAAGCATTGCACTCTCTATACTCTGGTGAAGTCTCT
ACTGAATCCCTAATTTACACTCTGAGGAACAAGGAAGTCAAAGGGGCAACTAAGAAGACTAGTGGGGAGGACCATAG
ATGCATGAGAAAGTTAACGCAGGGTTGCAGTTCCAACATTGTGCACTAGAAGACTGCTGAGAAGCTACAAACTA

```

The disclosed nucleic acid sequence has 615 of 939 bases (65%) identical to a *Homo sapiens* olfactory receptor-like protein (OR2C1) gene (GENBANK-ID: AF098654) (E value =  $1.7e^{-67}$ ).

The GPCR7 protein encoded by SEQ ID NO:28 has 327 amino acid residues, and is presented using the one-letter code in Table 7B (SEQ ID NO:29). The SignalP, Psort and/or Hydropathy profile for GPCR7 predict that GPCR7 has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. The SignalP shows a signal sequence is coded for in the first 44 amino acids, i.e., with a cleavage site at the slash in the sequence GNG-TI, between amino acids 43 and 44. This is typical of this type of membrane protein.

**Table 7B. Encoded GPCR7 protein sequence (SEQ ID NO:29).**

```
MERANDSTFSGFILLGFSNRPQLETALFVVILIIYFLSFLGNG/TIILLSIVDPRLHTPMYFFLSNL
SFMDLCLTTCTVPQTLVNFKGKDKTITYGGCVTQLFIALGLGGGVECVLLSAMAYDRYAAVCRPLHY
MVSMPQLCLQLVVTWTWLTGFGNSVIQTALTMTLPLCDKNQVDHFFCEVPVMLKLSCTNTSINEAEI
FAVSVFLLVPLSLILASYGHITHAVLKIKSAQGRQKAFGTGSHLLVVIIFGTLISMVYLQPPSSY
SQDVNKSIALFYTLVTPLLNPLIYTLRNKEVGATKKTSGEDHRCMRKLTQGLQFQTFVH
```

The full amino acid sequence of the protein of the invention was found to have 183 of 304 amino acid residues (60%) identical to, and 229 of 304 residues (75%) positive with, the 313 amino acid residue OL1 receptor protein from *Rattus norvegicus* (ptnr:SPTREMBL-ACC:Q63394) (E value =  $2.6e^{-97}$ ). Further BLAST analysis produced the significant results listed in Table 7C. The disclosed GPCR7 protein (SEQ ID NO:29) has good identity with a number of olfactory receptor proteins.

**Table 7C. BLAST results for GPCR7**

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect t
gi 11177906 ref NP_068632.1  (L34074)	OR <i>Rattus norvegicus</i>	313	168/304 (55%)	209/304 (68%)	2e-86
gi 10944516 emb CAC14158.1  (AL133267) dJ408B20.2	novel 7 TM -OR family (hS6M1-32) <i>Homo sapiens</i>	313	169/304 (55%)	207/304 (67%)	2e-85
gi 12054411 emb CAC20513.1  (AJ302593)	OR 41, K11 <i>Homo sapiens</i>	357	166/304 (54%)	206/304 (67%)	1e-83
gi 12054393 emb CAC20504.1  (AJ302584 - 592)	OR <i>Homo sapiens</i>	357	165/304 (54%)	206/304 (67%)	4e-83
gi 3080467 emb CAB11427.1  (Z98744)	OR <i>Homo sapiens</i>	310	165/304 (54%)	206/304 (67%)	4e-83

This information is presented graphically in the multiple sequence alignment given in Table 7D (with GPCR7 being shown on line 1) as a ClustalW analysis comparing GPCR7 with related protein sequences.

5

Table 7D. Information for the ClustalW proteins:

- 1) GPCR7 (SEQ ID NO:29)
- 2) gi|11177906|ref|NP\_068632.1| Olfactory receptor Rattus norvegicus (SEQ ID NO:73)
- 3) gi|10944516|emb|CAC14158.1| dJ408B20.2 (novel 7 TM receptor (olfactory family) (hS6M1-32) Homo sapiens (SEQ ID NO:74)
- 10 4) gi|12054411|emb|CAC20513.1| olfactory receptor Homo sapiens (SEQ ID NO:75)
- 5) gi|12054393|emb|CAC20504.1| olfactory receptor Homo sapiens (SEQ ID NO:76)
- 6) gi|3080467|emb|CAB11427.1| olfactory receptor Homo sapiens (SEQ ID NO:77)

	10	20	30	40	50	60
GPCR7	.....	.....	.....	.....	.....	.....
gi 11177906	.....	.....	.....	.....	.....	.....
gi 10944516	.....	.....	.....	.....	.....	.....
gi 12054411	.....	.....	.....	.....	.....	.....
gi 12054393	.....	.....	.....	.....	.....	.....
gi 3080467	.....	.....	.....	.....	.....	.....
	70	80	90	100	110	120
GPCR7	.....	.....	.....	.....	.....	.....
gi 11177906	.....	.....	.....	.....	.....	.....
gi 10944516	.....	.....	.....	.....	.....	.....
gi 12054411	.....	.....	.....	.....	.....	.....
gi 12054393	.....	.....	.....	.....	.....	.....
gi 3080467	.....	.....	.....	.....	.....	.....
	130	140	150	160	170	180
GPCR7	.....	.....	.....	.....	.....	.....
gi 11177906	.....	.....	.....	.....	.....	.....
gi 10944516	.....	.....	.....	.....	.....	.....
gi 12054411	.....	.....	.....	.....	.....	.....
gi 12054393	.....	.....	.....	.....	.....	.....
gi 3080467	.....	.....	.....	.....	.....	.....
	190	200	210	220	230	240
GPCR7	.....	.....	.....	.....	.....	.....
gi 11177906	.....	.....	.....	.....	.....	.....
gi 10944516	.....	.....	.....	.....	.....	.....
gi 12054411	.....	.....	.....	.....	.....	.....
gi 12054393	.....	.....	.....	.....	.....	.....
gi 3080467	.....	.....	.....	.....	.....	.....
	250	260	270	280	290	300
GPCR7	.....	.....	.....	.....	.....	.....
gi 11177906	.....	.....	.....	.....	.....	.....
gi 10944516	.....	.....	.....	.....	.....	.....
gi 12054411	.....	.....	.....	.....	.....	.....
gi 12054393	.....	.....	.....	.....	.....	.....
gi 3080467	.....	.....	.....	.....	.....	.....
	310	320	330	340	350	
GPCR7	.....	.....	.....	.....	.....	
gi 11177906	.....	.....	.....	.....	.....	
gi 10944516	.....	.....	.....	.....	.....	
gi 12054411	.....	.....	.....	.....	.....	
gi 12054393	.....	.....	.....	.....	.....	
gi 3080467	.....	.....	.....	.....	.....	

The presence of identifiable domains in GPCR7 was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>).

DOMAIN results for GPCR7 were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST. This BLAST samples domains found in the Smart and Pfam collections. The results are listed in Table 7E with the statistics and domain description. The results indicate that this protein contains the following protein domains (as defined by Interpro) at the indicated positions: domain name 7tm\_1 (InterPro) 7 transmembrane receptor (rhodopsin family). Residues 61-142 of 7tm\_1 (SEQ ID NO:45) are aligned with GPCR7 41-180 ( $E = 5e-18$ ) in Table 7E. Residues 307-377 of 7tm\_1 also have identity with residues 222-291 ( $E=0.001$ ) of GPCR7. This indicates that the sequence of GPCR7 has properties similar to those of other proteins known to contain this/these domain(s) and similar to the properties of these domains.

**Table 7E. DOMAIN results for GPCR7**

gnl|Pfam|pfam00001, 7tm\_1, 7 transmembrane receptor (rhodopsin family) Length = 377 (SEQ ID NO:45).

Score = 85.1 bits (209), Expect = 5e-18

GPCR7  
TM7

GPCR7  
TM7

GPCR7  
TM7

The similarity information for the GPCR7 protein and nucleic acid disclosed herein suggest that GPCR7 may have important structural and/or physiological functions characteristic of the Olfactory Receptor family and the GPCR family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue

regeneration in vitro and in vivo (vi) biological defense weapon. The novel nucleic acid encoding GPCR7, and the GPCR7 protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

5           The nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in used in the treatment of infections such as bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, 10 hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and treatment of Albright hereditary osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette 15 syndrome and/or other pathologies and disorders.

          The disclosed GPCR7 polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding the GPCR-like protein may be useful in gene therapy, and the GPCR-like protein may be useful when administered to 20 a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, 25 hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and treatment of Albright hereditary osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette 30 syndrome and/or other pathologies and disorders. The novel nucleic acid encoding GPCR-like protein, and the GPCR-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or

diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-GPCR Antibodies" section below.

## GPCR8

5 A novel nucleic acid was identified on chromosome 6 by TblastN using CuraGen Corporation's sequence file for GPCR probes or homologs and , run against the Genomic Daily Files made available by GenBank. The nucleic acid was further predicted by the program GenScan™, including selection of exons. These were further modified by means of similarities using BLAST searches. The sequences were then manually corrected for apparent  
10 inconsistencies, thereby obtaining the sequences encoding the full-length protein. The disclosed novel GPCR8 nucleic acid of 958 nucleotides (also referred to as dj408b20\_A) is shown in Table 8A. An open reading begins with an ATG initiation codon at nucleotides 4-6 and ends with a TGA codon at nucleotides 955-957. A putative untranslated region upstream from the initiation codon and downstream from the termination codon are underlined in Table  
15 8A, and the start and stop codons are in bold letters.

**Table 8A. GPCR8 Nucleotide Sequence (SEQ ID NO:30)**

```
GCAATGGAAAAATCCAATGTCAGCTCAGTGTATGGTTTATCTTGGTGGGTTTCTCTGATCGTCCCAAGCTG
GAGATGGTGTCTTTACAGTAAATTTTATTCTGTATTCACTGGCTGTGCTGGGAAATTCAACCATATCC
TTGTGTGTATATTAGACTCTCAACTTCATACCCCAATGTAATTCTTTCTGGCAAATCTTTCCTTCTAGA
TCTCTGCTTCAGTACTAGTTGCATCCCAAAATGCTGGTAAACCTCTGGGGCCCTGACAAGACTATTAGC
TGTGCTGGCTGTGTGTCAGCTTTTCTCTTCCCTTCTGTGAGGGGAATTGAGTGCATCCTTCTGGCTG
TCATGGCCTATGACAGCTATGCTGCAGTCTGCAAACCGTTGCGCTATCTGGTCATTATGCACCTCCAGCT
GTGCTAGGACTGATGGCTGCAGCCTGGGGGAGTGGACTGGTCAATGCCGTTGTCATGTCACCACTAACA
ATGACCCTCTCCAGAAGTGGCCGCCGCCGAGTTAACCATTTCCTCTGTGAAAAGCCAGCACTGATCAAGA
TGGCTTGTGGATGTTGCTGTCAGTGGAAATGCTGGCTTTTGCTTTTGCCGTTCTCATTGTCTACTGCC
CCTCACTCTTATTCTTGTCTCCTACGGCTACATTGCTGCAGCTGTGCTAAGCATCAAGTCAGCTGCCAGG
CAATGGAAGGCCTTCCATACCTGTAGCTCTCACCTCACAGTGGTCTCCCTGTTTATGGGAGCATCATCT
ATATGTATATGCAGCCAGGAAACAGTTCTTCCCAAGACCAAGGCAAGTTTCTCACTCTCTTCTACAACCT
GGTGACTCCTATGTTGAATCTGCTCATCTATACTTTAAGGAATAAGGAGGTGAAAGGAGCACTGAAGAAG
GTTTTGGGGAGGCAAAATGAACTGGAGAAATATGATAAGTTGTGAA
```

The disclosed nucleic acid sequence has 768 of 1148 bases (66%) identical to a *Homo sapiens* OR-like (gb:GENBANK-ID:HS88J8|acc:AL035402 Human DNA sequence from  
20 clone 88J8 on chromosome 6p21.31-21.33. Contains a gene for a novel 7 transmembrane receptor (rhodopsin family) (olfactory receptor like) protein, pseudogene similar to olfactory receptor genes and a GTP binding protein SARA (mouse) pseudogene. Contains ESTs, an STS and GSS, complete sequence - *Homo sapiens*, 47216 bp.) (E value = 1.3e<sup>-81</sup>).

The GPCR8 protein encoded by SEQ ID NO:30 has 317 amino acid residues, and is  
25 presented using the one-letter code in Table 8B (SEQ ID NO:31). The SignalP, Psort and/or

Hydropathy profile for GPCR8 predict that GPCR8 has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6850. The SignalP shows a signal sequence is coded for in the first 42 amino acids, *i.e.*, with a cleavage site at the slash in the sequence VLG-NS, between amino acids 41 and 42. This is typical of this type of membrane protein.

**Table 8B. Encoded GPCR8 protein sequence (SEQ ID NO:31).**

```
MEKSNVSSVYGFILVGFSRDKLEMVLFVNFIYLSVAVLG/NSTIILVCILDSQLHTPMYFFLANLSF
LDLCFSTSCIPQMLVNLWGPKDTISCAGCVVQLFSFLSVRGIECILLAVMAYDSYAAVCKPLRYLVMH
LQLCLGLMAAAWGSGLVNAVVMSPMTLSRSGRRRVNHFLCEKPALIKMACLDVRAVEMLAFAFAVLI
VLLPLTLILVSYGYIAAAVLSIKSAARQWKAFHTCSSHLTVVSLFYGSIIYMYMQPGNSSSQDQKFLT
LFYNLVTPLNLLIYTLRNKEVKGALKKVLGRQNELEKYDKL
```

The full amino acid sequence of the protein of the invention was found to have 187 of 305 amino acid residues (61%) identical to, and 239 of 305 residues (78%) positive with, the 320 amino acid residue novel transmembrane receptor (rhodopsin family, OR-like, HS6M1-15) protein from *Homo sapiens* (ptnr:SPTREMBL-ACC:Q9Y3N9) (E value =  $2.4e^{-101}$ ). Further BLAST analysis produced the significant results listed in Table 8C. The disclosed GPCR8 protein (SEQ ID NO:31) has good identity with a number of olfactory receptor proteins.

**Table 8C. BLAST results for GPCR8**

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identit y (%)	Positives (%)	Expect
Gi 4826521 emb CAC2 853.1  (AL035402, dJ88J8.1) (AJ302594-99) (AJ302600-01)	novel 7 tm receptor protein (rhodopsin fam., OR-like) (hs6M1-15) <i>Homo sapiens</i>	320	177/305 (58%)	226/305 (74%)	5e-92
Gi 12054431 emb CAC2 0523.1  (AJ302603)	OR <i>Homo sapiens</i>	320	176/305 (57%)	226/305 (73%)	1e-91
Gi 12054429 emb CAC2 0522.1  (AJ302602)	OR <i>Homo sapiens</i>	320	177/305 (58%)	225/305 (73%)	1e-91
Gi 6679170 ref NP_03 2788.1	OR 15 (OR3) <i>Mus musculus</i>	312	166/307 (54%)	211/307 (68%)	2e-81
Gi 12231029 sp Q1506 2 O2H3 HUMAN	OR 2H3 <i>Homo sapiens</i>	316	163/306 (53%)	208/306 (67%)	5e-81

This information is presented graphically in the multiple sequence alignment given in Table 8D (with GPCR8 being shown on line 1) as a ClustalW analysis comparing GPCR8 with related protein sequences.

Table 8D. Information for the ClustalW proteins:

- 1) GPCR8 (SEQ ID NO:31)
- 2) gi|4826521|emb|CAB42853.1| dJ88J8.1 (novel 7 TM receptor (rhodopsin family) (OR like) protein) (hs6M1-15)) Homo sapiens (SEQ ID NO:59)
- 3) gi|12054431|emb|CAC20523.1| olfactory receptor Homo sapiens (SEQ ID NO:60)
- 4) gi|12054429|emb|CAC20522.1| olfactory receptor Homo sapiens (SEQ ID NO:61)
- 5) gi|6679170|ref|NP\_032788.1| olfactory receptor 15 Mus musculus (SEQ ID NO:58)
- 6) gi|12231029|sp|Q15062|O2H3\_HUMAN OR 2H3 (OR-LIKE PRT FAT11) (SEQ ID NO:56)

	10	20	30	40	50	60
GPCR8	MDKSNVSSVYGFILMGFSRPRNEMVFTVNFILTSVAAGNSTIILVCLDSQLHTPMY					
gi 4826521	MDKSNVSSVYGFILMGFSRPRNEMVFTVNFILTSVAAGNSTIILVCLDSQLHTPMY					
gi 12054431	MDKSNVSSVYGFILMGFSRPRNEMVFTVNFILTSVAAGNSTIILVCLDSQLHTPMY					
gi 12054429	MDKSNVSSVYGFILMGFSRPRNEMVFTVNFILTSVAAGNSTIILVCLDSQLHTPMY					
gi 6679170	MDKSNVSSVYGFILMGFSRPRNEMVFTVNFILTSVAAGNSTIILVCLDSQLHTPMY					
gi 12231029	MDKSNVSSVYGFILMGFSRPRNEMVFTVNFILTSVAAGNSTIILVCLDSQLHTPMY					
	70	80	90	100	110	120
GPCR8	FFLNLSFLDLCSTSCIPQMLVNLWGPKDTISYVGCQOLYVVMWLGSECVLLAVMS					
gi 4826521	FFLNLSFLDLCSTSCIPQMLVNLWGPKDTISYVGCQOLYVVMWLGSECVLLAVMS					
gi 12054431	FFLNLSFLDLCSTSCIPQMLVNLWGPKDTISYVGCQOLYVVMWLGSECVLLAVMS					
gi 12054429	FFLNLSFLDLCSTSCIPQMLVNLWGPKDTISYVGCQOLYVVMWLGSECVLLAVMS					
gi 6679170	FFLNLSFLDLCSTSCIPQMLVNLWGPKDTISYVGCQOLYVVMWLGSECVLLAVMS					
gi 12231029	FFLNLSFLDLCSTSCIPQMLVNLWGPKDTISYVGCQOLYVVMWLGSECVLLAVMS					
	130	140	150	160	170	180
GPCR8	DSAAVCKPLHYFVMMNPHLCLEKMIINISISLANSVVVCTLTNLPCCNNIDHFLCE					
gi 4826521	DSAAVCKPLHYFVMMNPHLCLEKMIINISISLANSVVVCTLTNLPCCNNIDHFLCE					
gi 12054431	DSAAVCKPLHYFVMMNPHLCLEKMIINISISLANSVVVCTLTNLPCCNNIDHFLCE					
gi 12054429	DSAAVCKPLHYFVMMNPHLCLEKMIINISISLANSVVVCTLTNLPCCNNIDHFLCE					
gi 6679170	DSAAVCKPLHYFVMMNPHLCLEKMIINISISLANSVVVCTLTNLPCCNNIDHFLCE					
gi 12231029	DSAAVCKPLHYFVMMNPHLCLEKMIINISISLANSVVVCTLTNLPCCNNIDHFLCE					
	190	200	210	220	230	240
GPCR8	KPALVHACVDTITVEMSVFAGCIVLTPILILSYGYIAKAVLFTKSKASORKAMNT					
gi 4826521	KPALVHACVDTITVEMSVFAGCIVLTPILILSYGYIAKAVLFTKSKASORKAMNT					
gi 12054431	KPALVHACVDTITVEMSVFAGCIVLTPILILSYGYIAKAVLFTKSKASORKAMNT					
gi 12054429	KPALVHACVDTITVEMSVFAGCIVLTPILILSYGYIAKAVLFTKSKASORKAMNT					
gi 6679170	KPALVHACVDTITVEMSVFAGCIVLTPILILSYGYIAKAVLFTKSKASORKAMNT					
gi 12231029	KPALVHACVDTITVEMSVFAGCIVLTPILILSYGYIAKAVLFTKSKASORKAMNT					
	250	260	270	280	290	300
GPCR8	CGSHLTVVSIFYGIIYMYLQPGNRSSQDGKFLTLEYVITPSLNPLIYTLRNHMDA					
gi 4826521	CGSHLTVVSIFYGIIYMYLQPGNRSSQDGKFLTLEYVITPSLNPLIYTLRNHMDA					
gi 12054431	CGSHLTVVSIFYGIIYMYLQPGNRSSQDGKFLTLEYVITPSLNPLIYTLRNHMDA					
gi 12054429	CGSHLTVVSIFYGIIYMYLQPGNRSSQDGKFLTLEYVITPSLNPLIYTLRNHMDA					
gi 6679170	CGSHLTVVSIFYGIIYMYLQPGNRSSQDGKFLTLEYVITPSLNPLIYTLRNHMDA					
gi 12231029	CGSHLTVVSIFYGIIYMYLQPGNRSSQDGKFLTLEYVITPSLNPLIYTLRNHMDA					
	310	320				
GPCR8	LKKLVGRNHELESDRL---					
gi 4826521	LKKLVGRNHELESDRL---					
gi 12054431	LKKLVGRNHELESDRL---					
gi 12054429	LKKLVGRNHELESDRL---					
gi 6679170	LKKLVGRNHELESDRL---					
gi 12231029	LKKLVGRNHELESDRL---					

The presence of identifiable domains in GPCR8 was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>).



DOMAIN results for GPCR8 were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST. This BLAST samples domains found in the Smart and Pfam collections. The results are listed in Table 8E with the statistics and domain description. The results indicate that GPCR8 contains the 7tm\_1 (InterPro) 7 transmembrane receptor (rhodopsin family) domain (as defined by Interpro) at amino acid positions residues 41-170. This indicates that the sequence of GPCR8 has properties similar to those of other proteins known to contain this/these domain(s) and similar to the properties of these domains.

Table 8E. DOMAIN results for GPCR8	
gnl Pfam pfam00001, 7tm_1, 7 transmembrane receptor (rhodopsin family) Length = 377 (SEQ ID NO:45). Score = 85.9 bits (211), Expect = 3e-18	
GPCR8 TM7	<pre> GNSTIIVVCILSSQHHIPMYEFAALSLFLDLCSFISCHIQZVNLWGPFRTISCAGGVQ GNVLYCHAVSREKACQITTNELLEVLEAVADLLVAILVMFWVYLEVVGWKEFRIHDDF </pre>
GPCR8 TM7	<pre> EFSFSSRGIECHLAVMYDSVAVCKPRLVIM-HLGLCLGIVAAAGSGLVNVVN MTLDMMCTASINICAEISIRYITAVAMPDLINTRYSSKERVTVMAIVVLSFTISCP </pre>
GPCR8 TM7	<pre> SPL-TMILSRSG----- LFGLNNDQNE-----CIANP-----AFVVYSSIVSFYV---PFIIVTLVYI </pre>

The similarity information for the GPCR8 protein and nucleic acid disclosed herein suggest that GPCR8 may have important structural and/or physiological functions characteristic of the Olfactory Receptor family and the GPCR family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon. The novel nucleic acid encoding GPCR8, and the GPCR8 protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

The disclosed GPCR8 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer; immune response; AIDS; asthma; Crohn's disease; multiple sclerosis; and

treatment of Albright hereditary osteodystrophy and/or other pathologies and disorders. For example, a cDNA encoding the GPCR-like protein may be useful in gene therapy, and the GPCR-like protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer; immune response; AIDS; asthma; Crohn's disease; multiple sclerosis; and treatment of Albright hereditary osteodystrophy. The novel nucleic acid encoding GPCR-like protein, and the GPCR-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immuno-specifically to the novel GPCR8 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-GPCRX Antibodies" section below.

## GPCR9

A novel nucleic acid was identified on chromosome 11 by TblastN using CuraGen Corporation's sequence file for GPCR probe or homolog, run against the Genomic Daily Files made available by GenBank. The nucleic acid was further predicted by the program GenScan™, including selection of exons. These were further modified by means of similarities using BLAST searches. The sequences were then manually corrected for apparent inconsistencies, thereby obtaining the sequences encoding the full-length protein. The disclosed novel GPCR9 nucleic acid of 946 nucleotides (also referred to as 6-L-19-B) is shown in Table 9A. An open reading begins with an ATG initiation codon at nucleotides 5-7 and ends with a TAA codon at nucleotides 932-934. A putative untranslated region upstream from the initiation codon and downstream from the termination codon are underlined in Table 9A, and the start and stop codons are in bold letters.

In a search of sequence databases, it was found, for example, that the nucleic acid sequence has 563 of 902 bases (62%) identical to ( $E = 8.5e-47$ ) a *Mus musculus* gene for odorant receptor A16 (GENBANK-ID: AB030896|acc:AB030896). In a search of sequence databases, partial matches (353 of 373 bases, 94% identical) were also identified with the nucleotides 1- 372 of GPCR9 identical with nucleotides 306-678 of a *Homo sapiens* GPCR EST (GENBANK-ID: AW182678|acc:AW182678; xj45d11.x1 Soares\_NFL\_T\_GBC\_S1 *Homo sapiens* cDNA clone IMAGE:2660181 3' similar

to TR:Q9Z1V0 Q9Z1V0 OLFACTORY RECEPTOR C6). This 94% match ( $E=1.1e-69$ ) between regions of the public sequence and regions of the present invention (gene) suggests that the present invention (gene) could be a splice variant of the public GPCR EST (partial mRNA). This also supports identification of GPCR9 as a GPCR. In a search of sequence databases, partial matches (94 of 100 bases, 94% identical) of nucleotides 893-794 of GPCR9 with nucleotides 251-348 of a *Homo sapiens* GPCR EST (GENBANK-ID: AA206680|acc:AA206680: zq51c11.r1 Stratagene neuroepithelium (#937231) *Homo sapiens* cDNA clone IMAGE:645140 5' similar to contains L1.b2 L1 repetitive element). This 94% match between nucleotides of the public sequence and nucleotides of the GPCR9 sequence suggests that GPCR9 may be a splice variant of the public GPCR EST (partial mRNA).

**Table 9A. GPCR9 Nucleotide Sequence (SEQ ID NO:32)**

```
GTTTCATGGAAATAGGAATATTGTCACTGTCTTTATTCTCTGGGACTTTCTCAAAACAAGAACATTGAA
GTTTTTTGGTTTGTATTATTGTATTGCTACATTGCTATTGGATGGAAAACCTCATCATAATGATTT
CTATCATGTACATTTGGCTAATTGACCAACCCATGTATTCTTCTTAATTACCTCGCACTCTCAGATCT
TTGCTACATATCCACTGTGGCCCCCAAGCTAATGATTGACCTACTAACAGAAAGGAAGATCGTTTCCTAT
AATAACTGCATGATACAGCTATTTATCACTCACTTCCTTGGAGACATTGAGATCTTCATACTCAAAGCAA
TGGCCTATGACCACTACATAGCCATCTGCAAGCACTGCACTACACCATCATCAGACCAAGCAAAGCTG
TAACACCATCATCATAGCTTGTGTACTGGGGGATTATACACTCTGCCAGTCAGTTCTTCTTACCATC
TTCTTACCGTTCTGTGGTCTTAATGAGATAGATCAGTACTTCTGCTATGTGTATCCTCTGCTGAAGTTGG
CTCGCATTGATATATACAGAATTGGTTTCTTGGTAATTGTTAATTCAGGCCTGATTCTTTGTTGGCTTT
TGTGATTTTGATGGTGTCTTATTATTTGATATTATCCACCATCAGGGTTTACTCTGCTGAGAGTCATACC
AAAGCTCTTTCAACCTGTAGCTCTCACATAAAGTTGTGGTCTTCTTTGTGCCCTGCCCTCTTCATTT
ACATCAGACCAGCCATAACTTTTCCAGAAGATAAAGTGTGTTCTCTCTGTGCCATCATTGCTCCCAT
GTTTCAGTCTTCTTATCTACATGCTGAGAAAGGTGGAGATGAAGAACGCTGTAAGGAAAATGTGGTGTCT
CAATTGCTTCTGGCAAGGAAGTAAGTTGTATGAAG
```

The GPCR9 protein encoded by SEQ ID NO:32 has 309 amino acid residues, and is presented using the one-letter code in Table 9B (SEQ ID NO:33). The SignalP, Psort and/or Hydropathy profile for GPCR9 predict that GPCR9 has a signal peptide and is likely to be localized at the endoplasmic reticulum membrane with a certainty of 0.6850 or to the plasma membrane with a certainty of 0.6400. The SignalP predicts a cleavage site at the sequence IWM-EN between amino acids 38 and 39 as indicated by the slash in Table 9B.

**Table 9B. Encoded GPCR9 protein sequence (SEQ ID NO:33)**

```
MENRNIVTVFILLGLSQNKNIIEVFWFLVFCYIAIWM/ENFIIMISIMYIWLIDQPMYFFLNLYLALSDLC
YISTVAPKLMIDLLTERKIVSYNNCMIQFLFTHFLGDIEIFILKAMAYDHYIAICKHLHYTIIITKQSCN
TIIACCTGGFIHSASQFLITIFLFFCGLEIDQYFCYVYPLLKLARIDIYRIGFLVIVNSGLISLLAFV
ILMVSYLILSTIRVYSAESHTKALSTCSSHIIVVVLFFVPALFIYIRPAITFPEDKVFVLFCAIAPMF
SLLIYMLRKVEMKNAVRKMWCHQLLLARK
```

The full amino acid sequence of the protein of the invention was found to have 140 of 300 amino acid residues (46%) identical to, and 193 of 300 residues (64%) positive with, the

302 amino acid residue odorant receptor A16 protein from *Mus musculus* (ptnr:TREMBLNEW-ACC:BAA86127) (E value =  $1.0e^{-72}$ ). Further BLAST analysis produced the significant results listed in Table 9C. The disclosed GPCR8 protein (SEQ ID NO:33) has good identity with a number of olfactory receptor proteins.

5

Table 9C. BLAST results for GPCR9

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
Gi 11496249 ref NP_067343.1  (AB030895)	odorant receptor MOR18 <i>Mus musculus</i>	308	140/300 (46%)	185/300 (61%)	1e-59
Gi 11464995 ref NP_065261.1  (AB030896)	odorant receptor A16 <i>Mus musculus</i>	302	137/300 (45%)	185/300 (61%)	2e-59
Gi 423702 pir  S297 10	olfactory receptor OR18 - rat	307	142/303 (46%)	186/303 (60%)	6e-57
Gi 11464993 ref NP_065260.1  (AB030894)	odorant receptor MOR83 <i>Mus musculus</i>	308	133/297 (44%)	182/297 (60%)	7e-55
Gi 10644519 gb AAG2 1324.1 AF271051_1 (AF271051)	odorant receptor <i>Mus musculus</i>	264	124/262 (47%)	169/262 (64%)	6e-51

This information is presented graphically in the multiple sequence alignment given in Table 9D (with GPCR9 being shown on line 1) as a ClustalW analysis comparing GPCR9 with related protein sequences.

10

Table 9D. Information for the ClustalW proteins:

- 1) GPCR9 (SEQ ID NO:33)
- 2) gi|11496249|ref|NP\_067343.1| odorant receptor 16 *Mus musculus* (SEQ ID NO:78)
- 3) gi|11464995|ref|NP\_065261.1| gene for odorant receptor A16 *Mus musculus* (SEQ ID NO:79)
- 4) gi|423702|pir||S29710 olfactory receptor OR18 - rat (SEQ ID NO:80)
- 5) gi|11464993|ref|NP\_065260.1| gene for odorant receptor MOR83 *Mus musculus* (SEQ ID NO:81)
- 6) gi|10644519|gb|AAG21324.1|AF271051\_1 odorant receptor *Mus musculus* (SEQ ID NO:70)

15

	10	20	30	40	50	60
GPCR9	..	..	..	..	..	..
Gi 11496249	--	..	..	..	..	..
Gi 11464995	--	..	..	..	..	..
Gi 423702	--	..	..	..	..	..
Gi 11464993	..	..	..	..	..	..
Gi 10644519	..	..	..	..	..	..
	70	80	90	100	110	120
GPCR9	..	..	..	..	..	..
Gi 11496249	..	..	..	..	..	..
Gi 11464995	..	..	..	..	..	..
Gi 423702	..	..	..	..	..	..
Gi 11464993	..	..	..	..	..	..
Gi 10644519	..	..	..	..	..	..

	130	140	150	160	170	180
GPCR9	DHYEAI	CKRLHY	TTTTR	OSCNTE	IACTGG	FHSAS
gi 11496249	DRYVAI	CKPLHY	TTTTR	HCYVL	AVWEG	GGFHS
gi 11464995	DRYVAI	CKPLHY	TTTTR	HCYVL	AVWEG	GGFHS
gi 423702	DRYVAI	CKPLHY	TTTTR	HCYVL	AVWEG	GGFHS
gi 11464993	DRYVAI	CKPLHY	TTTTR	HCYVL	AVWEG	GGFHS
gi 10644519	DRYVAI	CKPLHY	TTTTR	HCYVL	AVWEG	GGFHS
	190	200	210	220	230	240
GPCR9	YPLLE	RLARID	IVRIG	FLVH	NSG	ETSL
gi 11496249	YPLLE	RLARID	IVRIG	FLVH	NSG	ETSL
gi 11464995	YPLLE	RLARID	IVRIG	FLVH	NSG	ETSL
gi 423702	YPLLE	RLARID	IVRIG	FLVH	NSG	ETSL
gi 11464993	YPLLE	RLARID	IVRIG	FLVH	NSG	ETSL
gi 10644519	YPLLE	RLARID	IVRIG	FLVH	NSG	ETSL
	250	260	270	280	290	300
GPCR9	SSHI	EVV	LVFF	VPAL	ETIR	PDIT
gi 11496249	SSHI	EVV	LVFF	VPAL	ETIR	PDIT
gi 11464995	SSHI	EVV	LVFF	VPAL	ETIR	PDIT
gi 423702	SSHI	EVV	LVFF	VPAL	ETIR	PDIT
gi 11464993	SSHI	EVV	LVFF	VPAL	ETIR	PDIT
gi 10644519	SSHI	EVV	LVFF	VPAL	ETIR	PDIT
	310					
GPCR9	CHQ	LLARK				
gi 11496249	CHQ	LLARK				
gi 11464995	CHQ	LLARK				
gi 423702	CHQ	LLARK				
gi 11464993	CHQ	LLARK				
gi 10644519	CHQ	LLARK				

The presence of identifiable domains in GPCR9 was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>).

DOMAIN results for GPCR9 were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST. This BLAST samples domains found in the Smart and Pfam collections. The results are listed in Table 9E with the statistics and domain description. The results indicate that GPCR9 contains the 7tm\_1 (InterPro) 7 transmembrane receptor (rhodopsin family) domain (as defined by Interpro) at amino acid positions residues 56-234. This indicates that the sequence of GPCR9 has properties similar to those of other proteins known to contain this/these domain(s) and similar to the properties of these domains.

**Table 9E. DOMAIN results for GPCR9**

gnl|Pfam|pfam00001, 7tm\_1, 7 transmembrane receptor (rhodopsin family) Length = 377 (SEQ ID NO:45).

Score = 73.6 bits (179), Expect = 1e-14

GPCR9 -----PMYFFNYAESDLCYISTVASKKIDLETERKIVSYNNCMIQ  
TM7 GNVLCMAVSREKALOTTNNELVLSAVADILVAVLMPWNYYLEVGEWKESRIHDSF

GPCR9  
TM7

268THFTGDIETFLKATDYDHIIECKHEHY-11IPTKGSCNTTIIACCTGGEIHSAQ  
VTEEDVMCTASLNLCAESIDRTITAMPILYNTRYSSRRVTVMIAI VVVLSTFICCPM

GPCR9 FLL-TIFLPFCGLNEIDQYFCYVYLLKLARIDIMRGFL--VINSGLISDAFVLL  
TM7 LFGLNNTDQNE-----CIIAN-----ASVQYSSIVSFYV--PFTLTLYV

GPCR9 VSYYELSTIIVYVAFSHK  
TM7 KIIIVRRRRRVNTRSRRAFRANLKAPLKGNCNTHPEDMKLCTVIMKSNGSFPVNR

The similarity information for the GPCR9 protein and nucleic acid disclosed herein suggest that GPCR9 may have important structural and/or physiological functions characteristic of the Olfactory Receptor family and the GPCR family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon. The novel nucleic acid encoding GPCR9, and the GPCR9 protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

The nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in used in the treatment of infections such as bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and treatment of Albright hereditary osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe

mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders.

The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding the GPCR-like protein may be useful in gene therapy, and the GPCR-like protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and treatment of Albright hereditary osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders. The novel nucleic acid encoding GPCR-like protein, and the GPCR-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

These materials are further useful in the generation of antibodies that bind immunospecifically to the novel GPCR9 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-GPCR<sub>X</sub> Antibodies" section below.

## GPCR10

GPCR10 includes a family of three similar nucleic acids and three similar proteins disclosed below. The disclosed nucleic acids encode GPCR, OR-like proteins.

### GPCR10a

The disclosed novel nucleic acid was identified on chromosome 11 by TblastN using CuraGen Corporation's sequence file for GPCR probe or homolog, run against the Genomic Daily Files made available by GenBank. The nucleic acid was further predicted by the program GenScan<sup>TM</sup>, including selection of exons. These were further modified by means of similarities using BLAST searches. The sequences were then manually corrected for apparent

inconsistencies, thereby obtaining the sequences encoding the full-length protein. GPCR10a is a 948 bp long nucleic acid (also referred to as 6-L-19-A) as shown in Table 10A (SEQ ID NO:34). An ORF begins with an ATG initiation codon at nucleotides 7-9 and ends with a TAA codon at nucleotides 934-936. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 10A, and the start and stop codons are in bold letters.

**Table 10A. GPCR10a Nucleotide Sequence (SEQ ID NO:34)**

TGAGAAATGGAAATCAAACAATGTGACTGAATTCATTCTTCTGGGTCTCACAGAGAACCTGGAGCTGT  
 GGAAATATTTTCTGCTGTGTTTCTTGTGATGTATGTAGCCACAGTGTGGAAATCTACTTATTGTGGT  
 AACTATTATCACAAGTCAGAGTCTGAGGTACCTATGTATTTTCTTACCTTCTTGTCCCTTTTGGAT  
 GTCATGTTCTCATCTGTCGTTGCCCAAGGTGATTGTAGACACCTCTCCAAGAGCACTACCATCTCTC  
 TCAAAGGCTGCCTCACCCAGCTGTTTGTGGAGCATTTCTTTGGTGGTGTGGGGATCATCCTCCTCACTGT  
 GATGGCCTATGACCGCTACGTGGCCATCTGTAAGCCCTGCACTACACGATCATCATGAGTCCACGGGTG  
 TGCTGCCTAATGGTAGGAGGGGCTTGGGTGGGGGATTATGCACGCAATGATACTTCTCTTCATGT  
 ATCAAATACCTTCTGTGGTCTAATATCATAGATCACTTTATATGTGATTGTTCAGTTGTTGACACT  
 TGCTGCACGGACACCCACATCCTGGGCTCTTAGTTACCCTCAACAGTGGGATGATGTGTGTGGCCATC  
 TTCTTATCTTAATTGCGTCTACACGGTCATCCTATGCTCCCTGAAGTCTTACAGCTCTAAAGGGCGGC  
 ACAAGCCCTCTACCTGCAGCTCCACCTCACGGTGGTTGATTGTTCTTGTCCCTGTATTTCTT  
 GTACATGAGGCTGTGGTCACTCACCCATAGACAAGCAATGGCTGTGTGAGACTCAATCATCACACCC  
 ATGTTAAATCCCTTGATCTATACACTGAGGAATGCAGAGGTGAAAAGTGCATGAAGAACTCTGGATGA  
 AATGGGAGGCTTGGCTGGGAAATAACTGCAATGCTGA

The GPCR10a protein encoded by SEQ ID NO:34 has 309 amino acid residues, and is presented using the one-letter code in Table 10B (SEQ ID NO:35). The SignalP, Psort and/or Hydropathy profile for GPCR10a predict that GPCR10a has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. The SignalP predicts a cleavage site at the sequence VLE-NL, between amino acids 39 and 40, as indicated by the slash in Table 10B.

In a search of sequence databases, it was found, for example, that the nucleic acid sequence has 625 of 908 bases (68%) identical to a 909 bp *Mus musculus* gene for odorant receptor A16 mRNA (GENBANK-ID: AB030896|acc:AB030896) (E= 3.0e-75).

**Table 10B. Encoded GPCR10a protein sequence (SEQ ID NO:35).**

MENQNNVTEFILLGLTENLELWKIFSAVFLVMYVATVLE/NLLIVVTIITSQSLRSPMYFFLTFLSLLDVM  
 FSSVVAPKVI VDTLSKSTTISLKGCLTQLFEVHFFGGVGI ILLTVMAYDRYVAICKPLHYTIIMS PRVCC  
 LMVGGAWVGGFMHAMIQLLEMYQIPFCGPNII DHFICDLFQLLTACTDTHILGLLVTLN SGMMCVAIFL  
 ILIASYTVILCSLKSYSKGRHKALSTCSSHLT VVVLFVPCIFLYMRPVVTHPIDKAMAVSDSIITPML  
 NPLIYTLR NAEVKSAMKKLWMKWEALAGK

The full amino acid sequence of the protein of the invention was found to have 183 of 302 amino acid residues (60%) identical to, and 232 of 302 residues (76%) positive with, the



307 amino acid residue OR18 odorant receptor protein from *Rattus sp.* (ptnr: TREMBLNEW-ACC:G264618).

### GPCR10b

5 GPCR10a (6-L-19-A) was subjected to an exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was  
10 encountered, or, in the case of the reverse primer, until the stop codon was reached. Such suitable sequences were then employed as the forward and reverse primers in a PCR amplification based on a wide range of cDNA libraries. The resulting amplicon was gel purified, cloned and sequenced to high redundancy to provide GPCR10b, which is also referred to as 6-L-19-A1.

15 The nucleotide sequence for GPCR10b (948 bp, SEQ ID NO:36) is presented in Table 10C. The nucleotide sequence differs from GPCR10a by one nucleotide change (numbered with respect to GPCR10a) T404 >C.

**Table 10C. GPCR10b Nucleotide Sequence (SEQ ID NO:36)**

```

TGAGAAATGGAAATCAAAACAATGTGACTGAATTCATTCTTCTGGGTCTCACAGAGAACCTGGAGCTGTGGAAATATT
TTCTGCTGTGTTTCTTGTCATGTATGTAGCCACAGTGCTGGAAATCTACTTATTGTGGTAACCTATTATCACAAGTCAGA
GTCTGAGGTCACCTATGTATTTTTTCTTACCTTCTTGTCCTTTTGGATGTCATGTTCTCATCTGTCGTTGCCCAAG
GTGATTGTAGACACCTCTCCAAGAGCACTACCATCTCTCTCAAGGCTGCCTCACCAGCTGTTTGTGGAGCATTTCCTT
TGGTGGTGTGGGGATCATCCTCCTCACTGTGATGGCCTATGACCGCTACGTGGCCATCTGTAAGCCCTGCACTACACGA
TCACCATGAGTCCACGGGTGTGCTGCCAATGGTAGGAGGGGCTTGGGTGGGGGATTATGCACGCAATGATACAACTT
CTCTTCATGTATCAAAATACCCTTCTGTGGTCCCTAATATCATAGTCACTTTATATGTGATTGTTTCAGTTGTTGCACT
TGCCTGACGGACACCCACATCCTGGGCCTCTTAGTTACCCTCAACAGTGGGATGATGTGTGTGGCCATCTTCTTATCT
TAATTGCGTCCTACACGGTCATCCTATGCTCCCTGAAGTCTTACAGCTCTAAAGGGCGGCACAAAGCCCTCTCTACCTGC
AGCTCCCACTCAGGGTGGTTGATTGTTCTTTGTCCCCTGTATTTCTTGTACATGAGGCCTGTGGTCACTCACCCTCAT
AGACAAGGCAATGGCTGTGTCAGACTCAATCATCACACCATGTAAATCCCTTGATCTATACACTGAGGAATGCAGAGG
TGAAAAGTGCCATGAAGAACTCTGGATGAAATGGGAGGCTTTGGCTGGGAAATAACTGCAATGCTGA

```

20 The encoded GPCR10b protein is presented in Table 10D. The disclosed protein is 309 amino acids long and is denoted by SEQ ID NO:37. GPCR10b differs from GPCR10a by one amino acid residues: I133>T. Like GPCR10a, the Psort profile for GPCR10b predicts that this sequence has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. The most likely cleavage site for a peptide is between amino acids  
25 39 and 40, i.e., at the slash in the amino acid sequence VLE-NL (shown as a slash in Table 10D) based on the SignalP result.

**Table 10D. Encoded GPCR10b protein sequence (SEQ ID NO:37)**

```

MENQNNVTEFILLGLTENLELWKIFSAVFLVMYVATVLE/NLLIVVTIITSQSLRSPMYFFLTFLSLLD
VMFSSVVAPKVIIVDTLSKSTTISLKGCLTQLFVEHFFGGVGIILLTVMAYDRYVAICKPLHYTITMSPR
VCCLMVGGAWVGGFMHMIQLLFMYQIPFCGPNIIDHFICDLFQLLTACTDTHILGLLVTLNSGMMCV
AIFLILIASYTVILCSLSYSSKGRHKALSTCSSHLTVVVLFFVPCIFLYMRPVVTHPIDKAMAVSDSI
ITPMLNPLIYTLRNAEVKSAMKKLWMKWEALAGK

```

Table 10E presents the BLASTP results for GPCR10b.

**Table 10E. BLASTP Results for GPCR10b**

<p>Score = 999 (351.7 bits), Expect = 1.2e-100, P = 1.2e-100 Identities = 182/302 (60%), Positives = 231/302 (76%) with PIR-ID:S29710 olfactory receptor OR18 - rat</p> <p>Score = 757 (266.5 bits), Expect = 5.2e-75, P = 5.2e-75 Identities = 144/298 (48%), Positives = 200/298 (67%) with ACC:O95013 WUGSC:H_DJ0855D21.1 PROTEIN - Homo sapiens (Human), 312 aa.</p> <p>Score = 757 (266.5 bits), Expect = 5.2e-75, P = 5.2e-75 Identities = 144/298 (48%), Positives = 200/298 (67%) with ACC:O95013 WUGSC:H_DJ0855D21.1 PROTEIN - Homo sapiens (Human), 312 aa.</p> <p>Score = 667 (234.8 bits), Expect = 1.1e-64, P = 1.1e-64 Identities = 131/300 (43%), Positives = 194/300 (64%), Frame = +1 with ACC:O43749 OLFACTORY RECEPTOR - Homo sapiens (Human), 312 aa.</p>
---

5

**GPCR10c**

Another nucleotide sequence resulted when GPCR10a (6-L-19-A) was subjected to an exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such suitable sequences were then employed as the forward and reverse primers in a PCR amplification based on a wide range of cDNA libraries.

10

These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain - whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp.

15

20

In addition, sequence traces were evaluated manually and edited for corrections if appropriate. The resulting amplicon was gel purified, cloned and sequenced to high redundancy to provide the sequence reported below, which is designated as Accession Number 6-L-19-A-da1, or GPCR10c.

- 5 The nucleotide sequence for GPCR10c (943 bp, SEQ ID NO:38) is presented in Table 10F. The GPCR10c nucleotide sequence differs from GPCR10a by having six fewer nucleotides at the 5' end and two nucleotide changes: (numbered with respect to GPCR10a) G466>A and C834>T.

**Table 10F. GPCR10c Nucleotide Sequence (SEQ ID NO:38)**

```
ATGGAAATCAAACAATGTGACTGAATTCATTCTTCTGGGTCTCAGAGAACCTGGAGCTGTGGAAA
TATTTCTGCTGTGTTTCTGTGTCATGTATGTAGCCACAGTGTGGAAAATCTACTTATTGTGGTAAC
TATCACAAGTCAGAGTCTGAGGTACCTATGATTTTTTTCTTACCTTCTTGTCCCTTTTGATGTCA
TTCTCATCTGTCGTTGCCCAAGGTGATTGTAGACACCCTCTCCAAGAGCACTACCATCTCTCTCA
AGGCTGCCTCACCAGCTGTTGTGGAGCATTTCTTGGTGGTGTGGGGATCATCCTCCTCACTGTGAT
GCTCTATGACCGCTACGTGGCCATCTGTAAGCCCCCTGCATACAGATCATCATGAGTCCACGGGT
GTCGCTCTAATGGTAGGAGGGGCTTGGGTGGGGGATTATGCACACAATGATACAACCTCTCTTCA
TATCAAAATACCCTTCTGTGGTCCTAATATCATAGATCACTTTATATGTGATTTGTTTCAGTGT
TGACACTTGCCTGCACGGACACCCACATCCTGGGCCTCTTAGTTACCCTCAACAGTGGGATGAT
GTGTGTGGCCATCTTTCTTATCTTAATTGCGTCCTACACGGTCATCCTATGCTCCCTGAAGTCT
TACAGCTCTAAAGGGCGGCACAAAGCCCTCTCTACCTGCAGCTCCCACCTCACGGTGGTGTGAT
TGTCTTGTCCCCTGTATTCTTGTATCATGAGGCTGTGGTCACTCACCCTATAGACAAGGCAAT
GGCTGTGTCAGACTCAATCATTACACCCATGTTAATCCCTTGATCTATACACTGAGGAATGC
AGAGGTGAAAGTGCCATGAAGAACTCTGGATGAAATGGGAGGCTTGGCTGGGAAATAACTGCA
ATGCTGA
```

10

The coding region of GPCR10c is from nucleotide 1 to 928, giving the encoded GPCR10c protein, as presented in Table 10G. The disclosed protein is 309 amino acids long and is denoted by SEQ ID NO: 83. GPCR10c differs from GPCR10a by one amino acid residue: A154>T. Like GPCR10a, the Psort profile for GPCR5c predicts that this sequence

15 has a signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6000. The most likely cleavage site for a peptide is between amino acids 39 and 40, *i.e.*, at the slash in the amino acid sequence VLE-NL (shown as a slash in Table10G) based on the SignalP result.

**Table 10G. Encoded GPCR10c protein sequence (SEQ ID NO:83)**

```
MENQNNVTEFILLGLTENLELWKIFSAVFLVMYVATVLE/NLLIVVTIITSQSLRSPMYFFLTFLSLDVM
FSSVVPKVIQVDTLSKSTTISLKGCLTQLFVEHFFGGVGIILLTMAYDRYVAICKPLHYTIIMS
PRVCCLMVGGAWVGGFMHTMIQLLFMYQIPFCGPNIIDHFICDLFOLLTLACTDTHILGLLVTLNS
GMMCVAI FLILIASYTVILCSLKSYSKGRHKALSTCSSHLTVVVLFFVPCIFLYMRPVVTHPIDK
AMAVSDSIITPMLNPLIYTLRNAEVKSAMKKLWMKWEALAGK
```

20

Possible SNPs found for GPCR10 are listed in Table10H.

Table 10H: SNPs		
Base Position	Base Before	Base After
65	T	A(2)
120	T	Gap(2)
147	T	C(2)
234	A	G(3)
412	T	C(7)
471	G	A(2)
814	A	G(3)

The disclosed GPCR10 protein (SEQ ID NO:35) has good identity with a number of olfactory receptor proteins. The identity information used for ClustalW analysis is presented in Table 10I. Unless specifically addressed as GPCR10a GPCR10b, or GPCR10c, any reference to GPCR10 is assumed to encompass all variants. Residue differences between any GPCRX variant sequences herein are written to show the residue in the "a" variant and the residue position with respect to the "a" variant. GPCR residues in all following sequence alignments that differ between the individual GPCR variants are highlighted with a box and marked with the (o) symbol above the variant residue in all alignments herein. For example, the protein shown in line 1 of Table 10J depicts the sequence for GPCR10a, and the positions where GPCR10b or GPCR10c differs are marked with a (o) symbol and are highlighted with a box. All GPCR10 proteins have significant homology to olfactory receptor (OR) proteins:

Table 10I. BLAST results for GPCR10					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
Gi 11496249 ref NP_067343.1  (AB030895)	Odorant receptor MOR18 <i>Mus musculus</i>	308	184/306 (60%)	241/306 (78%)	6e-91
Gi 423702 pir S29710	OR OR18 - rat	307	183/302 (60%)	232/302 (76%)	2e-88
Gi 11464995 ref NP_065261.1  (AB030896)	Odorant receptor A16 <i>Mus musculus</i>	302	175/302 (57%)	232/302 (75%)	8e-86
Gi 11464993 ref NP_065260.1  (AB030894)	Odorant receptor MOR83 <i>Mus musculus</i>	308	157/297 (52%)	208/297 (69%)	3e-72
Gi 10644517 gb AAG21323.1 AF271050_1 (AF271050)	Odorant receptor <i>Rattus norvegicus</i>	264	155/260 (59%)	202/260 (77%)	2e-71

This information is presented graphically in the multiple sequence alignment given in Table 10J (with GPCR10 being shown on line 1) as a ClustalW analysis comparing GPCR10 with related protein sequences.

5

Table 10J Information for the ClustalW proteins:

- 1) GPCR10 (SEQ ID NO:35)
- 2) gi|11496249|ref|NP\_067343.1| odorant receptor 16 Mus musculus (SEQ ID NO:78)
- 3) gi|423702|pir||S29710 olfactory receptor OR18 - rat (SEQ ID NO:80)
- 4) gi|11464995|ref|NP\_065261.1| gene for odorant receptor A16 Mus musculus (SEQ ID NO:79)
- 5) gi|11464993|ref|NP\_065260.1| gene for odorant receptor MOR83 Mus musculus (SEQ ID NO:81)
- 6) gi|10644517|gb|AAG21323.1|AF271050\_1 odorant receptor Rattus norvegicus (SEQ ID NO:82)

10

	10	20	30	40	50	60
GPCR10	MEINQ---	YTEFLLGLDENLEWKEFSALFLVM	EAIVENELIVVT	ELITSQSLRSPMY		
gi 11496249	MEIPHH---	YTEFLLGLSORPEHQRLLFVFLV	IAVTVCGNMLIVVT	VFSSGLASPMY		
gi 423702	MGNNH---	YTEFLLGLSEPDGRALFVFF	YVYLMGNELIVVT	VIAFSLGSPMY		
gi 11464995	MDSPRH---	YTEFLLGLSONPOVORMLFGL	FLVEEUSVCGNMLI	ELITFSPGLGSPMY		
gi 11464993	MGALQTRV	YTEFLLGLIDWVHEIFVFP	ETVYMETLGNELIVVT	IVETPRHNP		
gi 10644517	-----	YCFVEFLPYEAIVLSNGLIVVT	UNISKSYSPMY			
	70	80	90	100	110	120
GPCR10	FFLFLSLDVMSSVAPRMIVDTL	SKSTTISLKGCLTOLFVERHF	FCGVGHI	LLTVMAY		
gi 11496249	FFLSNLSFIDTCSSSSAPKELADSL	YEGTTSYEGGCAOLEGAHFL	GGVEI	LLTVMAY		
gi 423702	FFLASLSLDAISAAESPKELADLL	YDRTISFRACKSOLIEH	FGGVV	LLVMAY		
gi 11464995	FFLSYLSFIDTCYSSCTPKELADSL	HEGRAISEEGCAQOFFVAHLL	CGTEI	LLTVMAY		
gi 11464993	FFLSNLSFIDTCSSSVTPKHEGL	LLERKTISDNCAOLEFLIL	FACSEI	FLLTVMAY		
gi 10644517	FFLSYLSLVEILSSSTVPRF	ITDLERKIKTISLKGCL	EAOLF	FFHFGVTEI	LLTVMAY	
	130	140	150	160	170	180
GPCR10	DRYVAICKPLHYTIT	SPRVCLVGGAWVGGF	HSNLLFLFY	PF	CGPNHIDHFC	
gi 11496249	DRYVAICKPLHYTTT	SPHCVLVAVAWGGF	HSNVOHL	PF	CGPNV	IDHFC
gi 423702	DRYVAICKPLHYLA	SNRVCTELIFAWTGGF	HSNCHVEVYNL	PF	CGPNVIDHFC	
gi 11464995	DRYVAICKPLHYTTT	SRHVCVLVAVAWGGI	HSNDAHFFV	LP	CGPNVIDHFC	
gi 11464993	DRYVAICIP	PLHYNNMMKVCCQV	FALWGGT	HSNCTFT	ITSL	CGPNHIDSMFC
gi 10644517	DRYVAICKPLHYTTT	SPPECHRLVAGEWVGGF	HSNLLPFP	TIPL	PF	CGPNHIDHFC
	190	200	210	220	230	240
GPCR10	LPFLFLACTDTT	HEGLLVNSGVVCAFL	ELFESYIVILCSL	KSYSS	SGRHNALSTC	
gi 11496249	LYPLLELACTNTY	IGLLVANSVGCN	FLMLANSYIVIL	SLRSHSAEGR	RRKALSTC	
gi 423702	YSPLLVACTDTY	ETGLVANGGVN	CVITLLEGSYGHIL	SLRSHSAEGR	RRKALSTC	
gi 11464995	LYPLLELACTDTY	IGLLVANSVGCN	FLMLANSYIVIL	SLRSHSAEGR	RRKALSTC	
gi 11464993	LPFLFLACTDTT	ITGLVNSGTS	ESVCFALNTSYIVIL	SLPKSAEGR	RRKALSTC	
gi 10644517	LPFLFLACTDT	ETVGVVNFVNSG	HSXSFPELXV	ESYIVILYNL	RSHSAEGR	RRKALSTC
	250	260	270	280	290	300
GPCR10	SSHLTVVVF	FFVPCIF	ETRRPVVTHPT	DSAMAVSDS	ITPMLNPLIYTLR	NAEVSAMAK
gi 11496249	GAHFTVVT	FFVPCIF	SYMRPSTLPL	DKNAVEFYGI	ITPMLNPLIYTLR	NEEVEDAMAK
gi 423702	SSHLTVVIL	FFVPCIF	SYMRPVYNFP	IDACITVFYTH	ITPMLNPLIYTLR	NEEVSAMAK
gi 11464995	GAHFTVVAL	FFVPCIF	ETRRPSSIL	SDRIIAVEFYCI	ETPMLNPLIYTLR	NAEVSAMAK
gi 11464993	GAHFTVVT	FFVPCIF	ETRRDSSFS	IDRVISVEFYV	ITPMLNPLIYTLR	NEEVEDAMAK
gi 10644517	SSHLTVVVF	FFVPCIF	ETRRPASTYTE	DKNAVEFYV	ITPMLNPLIY	TI
	310					
GPCR10	-----	-----	-----	-----	-----	-----
gi 11496249	-----	-----	-----	-----	-----	-----
gi 423702	-----	-----	-----	-----	-----	-----
gi 11464995	-----	-----	-----	-----	-----	-----
gi 11464993	-----	-----	-----	-----	-----	-----
gi 10644517	-----	-----	-----	-----	-----	-----

The presence of identifiable domains in GPCR10 was determined by searches using algorithms such as PROSITE, Blocks, Pfam, ProDomain, Prints and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (<http://www.ebi.ac.uk/interpro/>).

5 DOMAIN results for GPCR10 were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST. This BLAST samples domains found in the Smart and Pfam collections. The results are listed in Table 10K with the statistics and domain description. The results indicate that this protein contains the following protein domains (as defined by Interpro) at the indicated positions: domain name 7tm\_1 (InterPro) 7  
10 transmembrane receptor (rhodopsin family) at amino acid positions 39 to 213. This indicates that the sequence of GPCR10 has properties similar to those of other proteins known to contain this domain and similar to the properties of this domain.

[illegible]

The similarity information for the GPCR10 protein and nucleic acid disclosed herein suggest that GPCR10 may have important structural and/or physiological functions characteristic of the Olfactory Receptor family and the GPCR family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue

regeneration in vitro and in vivo (vi) biological defense weapon. The novel nucleic acid encoding GPCR10, and the GPCR10 protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.

5           The nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in used in the treatment of infections such as bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, 10 hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and treatment of Albright hereditary osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette 15 syndrome and/or other pathologies and disorders. The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding the GPCR-like protein may be useful in gene therapy, and the GPCR-like protein may be useful when administered to a subject in need thereof. By way of nonlimiting 20 example, the compositions of the present invention will have efficacy for treatment of patients suffering from bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; 25 multiple sclerosis; and treatment of Albright hereditary osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders. These materials are further 30 useful in the generation of antibodies that bind immuno-specifically to the novel GPCR10 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-GPCR<sub>X</sub> Antibodies" section below.

A summary of the GPCR<sub>X</sub> nucleic acids and proteins of the invention is provided in Table 11.

**TABLE 11: Summary Of Nucleic Acids And Proteins Of The Invention**

Name	Tables	Clone; Description of Homolog	Nucleic Acid SEQ ID NO	Amino Acid SEQ ID NO
GPCR1	1A, 1B, 1D, 1E, 1G, 1H	GPCR1a: ba113a10_B, olfactory receptor	1	2
		GPCR1b: ba32713_A, olfactory receptor	3	4
		GPCR1c: ba113a10_C, olfactory receptor	5	6
GPCR2	2A, 2B	GPCR2: 11612531_1, olfactory receptor	7	8
GPCR3	3A, 3B	GPCR3: ba145L22_B, olfactory receptor	9	10
GPCR4	4A, 4B, 4C, 4G, 4H	GPCR4a1: dj408b20_C, olfactory receptor	11	12
		GPCR4a2: dj408b20_C_da1, olfactory receptor	13	17
		GPCR4a3: CG55358_03, olfactory receptor	16	
GPCR5	5A, 5B, 5C, 5D 5G, 5H	GPCR5a1: 115-a-12-A, olfactory receptor	18	19
		GPCR5a2: 115-a-12-B, olfactory receptor	20	21
		GPCR5a3: 115-a-12-A_da1, olfactory receptor	22	23
GPCR6	6A, 6B	GPCR6: 6-L-19-C, olfactory receptor	24	25
GPCR7	7A, 7B	GPCR7: dj313i6_D olfactory receptor	28	29
GPCR8	8A, 8B	GPCR8: dj408b20_A, olfactory receptor	30	31
GPCR9	9A, 9B	GPCR9: 6-L-19-B, olfactory receptor	32	33
GPCR10	10A, 10B, 10C, 10D, 10F, 10G	GPCR10a: 6-L-19-A, olfactory receptor	34	35
		GPCR10b: 6-L-19-A1, olfactory receptor	36	37
		GPCR10c: 6-L-19-A_da1, olfactory receptor	38	83

## 5 GPCR<sub>X</sub> Nucleic Acids and Polypeptides

One aspect of the invention pertains to isolated nucleic acid molecules that encode GPCR<sub>X</sub> polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify GPCR<sub>X</sub>-encoding nucleic acids (*e.g.*, GPCR<sub>X</sub> mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of GPCR<sub>X</sub> nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

An GPCR<sub>X</sub> nucleic acid can encode a mature GPCR<sub>X</sub> polypeptide. As used herein, a “mature” form of a polypeptide or protein disclosed in the present invention is the product of a



naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product

5 "mature" form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps as they may take place within the cell, or host cell, in which the gene product arises. Examples of such processing steps leading to a "mature" form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader

10 sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to

15 residue N remaining. Further as used herein, a "mature" form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

20 The term "probes", as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as approximately, *e.g.*, 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and

25 much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

The term "isolated" nucleic acid molecule, as utilized herein, is one, which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid.

30 Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated GPCR<sub>X</sub> nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule

in genomic DNA of the cell/tissue from which the nucleic acid is derived (*e.g.*, brain, heart, liver, spleen, etc.). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38 as a hybridization probe, GPCR<sub>X</sub> molecules can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook, *et al.*, (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2<sup>nd</sup> Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to GPCR<sub>X</sub> nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.

In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID

NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, or a portion of this nucleotide sequence (*e.g.*, a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of an GPCR<sub>X</sub> polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, is one that is sufficiently complementary to the nucleotide sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, thereby forming a stable duplex.

As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence.

Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.

Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or

proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. See *e.g.* Ausubel, *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of GPCR<sub>X</sub> polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for an GPCR<sub>X</sub> polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, *e.g.*, frog, mouse, rat, rabbit, dog, cat, cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human GPCR<sub>X</sub> protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, as well as a polypeptide possessing GPCR<sub>X</sub> biological activity. Various biological activities of the GPCR<sub>X</sub> proteins are described below.

An GPCR<sub>X</sub> polypeptide is encoded by the open reading frame ("ORF") of an GPCR<sub>X</sub> nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a *bona fide* cellular protein, a minimum size requirement is often set, *e.g.*, a stretch of DNA that would encode a protein of 50 amino acids or more.

The nucleotide sequences determined from the cloning of the human GPCR<sub>X</sub> genes allows for the generation of probes and primers designed for use in identifying and/or cloning

GPCRX homologues in other cell types, *e.g.* from other tissues, as well as GPCR<sub>X</sub> homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38; or an anti-sense strand nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38; or of a naturally occurring mutant of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38.

Probes based on the human GPCR<sub>X</sub> nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, *e.g.* the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express an GPCR<sub>X</sub> protein, such as by measuring a level of an GPCR<sub>X</sub>-encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting GPCR<sub>X</sub> mRNA levels or determining whether a genomic GPCR<sub>X</sub> gene has been mutated or deleted.

"A polypeptide having a biologically-active portion of an GPCR<sub>X</sub> polypeptide" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically-active portion of GPCR<sub>X</sub>" can be prepared by isolating a portion SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38 that encodes a polypeptide having an GPCR<sub>X</sub> biological activity (the biological activities of the GPCR<sub>X</sub> proteins are described below), expressing the encoded portion of GPCR<sub>X</sub> protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of GPCR<sub>X</sub>.

#### GPCR<sub>X</sub> Nucleic Acid and Polypeptide Variants

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38 due to degeneracy of the genetic code and thus encode the same GPCR<sub>X</sub> proteins as that encoded by the nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino

acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 33.

In addition to the human GPCR<sub>X</sub> nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38 it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the GPCR<sub>X</sub> polypeptides may exist within a population (*e.g.*, the human population). Such genetic polymorphism in the GPCR<sub>X</sub> genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame (ORF) encoding an GPCR<sub>X</sub> protein, preferably a vertebrate GPCR<sub>X</sub> protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the GPCR<sub>X</sub> genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the GPCR<sub>X</sub> polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the GPCR<sub>X</sub> polypeptides, are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding GPCR<sub>X</sub> proteins from other species, and thus that have a nucleotide sequence that differs from the human sequence SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38 are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the GPCR<sub>X</sub> cDNAs of the invention can be isolated based on their homology to the human GPCR<sub>X</sub> nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (*i.e.*, nucleic acids encoding GPCR<sub>X</sub> proteins derived from species other than human) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or

high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength and pH. The T<sub>m</sub> is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at T<sub>m</sub>, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (*e.g.*, 10 nt to 50 nt) and at least about 60°C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38 or fragments, analogs or derivatives thereof, under

conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well-known within the art. See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38 or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. *Proc Natl Acad Sci USA* 78: 6789-6792.

### Conservative Mutations

In addition to naturally-occurring allelic variants of GPCR<sub>X</sub> sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38 thereby leading to changes in the amino acid sequences of the encoded GPCR<sub>X</sub> proteins, without altering the functional ability of said GPCR<sub>X</sub> proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequences of the GPCR<sub>X</sub> proteins without altering their biological activity, whereas an "essential" amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the GPCR<sub>X</sub> proteins of the invention



are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

Another aspect of the invention pertains to nucleic acid molecules encoding GPCR<sub>X</sub> proteins that contain changes in amino acid residues that are not essential for activity. Such GPCR<sub>X</sub> proteins differ in amino acid sequence from SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83; more preferably at least about 70% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83; still more preferably at least about 80% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83; even more preferably at least about 90% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83; and most preferably at least about 95% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83.

An isolated nucleic acid molecule encoding an GPCR<sub>X</sub> protein homologous to the protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38 such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced into SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and

aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the GPCR<sub>X</sub> protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an GPCR<sub>X</sub> coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for GPCR<sub>X</sub> biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved "strong" residues or fully conserved "weak" residues. The "strong" group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the "weak" group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, VLIM, HFY, wherein the letters within each group represent the single letter amino acid code.

In one embodiment, a mutant GPCR<sub>X</sub> protein can be assayed for (i) the ability to form protein:protein interactions with other GPCR<sub>X</sub> proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant GPCR<sub>X</sub> protein and an GPCR<sub>X</sub> ligand; or (iii) the ability of a mutant GPCR<sub>X</sub> protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).

In yet another embodiment, a mutant GPCR<sub>X</sub> protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).

#### **Antisense Nucleic Acids**

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire GPCR<sub>X</sub> coding strand, or to only a portion thereof. Nucleic acid molecules

encoding fragments, homologs, derivatives and analogs of an GPCR<sub>X</sub> protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, or antisense nucleic acids complementary to an GPCR<sub>X</sub> nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, are additionally provided.

5 In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an GPCR<sub>X</sub> protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence  
10 encoding the GPCR<sub>X</sub> protein. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding the GPCR<sub>X</sub> protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and  
15 Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of GPCR<sub>X</sub> mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of GPCR<sub>X</sub> mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of GPCR<sub>X</sub> mRNA. An antisense oligonucleotide can be, for example,  
20 about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or  
25 to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (*e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used).

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-  
30 2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil,

2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an GPCR protein to thereby inhibit expression of the protein (*e.g.*, by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (*e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other. See, *e.g.*, Gaultier, *et al.*, 1987. *Nucl. Acids Res.* 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (see, *e.g.*, Inoue, *et al.* 1987. *Nucl. Acids Res.* 15: 6131-6148) or a chimeric RNA-DNA analogue (see, *e.g.*, Inoue, *et al.*, 1987. *FEBS Lett.* 215: 327-330).

### Ribozymes and PNA Moieties

Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. *Nature* 334: 585-591) can be used to catalytically cleave GPCR<sub>X</sub> mRNA transcripts to thereby inhibit translation of GPCR<sub>X</sub> mRNA. A ribozyme having specificity for an GPCR<sub>X</sub>-encoding nucleic acid can be designed based upon the nucleotide sequence of an GPCR<sub>X</sub> cDNA disclosed herein (i.e., SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an GPCR<sub>X</sub>-encoding mRNA. See, e.g., U.S. Patent 4,987,071 to Cech, *et al.* and U.S. Patent 5,116,742 to Cech, *et al.* GPCR<sub>X</sub> mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel *et al.*, (1993) *Science* 261:1411-1418.

Alternatively, GPCR<sub>X</sub> gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the GPCR<sub>X</sub> nucleic acid (e.g., the GPCR<sub>X</sub> promoter and/or enhancers) to form triple helical structures that prevent transcription of the GPCR<sub>X</sub> gene in target cells. See, e.g., Helene, 1991. *Anticancer Drug Des.* 6: 569-84; Helene, *et al.* 1992. *Ann. N.Y. Acad. Sci.* 660: 27-36; Maher, 1992. *Bioassays* 14: 807-15.

In various embodiments, the GPCR<sub>X</sub> nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, *et al.*, 1996. *Bioorg Med Chem* 4: 5-23. As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using

standard solid phase peptide synthesis protocols as described in Hyrup, *et al.*, 1996. *supra*; Perry-O'Keefe, *et al.*, 1996. *Proc. Natl. Acad. Sci. USA* 93: 14670-14675.

PNAs of GPCR<sub>X</sub> can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication. PNAs of GPCR<sub>X</sub> can also be used, for example, in the analysis of single base pair mutations in a gene (*e.g.*, PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, *e.g.*, S<sub>1</sub> nucleases (*see*, Hyrup, *et al.*, 1996. *supra*); or as probes or primers for DNA sequence and hybridization (*see*, Hyrup, *et al.*, 1996, *supra*; Perry-O'Keefe, *et al.*, 1996. *supra*).

In another embodiment, PNAs of GPCR<sub>X</sub> can be modified, *e.g.*, to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of GPCR<sub>X</sub> can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (*e.g.*, RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (*see*, Hyrup, *et al.*, 1996. *supra*).

The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, *et al.*, 1996. *supra* and Finn, *et al.*, 1996. *Nucl Acids Res* 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA. *See, e.g.*, Mag, *et al.*, 1989. *Nucl Acid Res* 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. *See, e.g.*, Finn, *et al.*, 1996. *supra*. Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. *See, e.g.*, Petersen, *et al.*, 1975. *Bioorg. Med. Chem. Lett.* 5: 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (*see, e.g.*, Letsinger, *et al.*, 1989. *Proc. Natl. Acad. Sci. U.S.A.* 86: 6553-6556; Lemaitre, *et al.*, 1987. *Proc. Natl. Acad. Sci.* 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (*see, e.g.*, PCT Publication No. WO'89/10134). In

addition, oligonucleotides can be modified with hybridization triggered cleavage agents (*see, e.g., Krol, et al., 1988. BioTechniques 6:958-976*) or intercalating agents (*see, e.g., Zon, 1988. Pharm. Res. 5: 539-549*). To this end, the oligonucleotide may be conjugated to another molecule, *e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.*

### GPCRX Polypeptides

A polypeptide according to the invention includes a polypeptide including the amino acid sequence of GPCR<sub>X</sub> polypeptides whose sequences are provided in SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83 while still encoding a protein that maintains its GPCR<sub>X</sub> activities and physiological functions, or a functional fragment thereof.

In general, an GPCR<sub>X</sub> variant that preserves GPCR<sub>X</sub>-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated GPCR<sub>X</sub> proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-GPCR<sub>X</sub> antibodies. In one embodiment, native GPCR<sub>X</sub> proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, GPCR<sub>X</sub> proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, an GPCR<sub>X</sub> protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the GPCR<sub>X</sub> protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of GPCR<sub>X</sub> proteins in which the protein is

separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of GPCR<sub>X</sub> proteins having less than about 30% (by dry weight) of non-GPCR<sub>X</sub> proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-GPCR<sub>X</sub> proteins, still more preferably less than about 10% of non-GPCR<sub>X</sub> proteins, and most preferably less than about 5% of non-GPCR<sub>X</sub> proteins. When the GPCR<sub>X</sub> protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the GPCR<sub>X</sub> protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of GPCR<sub>X</sub> proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of GPCR<sub>X</sub> proteins having less than about 30% (by dry weight) of chemical precursors or non-GPCR<sub>X</sub> chemicals, more preferably less than about 20% chemical precursors or non-GPCR<sub>X</sub> chemicals, still more preferably less than about 10% chemical precursors or non-GPCR<sub>X</sub> chemicals, and most preferably less than about 5% chemical precursors or non-GPCR<sub>X</sub> chemicals.

Biologically-active portions of GPCR<sub>X</sub> proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the GPCR<sub>X</sub> proteins (*e.g.*, the amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83) that include fewer amino acids than the full-length GPCR<sub>X</sub> proteins, and exhibit at least one activity of an GPCR<sub>X</sub> protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the GPCR<sub>X</sub> protein. A biologically-active portion of an GPCR<sub>X</sub> protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native GPCR<sub>X</sub> protein.

In an embodiment, the GPCR<sub>X</sub> protein has an amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83. In other embodiments, the GPCR<sub>X</sub> protein is substantially homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, and retains the functional activity of the protein of SEQ ID



NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below.

Accordingly, in another embodiment, the GPCR<sub>X</sub> protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, and retains the functional activity of the GPCR<sub>X</sub> proteins of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83.

#### Determining Homology Between Two or More Sequences

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. *See*, Needleman and Wunsch, 1970. *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38.

The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*i.e.*,

the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

### Chimeric and Fusion Proteins

The invention also provides GPCR<sub>X</sub> chimeric or fusion proteins. As used herein, an GPCR<sub>X</sub> "chimeric protein" or "fusion protein" comprises an GPCR<sub>X</sub> polypeptide operatively-linked to a non-GPCR<sub>X</sub> polypeptide. An "GPCR<sub>X</sub> polypeptide" refers to a polypeptide having an amino acid sequence corresponding to an GPCR<sub>X</sub> protein (SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83), whereas a "non-GPCR<sub>X</sub> polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the GPCR<sub>X</sub> protein, *e.g.*, a protein that is different from the GPCR<sub>X</sub> protein and that is derived from the same or a different organism. Within an GPCR<sub>X</sub> fusion protein the GPCR<sub>X</sub> polypeptide can correspond to all or a portion of an GPCR<sub>X</sub> protein. In one embodiment, an GPCR<sub>X</sub> fusion protein comprises at least one biologically-active portion of an GPCR<sub>X</sub> protein. In another embodiment, an GPCR<sub>X</sub> fusion protein comprises at least two biologically-active portions of an GPCR<sub>X</sub> protein. In yet another embodiment, an GPCR<sub>X</sub> fusion protein comprises at least three biologically-active portions of an GPCR<sub>X</sub> protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the GPCR<sub>X</sub> polypeptide and the non-GPCR<sub>X</sub> polypeptide are fused in-frame with one another. The non-GPCR<sub>X</sub> polypeptide can be fused to the N-terminus or C-terminus of the GPCR<sub>X</sub> polypeptide.

In one embodiment, the fusion protein is a GST-GPCR<sub>X</sub> fusion protein in which the GPCR<sub>X</sub> sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant GPCR<sub>X</sub> polypeptides.

In another embodiment, the fusion protein is an GPCR<sub>X</sub> protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of GPCR<sub>X</sub> can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is an GPCR<sub>X</sub>-immunoglobulin fusion protein in which the GPCR<sub>X</sub> sequences are fused to sequences derived from a member of the immunoglobulin protein family. The GPCR<sub>X</sub>-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between an GPCR<sub>X</sub> ligand and an GPCR<sub>X</sub> protein on the surface of a cell, to thereby suppress GPCR<sub>X</sub>-mediated signal transduction *in vivo*. The GPCR<sub>X</sub>-immunoglobulin fusion proteins can be used to affect the bioavailability of an GPCR<sub>X</sub> cognate ligand. Inhibition of the GPCR<sub>X</sub> ligand/GPCR<sub>X</sub> interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g. promoting or inhibiting) cell survival. Moreover, the GPCR<sub>X</sub>-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-GPCR<sub>X</sub> antibodies in a subject, to purify GPCR<sub>X</sub> ligands, and in screening assays to identify molecules that inhibit the interaction of GPCR<sub>X</sub> with an GPCR<sub>X</sub> ligand.

An GPCR<sub>X</sub> chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, *et al.* (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An GPCR<sub>X</sub>-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the GPCR<sub>X</sub> protein.

### **GPCR<sub>X</sub> Agonists and Antagonists**

The invention also pertains to variants of the GPCR<sub>X</sub> proteins that function as either GPCR<sub>X</sub> agonists (*i.e.*, mimetics) or as GPCR<sub>X</sub> antagonists. Variants of the GPCR<sub>X</sub> protein can be generated by mutagenesis (e.g., discrete point mutation or truncation of the GPCR<sub>X</sub> protein). An agonist of the GPCR<sub>X</sub> protein can retain substantially the same, or a subset of,

the biological activities of the naturally occurring form of the GPCR<sub>X</sub> protein. An antagonist of the GPCR<sub>X</sub> protein can inhibit one or more of the activities of the naturally occurring form of the GPCR<sub>X</sub> protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the GPCR<sub>X</sub> protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the GPCR<sub>X</sub> proteins.

Variants of the GPCR<sub>X</sub> proteins that function as either GPCR<sub>X</sub> agonists (*i.e.*, mimetics) or as GPCR<sub>X</sub> antagonists can be identified by screening combinatorial libraries of mutants (*e.g.*, truncation mutants) of the GPCR<sub>X</sub> proteins for GPCR<sub>X</sub> protein agonist or antagonist activity. In one embodiment, a variegated library of GPCR<sub>X</sub> variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of GPCR<sub>X</sub> variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential GPCR<sub>X</sub> sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of GPCR<sub>X</sub> sequences therein. There are a variety of methods which can be used to produce libraries of potential GPCR<sub>X</sub> variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential GPCR<sub>X</sub> sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. *See, e.g.*, Narang, 1983. *Tetrahedron* 39: 3; Itakura, *et al.*, 1984. *Annu. Rev. Biochem.* 53: 323; Itakura, *et al.*, 1984. *Science* 198: 1056; Ike, *et al.*, 1983. *Nucl. Acids Res.* 11: 477.

### Polypeptide Libraries

In addition, libraries of fragments of the GPCR<sub>X</sub> protein coding sequences can be used to generate a variegated population of GPCR<sub>X</sub> fragments for screening and subsequent selection of variants of an GPCR<sub>X</sub> protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an GPCR<sub>X</sub> coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded

DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with  $S_1$  nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the GPCR $\chi$  proteins.

Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of GPCR $\chi$  proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify GPCR $\chi$  variants. See, e.g., Arkin and Yourvan, 1992. *Proc. Natl. Acad. Sci. USA* 89: 7811-7815; Delgrave, et al., 1993. *Protein Engineering* 6:327-331.

#### Anti-GPCR $\chi$ Antibodies

The invention encompasses antibodies and antibody fragments, such as  $F_{ab}$  or  $(F_{ab})_2$ , that bind immunospecifically to any of the GPCR $\chi$  polypeptides of said invention.

An isolated GPCR $\chi$  protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind to GPCR $\chi$  polypeptides using standard techniques for polyclonal and monoclonal antibody preparation. The full-length GPCR $\chi$  proteins can be used or, alternatively, the invention provides antigenic peptide fragments of GPCR $\chi$  proteins for use as immunogens. The antigenic GPCR $\chi$  peptides comprises at least 4 amino acid residues of the amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83 and encompasses an epitope of GPCR $\chi$  such that an antibody raised against the peptide forms a specific immune complex with GPCR $\chi$ .

Preferably, the antigenic peptide comprises at least 6, 8, 10, 15, 20, or 30 amino acid residues. Longer antigenic peptides are sometimes preferable over shorter antigenic peptides, depending on use and according to methods well known to someone skilled in the art.

In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of GPCR<sub>X</sub> that is located on the surface of the protein (e.g., a hydrophilic region). As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation (*see, e.g.,* Hopp and Woods, 1981. *Proc. Nat. Acad. Sci. USA* 78: 3824-3828; Kyte and Doolittle, 1982. *J. Mol. Biol.* 157: 105-142, each incorporated herein by reference in their entirety).

As disclosed herein, GPCR<sub>X</sub> protein sequences of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, or derivatives, fragments, analogs or homologs thereof, may be utilized as immunogens in the generation of antibodies that immunospecifically-bind these protein components. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically-active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site that specifically-binds (immunoreacts with) an antigen, such as GPCR<sub>X</sub>. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F<sub>ab</sub> and F<sub>(ab)<sub>2</sub></sub> fragments, and an F<sub>ab</sub> expression library. In a specific embodiment, antibodies to human GPCR<sub>X</sub> proteins are disclosed. Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies to an GPCR<sub>X</sub> protein sequence of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, or a derivative, fragment, analog or homolog thereof. Some of these proteins are discussed below.

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by injection with the native protein, or a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, recombinantly-expressed GPCR<sub>X</sub> protein or a chemically-synthesized GPCR<sub>X</sub> polypeptide. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), human adjuvants such as *Bacille Calmette-Guerin* and *Corynebacterium parvum*, or similar immunostimulatory agents. If desired, the antibody molecules directed against GPCR<sub>X</sub> can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction.

The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of GPCR<sub>X</sub>. A monoclonal antibody composition thus typically displays a single binding affinity for a particular GPCR<sub>X</sub> protein with which it immunoreacts. For preparation of monoclonal antibodies directed towards a particular GPCR<sub>X</sub> protein, or derivatives, fragments, analogs or homologs thereof, any technique that provides for the production of antibody molecules by continuous cell line culture may be utilized. Such techniques include, but are not limited to, the hybridoma technique (*see, e.g., Kohler & Milstein, 1975. Nature 256: 495-497*); the trioma technique; the human B-cell hybridoma technique (*see, e.g., Kozbor, et al., 1983. Immunol. Today 4: 72*) and the EBV hybridoma technique to produce human monoclonal antibodies (*see, e.g., Cole, et al., 1985. In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96*). Human monoclonal antibodies may be utilized in the practice of the invention and may be produced by using human hybridomas (*see, e.g., Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030*) or by transforming human B-cells with Epstein Barr Virus *in vitro* (*see, e.g., Cole, et al., 1985. In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96*). Each of the above citations is incorporated herein by reference in their entirety.

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an GPCR<sub>X</sub> protein (*see, e.g., U.S. Patent No. 4,946,778*). In addition, methods can be adapted for the construction of F<sub>ab</sub> expression libraries (*see, e.g., Huse, et al., 1989. Science 246: 1275-1281*) to allow rapid and effective identification of monoclonal F<sub>ab</sub> fragments with the desired specificity for an GPCR<sub>X</sub> protein or derivatives, fragments, analogs or homologs thereof. Non-human antibodies can be "humanized" by techniques well known in the art. *See, e.g., U.S. Patent No. 5,225,539*. Antibody fragments that contain the idiotypes to an GPCR<sub>X</sub> protein may be produced by techniques known in the art including, but not limited to: (i) an F<sub>(ab)<sub>2</sub></sub> fragment produced by pepsin digestion of an antibody molecule; (ii) an F<sub>ab</sub> fragment generated by reducing the disulfide bridges of an F<sub>(ab)<sub>2</sub></sub> fragment; (iii) an F<sub>ab</sub> fragment generated by the treatment of the antibody molecule with papain and a reducing agent; and (iv) F<sub>v</sub> fragments.

Additionally, recombinant anti-GPCR<sub>X</sub> antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in International Application

No. PCT/US86/02269; European Patent Application No. 184,187; European Patent Application No. 171,496; European Patent Application No. 173,494; PCT International Publication No. WO 86/01533; U.S. Patent No. 4,816,567; U.S. Pat. No. 5,225,539; European Patent Application No. 125,023; Better, *et al.*, 1988. *Science* 240: 1041-1043; Liu, *et al.*, 1987. *Proc. Natl. Acad. Sci. USA* 84: 3439-3443; Liu, *et al.*, 1987. *J. Immunol.* 139: 3521-3526; Sun, *et al.*, 1987. *Proc. Natl. Acad. Sci. USA* 84: 214-218; Nishimura, *et al.*, 1987. *Cancer Res.* 47: 999-1005; Wood, *et al.*, 1985. *Nature* 314: 446-449; Shaw, *et al.*, 1988. *J. Natl. Cancer Inst.* 80: 1553-1559; Morrison(1985) *Science* 229:1202-1207; Oi, *et al.* (1986) *BioTechniques* 4:214; Jones, *et al.*, 1986. *Nature* 321: 552-525; Verhoeyan, *et al.*, 1988. *Science* 239: 1534; and Beidler, *et al.*, 1988. *J. Immunol.* 141: 4053-4060. Each of the above citations are incorporated herein by reference in their entirety.

In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of an GPCR<sub>X</sub> protein is facilitated by generation of hybridomas that bind to the fragment of an GPCR<sub>X</sub> protein possessing such a domain. Thus, antibodies that are specific for a desired domain within an GPCR<sub>X</sub> protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

Anti-GPCR<sub>X</sub> antibodies may be used in methods known within the art relating to the localization and/or quantitation of an GPCR<sub>X</sub> protein (*e.g.*, for use in measuring levels of the GPCR<sub>X</sub> protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies for GPCR<sub>X</sub> proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antibody derived binding domain, are utilized as pharmacologically-active compounds (hereinafter "Therapeutics").

An anti-GPCR<sub>X</sub> antibody (*e.g.*, monoclonal antibody) can be used to isolate an GPCR<sub>X</sub> polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-GPCR<sub>X</sub> antibody can facilitate the purification of natural GPCR<sub>X</sub> polypeptide from cells and of recombinantly-produced GPCR<sub>X</sub> polypeptide expressed in host cells. Moreover, an anti-GPCR<sub>X</sub> antibody can be used to detect GPCR<sub>X</sub> protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the GPCR<sub>X</sub> protein. Anti-GPCR<sub>X</sub> antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to,



for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

### GPCRX Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an GPCR $\times$  protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the

basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., GPCR proteins, mutant forms of GPCR proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of GPCR proteins in prokaryotic or eukaryotic cells. For example, GPCR proteins can be expressed in bacterial cells such as *Escherichia coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *Escherichia coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety

subsequent fusion protein. Such enzymes, and their cognate recognition sequences, include pG<sub>Inc</sub>; Smith and Johnson, 1988. *Gene* 67: 31-40), pMAL<sup>+</sup> (New England Biolabs.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase E binding protein, or protein A, respectively, to the target recombinant

5 Example non-fusion *E. coli* expression vectors include pTrc (Amrann *et al.*, 1987, *GENE EXPRESSION TECHNOLOGY* 185, Academic Press, San Diego, Calif. (1990) 60-89).

10 One strategy for recombinant protein expression in *E. coli* is to express the protein in a host cell having a reduced capacity to proteolytically cleave the recombinant protein. See, *GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY* 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence to be inserted into an expression vector so that the individual codons are those preferentially utilized in *E. coli* (see, e.g., Wada, *et al.*, 1987, *Gene* 20: 2111-2118). Such alteration of nucleic acid sequences of the gene can be carried out by standard DNA synthesis techniques.

15 In another embodiment, a GPCR expression vector is a yeast expression vector. Examples of vectors in yeast *Saccharomyces cerevisiae* include pYepSec1 (Baldari, *et al.*, 1987, *Gene* 54: 113-123), pMFa (Kurjan and Herskowitz, 1982, *Cell* 30: 933-943), pJRY1 (1987, *Gene* 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif. (1990) 1-10).

20 Alternatively, a nucleic acid of the invention can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors for expression of proteins in cultured insect cells (e.g., SF9 cells) include pBac1 (Smith, *et al.*, 1983, *Mol. Cell. Biol.* 3: 2156-2165) and the pVL series (Luckysmith, 1989, *Virology* 170: 31-39).

25 In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian vector. Examples of mammalian expression vectors include pCDM8 (Sreter, 1987, *Gene* 329: 840) and pMT2PC (Kaufman, *et al.*, 1987, *EMBO J.* 6: 187-195). In mammalian cells, the expression vector's control functions are often provided by elements. For example, commonly used promoters are derived from polyoma virus, cytomegalovirus, and simian virus 40. For other suitable expression systems in prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of

Sambrook, *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, *et al.*, 1987. *Genes Dev.* 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. *Adv. Immunol.* 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. *EMBO J.* 8: 729-733) and immunoglobulins (Banerji, *et al.*, 1983. *Cell* 33: 729-740; Queen and Baltimore, 1983. *Cell* 33: 741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle, 1989. *Proc. Natl. Acad. Sci. USA* 86: 5473-5477), pancreas-specific promoters (Edlund, *et al.*, 1985. *Science* 230: 912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, *e.g.*, the murine hox promoters (Kessel and Gruss, 1990. *Science* 249: 374-379) and the  $\alpha$ -fetoprotein promoter (Campes and Tilghman, 1989. *Genes Dev.* 3: 537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to GPCR<sub>X</sub> mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes *see, e.g.*, Weintraub, *et al.*, "Antisense RNA as a molecular tool for genetic analysis," *Reviews-Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer

not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

5           A host cell can be any prokaryotic or eukaryotic cell. For example, GPCR<sub>X</sub> protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

          Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional  
10   transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in  
15   Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

          For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate  
20   the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding  
25   GPCR<sub>X</sub> or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

          A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) GPCR<sub>X</sub> protein. Accordingly, the invention further provides  
30   methods for producing GPCR<sub>X</sub> protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding GPCR<sub>X</sub> protein has been introduced) in a suitable medium such that GPCR<sub>X</sub> protein is produced. In another embodiment, the method further comprises isolating GPCR<sub>X</sub> protein from the medium or the host cell.

## Transgenic GPCR<sub>X</sub> Animals

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which GPCR<sub>X</sub> protein-coding sequences have been introduced.

5 Such host cells can then be used to create non-human transgenic animals in which exogenous GPCR<sub>X</sub> sequences have been introduced into their genome or homologous recombinant animals in which endogenous GPCR<sub>X</sub> sequences have been altered. Such animals are useful for studying the function and/or activity of GPCR<sub>X</sub> protein and for identifying and/or evaluating modulators of GPCR<sub>X</sub> protein activity. As used herein, a "transgenic animal" is a  
10 non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature  
15 animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous GPCR<sub>X</sub> gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell  
20 of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing GPCR<sub>X</sub>-encoding nucleic acid into the male pronuclei of a fertilized oocyte (*e.g.*, by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human GPCR<sub>X</sub> cDNA sequences of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28,  
25 30, 32, 34, 36, and 38 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human GPCR<sub>X</sub> gene, such as a mouse GPCR<sub>X</sub> gene, can be isolated based on hybridization to the human GPCR<sub>X</sub> cDNA (described further *supra*) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A  
30 tissue-specific regulatory sequence(s) can be operably-linked to the GPCR<sub>X</sub> transgene to direct expression of GPCR<sub>X</sub> protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold

Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the GPCR<sub>X</sub> transgene in its genome and/or expression of GPCR<sub>X</sub> mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to  
5 breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding GPCR<sub>X</sub> protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of an GPCR<sub>X</sub> gene into which a deletion, addition or substitution has been  
10 introduced to thereby alter, *e.g.*, functionally disrupt, the GPCR<sub>X</sub> gene. The GPCR<sub>X</sub> gene can be a human gene (*e.g.*, the cDNA of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38), but more preferably, is a non-human homologue of a human GPCR<sub>X</sub> gene. For example, a mouse homologue of human GPCR<sub>X</sub> gene of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38 can be used to construct a homologous  
15 recombination vector suitable for altering an endogenous GPCR<sub>X</sub> gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous GPCR<sub>X</sub> gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination,  
20 the endogenous GPCR<sub>X</sub> gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous GPCR<sub>X</sub> protein). In the homologous recombination vector, the altered portion of the GPCR<sub>X</sub> gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the GPCR<sub>X</sub> gene to allow for homologous recombination to occur between the exogenous  
25 GPCR<sub>X</sub> gene carried by the vector and an endogenous GPCR<sub>X</sub> gene in an embryonic stem cell. The additional flanking GPCR<sub>X</sub> nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included in the vector. *See, e.g.*, Thomas, *et al.*, 1987. *Cell* 51: 503 for a description of homologous recombination vectors. The vector is  
30 ten introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced GPCR<sub>X</sub> gene has homologously-recombined with the endogenous GPCR<sub>X</sub> gene are selected. *See, e.g.*, Li, *et al.*, 1992. *Cell* 69: 915.

The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse) to form aggregation chimeras. *See, e.g.*, Bradley, 1987. In: TERATOCARCINOMAS AND

EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. *Curr. Opin. Biotechnol.* 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, See, e.g., Lakso, et al., 1992. *Proc. Natl. Acad. Sci. USA* 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae*. See, O'Gorman, et al., 1991. *Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et al., 1997. *Nature* 385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G<sub>0</sub> phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.

### Pharmaceutical Compositions

The GPCR<sub>X</sub> nucleic acid molecules, GPCR<sub>X</sub> proteins, and anti-GPCR<sub>X</sub> antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein,



or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (*i.e.*, topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol,

propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various  
5 antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum  
10 monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (*e.g.*, an GPCR<sub>X</sub> protein or anti-GPCR<sub>X</sub> antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a  
15 sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and  
25 swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a  
30 lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For  
5 transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into  
10 ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect  
15 the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be  
20 obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

25 It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The  
30 specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (*see, e.g.,* U.S. Patent No. 5,328,470) or by stereotactic injection (*see, e.g.,* Chen, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 3054-3057).

5 The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.,* retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

10 The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

### Screening and Detection Methods

The isolated nucleic acid molecules of the invention can be used to express GPCR<sub>X</sub> protein (*e.g.,* via a recombinant expression vector in a host cell in gene therapy applications),  
15 to detect GPCR<sub>X</sub> mRNA (*e.g.,* in a biological sample) or a genetic lesion in an GPCR<sub>X</sub> gene, and to modulate GPCR<sub>X</sub> activity, as described further, below. In addition, the GPCR<sub>X</sub> proteins can be used to screen drugs or compounds that modulate the GPCR<sub>X</sub> protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of GPCR<sub>X</sub> protein or production of GPCR<sub>X</sub> protein forms that have decreased or aberrant  
20 activity compared to GPCR<sub>X</sub> wild-type protein (*e.g.,* diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-GPCR<sub>X</sub> antibodies of the invention can be used to  
25 detect and isolate GPCR<sub>X</sub> proteins and modulate GPCR<sub>X</sub> activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, *supra*.

### Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.,* candidate or test compounds or agents (*e.g.,* peptides,

peptidomimetics, small molecules or other drugs) that bind to GPCR<sub>X</sub> proteins or have a stimulatory or inhibitory effect on, e.g., GPCR<sub>X</sub> protein expression or GPCR<sub>X</sub> protein activity. The invention also includes compounds identified in the screening assays described herein.

5 In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of an GPCR<sub>X</sub> protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid  
10 phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997. *Anticancer Drug Design* 12: 145.

15 A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened  
20 with any of the assays of the invention.

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, *et al.*, 1993. *Proc. Natl. Acad. Sci. U.S.A.* 90: 6909; Erb, *et al.*, 1994. *Proc. Natl. Acad. Sci. U.S.A.* 91: 11422; Zuckermann, *et al.*, 1994. *J. Med. Chem.* 37: 2678; Cho, *et al.*, 1993. *Science* 261: 1303; Carrell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2059; Carell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2061; and Gallop, *et al.*, 1994. *J. Med. Chem.* 37: 1233.

Libraries of compounds may be presented in solution (e.g., Houghten, 1992. *Biotechniques* 13: 412-421), or on beads (Lam, 1991. *Nature* 354: 82-84), on chips (Fodor, 1993. *Nature* 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 5,233,409), plasmids (Cull, *et al.*, 1992. *Proc. Natl. Acad. Sci. USA* 89: 1865-1869) or on phage (Scott and Smith, 1990. *Science* 249: 386-390; Devlin, 1990. *Science* 249: 404-406; Cwirla, *et al.*, 1990. *Proc. Natl. Acad. Sci. U.S.A.* 87: 6378-6382; Felici, 1991. *J. Mol. Biol.* 222: 301-310; Ladner, U.S. Patent No. 5,233,409.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of GPCR<sub>X</sub> protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to an GPCR<sub>X</sub> protein determined. The cell, for example, can of mammalian origin or a yeast cell.

- 5 Determining the ability of the test compound to bind to the GPCR<sub>X</sub> protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the GPCR<sub>X</sub> protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with <sup>125</sup>I, <sup>35</sup>S, <sup>14</sup>C, or <sup>3</sup>H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. 10 Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of GPCR<sub>X</sub> 15 protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds GPCR<sub>X</sub> to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an GPCR<sub>X</sub> protein, wherein determining the ability of the test compound to interact with an GPCR<sub>X</sub> protein comprises determining the ability of the test compound to preferentially bind to 20 GPCR<sub>X</sub> protein or a biologically-active portion thereof as compared to the known compound.

- In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of GPCR<sub>X</sub> protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the GPCR<sub>X</sub> protein or 25 biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of GPCR<sub>X</sub> or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the GPCR<sub>X</sub> protein to bind to or interact with an GPCR<sub>X</sub> target molecule. As used herein, a "target molecule" is a molecule with which an GPCR<sub>X</sub> protein binds or interacts in nature, for example, a molecule on the surface of a cell 30 which expresses an GPCR<sub>X</sub> interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. An GPCR<sub>X</sub> target molecule can be a non-GPCR<sub>X</sub> molecule or an GPCR<sub>X</sub> protein or polypeptide of the invention. In one embodiment, an GPCR<sub>X</sub> target molecule is a component of a signal transduction pathway that facilitates

transduction of an extracellular signal (e.g. a signal generated by binding of a compound to a membrane-bound GPCR<sub>X</sub> molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with GPCR<sub>X</sub>.

5           Determining the ability of the GPCR<sub>X</sub> protein to bind to or interact with an GPCR<sub>X</sub> target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the GPCR<sub>X</sub> protein to bind to or interact with an GPCR<sub>X</sub> target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by  
10   detecting induction of a cellular second messenger of the target (*i.e.* intracellular Ca<sup>2+</sup>, diacylglycerol, IP<sub>3</sub>, etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising an GPCR<sub>X</sub>-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation,  
15   or cell proliferation.

          In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting an GPCR<sub>X</sub> protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the GPCR<sub>X</sub> protein or biologically-active portion thereof. Binding of the test compound to the GPCR<sub>X</sub> protein can be determined  
20   either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the GPCR<sub>X</sub> protein or biologically-active portion thereof with a known compound which binds GPCR<sub>X</sub> to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an GPCR<sub>X</sub> protein, wherein determining the ability of the test compound to interact with an GPCR<sub>X</sub>  
25   protein comprises determining the ability of the test compound to preferentially bind to GPCR<sub>X</sub> or biologically-active portion thereof as compared to the known compound.

          In still another embodiment, an assay is a cell-free assay comprising contacting GPCR<sub>X</sub> protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (*e.g.* stimulate or inhibit) the activity of the  
30   GPCR<sub>X</sub> protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of GPCR<sub>X</sub> can be accomplished, for example, by determining the ability of the GPCR<sub>X</sub> protein to bind to an GPCR<sub>X</sub> target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of GPCR<sub>X</sub> protein can

be accomplished by determining the ability of the GPCR<sub>X</sub> protein further modulate an GPCR<sub>X</sub> target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, *supra*.

In yet another embodiment, the cell-free assay comprises contacting the GPCR<sub>X</sub> protein or biologically-active portion thereof with a known compound which binds GPCR<sub>X</sub> protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an GPCR<sub>X</sub> protein, wherein determining the ability of the test compound to interact with an GPCR<sub>X</sub> protein comprises determining the ability of the GPCR<sub>X</sub> protein to preferentially bind to or modulate the activity of an GPCR<sub>X</sub> target molecule.

The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of GPCR<sub>X</sub> protein. In the case of cell-free assays comprising the membrane-bound form of GPCR<sub>X</sub> protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of GPCR<sub>X</sub> protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton<sup>®</sup> X-100, Triton<sup>®</sup> X-114, Thesit<sup>®</sup>, Isotridecypoly(ethylene glycol ether)<sub>n</sub>, N-dodecyl--N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either GPCR<sub>X</sub> protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to GPCR<sub>X</sub> protein, or interaction of GPCR<sub>X</sub> protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-GPCR<sub>X</sub> fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or GPCR<sub>X</sub> protein, and the mixture is incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are



washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, *supra*.

Alternatively, the complexes can be dissociated from the matrix, and the level of GPCR<sub>X</sub> protein binding or activity determined using standard techniques.

5           Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the GPCR<sub>X</sub> protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated GPCR<sub>X</sub> protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, 10   Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with GPCR<sub>X</sub> protein or target molecules, but which do not interfere with binding of the GPCR<sub>X</sub> protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or GPCR<sub>X</sub> protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in 15   addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the GPCR<sub>X</sub> protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the GPCR<sub>X</sub> protein or target molecule.

          In another embodiment, modulators of GPCR<sub>X</sub> protein expression are identified in a 20   method wherein a cell is contacted with a candidate compound and the expression of GPCR<sub>X</sub> mRNA or protein in the cell is determined. The level of expression of GPCR<sub>X</sub> mRNA or protein in the presence of the candidate compound is compared to the level of expression of GPCR<sub>X</sub> mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of GPCR<sub>X</sub> mRNA or protein expression 25   based upon this comparison. For example, when expression of GPCR<sub>X</sub> mRNA or protein is greater (*i.e.*, statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of GPCR<sub>X</sub> mRNA or protein expression. Alternatively, when expression of GPCR<sub>X</sub> mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, 30   the candidate compound is identified as an inhibitor of GPCR<sub>X</sub> mRNA or protein expression. The level of GPCR<sub>X</sub> mRNA or protein expression in the cells can be determined by methods described herein for detecting GPCR<sub>X</sub> mRNA or protein.

          In yet another aspect of the invention, the GPCR<sub>X</sub> proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (*see, e.g.*, U.S. Patent No. 5,283,317;

Zervos, *et al.*, 1993. *Cell* 72: 223-232; Madura, *et al.*, 1993. *J. Biol. Chem.* 268: 12046-12054; Bartel, *et al.*, 1993. *Biotechniques* 14: 920-924; Iwabuchi, *et al.*, 1993. *Oncogene* 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with GPCR<sub>X</sub> ("GPCR<sub>X</sub>-binding proteins" or "GPCR<sub>X</sub>-bp") and modulate GPCR<sub>X</sub> activity. Such GPCR<sub>X</sub>-binding proteins are also likely to be involved in the propagation of signals by the GPCR<sub>X</sub> proteins as, for example, upstream or downstream elements of the GPCR<sub>X</sub> pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for GPCR<sub>X</sub> is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming an GPCR<sub>X</sub>-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with GPCR<sub>X</sub>.

The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

### Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

### Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called

chromosome mapping. Accordingly, portions or fragments of the GPCR<sub>X</sub> sequences, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, or fragments or derivatives thereof, can be used to map the location of the GPCR<sub>X</sub> genes, respectively, on a chromosome. The mapping of the GPCR<sub>X</sub> sequences to chromosomes is an important first  
5 step in correlating these sequences with genes associated with disease.

Briefly, GPCR<sub>X</sub> genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the GPCR<sub>X</sub> sequences. Computer analysis of the GPCR<sub>X</sub> sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be  
10 used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the GPCR<sub>X</sub> sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they  
15 gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small  
20 number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, *et al.*, 1983. *Science* 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

25 PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the GPCR<sub>X</sub> sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase  
30 chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually.

The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, *et al.*, HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, *e.g.*, in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, *e.g.*, Egeland, *et al.*, 1987. *Nature*, 325: 783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the GPCR<sub>X</sub> gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

### Tissue Typing

The GPCR<sub>X</sub> sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for

identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the GPCR<sub>X</sub> sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The GPCR<sub>X</sub> sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

### **Predictive Medicine**

The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining GPCR<sub>X</sub> protein and/or nucleic acid expression as well as GPCR<sub>X</sub> activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant GPCR<sub>X</sub>

expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with GPCR<sub>X</sub> protein, nucleic acid expression or activity. For example, mutations in an GPCR<sub>X</sub> gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with GPCR<sub>X</sub> protein, nucleic acid expression, or biological activity.

Another aspect of the invention provides methods for determining GPCR<sub>X</sub> protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (*e.g.*, drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (*e.g.*, the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of GPCR<sub>X</sub> in clinical trials.

These and other agents are described in further detail in the following sections.

### Diagnostic Assays

An exemplary method for detecting the presence or absence of GPCR<sub>X</sub> in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting GPCR<sub>X</sub> protein or nucleic acid (*e.g.*, mRNA, genomic DNA) that encodes GPCR<sub>X</sub> protein such that the presence of GPCR<sub>X</sub> is detected in the biological sample. An agent for detecting GPCR<sub>X</sub> mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to GPCR<sub>X</sub> mRNA or genomic DNA.

The nucleic acid probe can be, for example, a full-length GPCR<sub>X</sub> nucleic acid, such as the nucleic acid of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to

GPCRX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

An agent for detecting GPCR<sub>X</sub> protein is an antibody capable of binding to GPCR<sub>X</sub> protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')<sub>2</sub>) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect GPCR<sub>X</sub> mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of GPCR<sub>X</sub> mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of GPCR<sub>X</sub> protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of GPCR<sub>X</sub> genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of GPCR<sub>X</sub> protein include introducing into a subject a labeled anti-GPCR<sub>X</sub> antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting GPCR<sub>X</sub> protein, mRNA, or genomic DNA, such that the presence of GPCR<sub>X</sub> protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of GPCR<sub>X</sub> protein, mRNA or genomic DNA in the control sample with the presence of GPCR<sub>X</sub> protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of GPCR<sub>X</sub> in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting GPCR<sub>X</sub> protein or mRNA in a biological sample; means for determining the amount of GPCR<sub>X</sub> in the sample; and means for comparing the amount of GPCR<sub>X</sub> in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect GPCR<sub>X</sub> protein or nucleic acid.

### Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant GPCR<sub>X</sub> expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with GPCR<sub>X</sub> protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant GPCR<sub>X</sub> expression or activity in which a test sample is obtained from a subject and GPCR<sub>X</sub> protein or nucleic acid (*e.g.*, mRNA, genomic DNA) is detected, wherein the presence of GPCR<sub>X</sub> protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant GPCR<sub>X</sub> expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant GPCR<sub>X</sub> expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant GPCR<sub>X</sub> expression or activity in which a test sample is obtained and GPCR<sub>X</sub> protein or nucleic acid is detected (*e.g.*, wherein the presence of GPCR<sub>X</sub> protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant GPCR<sub>X</sub> expression or activity).



The methods of the invention can also be used to detect genetic lesions in an GPCR<sub>X</sub> gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding an GPCR<sub>X</sub>-protein, or the misexpression of the GPCR<sub>X</sub> gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from an GPCR<sub>X</sub> gene; (ii) an addition of one or more nucleotides to an GPCR<sub>X</sub> gene; (iii) a substitution of one or more nucleotides of an GPCR<sub>X</sub> gene, (iv) a chromosomal rearrangement of an GPCR<sub>X</sub> gene; (v) an alteration in the level of a messenger RNA transcript of an GPCR<sub>X</sub> gene, (vi) aberrant modification of an GPCR<sub>X</sub> gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of an GPCR<sub>X</sub> gene, (viii) a non-wild-type level of an GPCR<sub>X</sub> protein, (ix) allelic loss of an GPCR<sub>X</sub> gene, and (x) inappropriate post-translational modification of an GPCR<sub>X</sub> protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in an GPCR<sub>X</sub> gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (*see, e.g.*, U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (*see, e.g.*, Landegran, *et al.*, 1988. *Science* 241: 1077-1080; and Nakazawa, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the GPCR<sub>X</sub>-gene (*see, Abravaya, et al.*, 1995. *Nucl. Acids Res.* 23: 675-682).

This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to an GPCR<sub>X</sub> gene under conditions such that hybridization and amplification of the GPCR<sub>X</sub> gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (*see*, Guatelli, *et al.*, 1990. *Proc. Natl. Acad. Sci. USA* 87: 1874-1878), transcriptional amplification system (*see*, Kwoh, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA* 86: 1173-1177); Q $\beta$  Replicase (*see*, Lizardi, *et al.*, 1988. *BioTechnology* 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in an GPCR $\alpha$  gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (*see, e.g.*, U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in GPCR $\alpha$  can be identified by hybridizing a sample and control nucleic acids, *e.g.*, DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. *See, e.g.*, Cronin, *et al.*, 1996. *Human Mutation* 7: 244-255; Kozal, *et al.*, 1996. *Nat. Med.* 2: 753-759. For example, genetic mutations in GPCR $\alpha$  can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, *et al.*, *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the GPCR $\alpha$  gene and detect mutations by comparing the sequence of the sample GPCR $\alpha$  with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. *Proc. Natl. Acad. Sci. USA* 74: 560 or Sanger, 1977. *Proc. Natl. Acad. Sci. USA* 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures

can be utilized when performing the diagnostic assays (see, e.g., Naeye, *et al.*, 1995. *Biotechniques* 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, *et al.*, 1996. *Adv. Chromatography* 36: 127-162; and Griffin, *et al.*, 1993. *Appl. Biochem. Biotechnol.* 38: 147-159).

5 Other methods for detecting mutations in the GPCR<sub>X</sub> gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, *et al.*, 1985. *Science* 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type GPCR<sub>X</sub> sequence with  
10 potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S<sub>1</sub> nuclease to enzymatically digesting the mismatched regions. In other embodiments, either  
15 DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, *et al.*, 1988. *Proc. Natl. Acad. Sci. USA* 85: 4397; Saleeba, *et al.*, 1992. *Methods Enzymol.* 217: 286-295. In an embodiment, the control  
20 DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in GPCR<sub>X</sub> cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli*  
25 cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, *et al.*, 1994. *Carcinogenesis* 15: 1657-1662. According to an exemplary embodiment, a probe based on an GPCR<sub>X</sub> sequence, e.g., a wild-type GPCR<sub>X</sub> sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be  
30 detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in GPCR<sub>X</sub> genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA*: 86: 2766; Cotton,

1993. *Mutat. Res.* 285: 125-144; Hayashi, 1992. *Genet. Anal. Tech. Appl.* 9: 73-79.

Single-stranded DNA fragments of sample and control GPCRX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991. *Trends Genet.* 7: 5.

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985. *Nature* 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987. *Biophys. Chem.* 265: 12753.

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986. *Nature* 324: 163; Saiki, et al., 1989. *Proc. Natl. Acad. Sci. USA* 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al., 1989. *Nucl. Acids Res.* 17: 2437-2448) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993. *Tibtech.* 11: 238). In addition it may be desirable to introduce a novel

restriction site in the region of the mutation to create cleavage-based detection. *See, e.g.,* Gasparini, *et al.*, 1992. *Mol. Cell Probes* 6: 1. It is anticipated that in certain embodiments amplification may also be performed using *Taq* ligase for amplification. *See, e.g.,* Barany, 1991. *Proc. Natl. Acad. Sci. USA* 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.*, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an GPCR<sub>X</sub> gene.

Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which GPCR<sub>X</sub> is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

### Pharmacogenomics

Agents, or modulators that have a stimulatory or inhibitory effect on GPCR<sub>X</sub> activity (*e.g.*, GPCR<sub>X</sub> gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such treatment, the pharmacogenomics (*i.e.*, the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.*, drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of GPCR<sub>X</sub> protein, expression of GPCR<sub>X</sub> nucleic acid, or mutation content of GPCR<sub>X</sub> genes in an

individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See  
5 *e.g.*, Eichelbaum, 1996. *Clin. Exp. Pharmacol. Physiol.*, 23: 983-985; Linder, 1997. *Clin. Chem.*, 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can  
10 occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major  
15 determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are  
20 expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side  
25 effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

30 Thus, the activity of GPCR<sub>X</sub> protein, expression of GPCR<sub>X</sub> nucleic acid, or mutation content of GPCR<sub>X</sub> genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness

phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with an GPCR<sub>X</sub> modulator, such as a modulator identified by one of the exemplary screening assays described herein.

5

### Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of GPCR<sub>X</sub> (*e.g.*, the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase GPCR<sub>X</sub> gene expression, protein levels, or upregulate GPCR<sub>X</sub> activity, can be monitored in clinical trials of subjects exhibiting decreased GPCR<sub>X</sub> gene expression, protein levels, or downregulated GPCR<sub>X</sub> activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease GPCR<sub>X</sub> gene expression, protein levels, or downregulate GPCR<sub>X</sub> activity, can be monitored in clinical trials of subjects exhibiting increased GPCR<sub>X</sub> gene expression, protein levels, or upregulated GPCR<sub>X</sub> activity. In such clinical trials, the expression or activity of GPCR<sub>X</sub> and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

By way of example, and not of limitation, genes, including GPCR<sub>X</sub>, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) that modulates GPCR<sub>X</sub> activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of GPCR<sub>X</sub> and other genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of GPCR<sub>X</sub> or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the

screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an GPCR<sub>X</sub> protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the GPCR<sub>X</sub> protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the GPCR<sub>X</sub> protein, mRNA, or genomic DNA in the pre-administration sample with the GPCR<sub>X</sub> protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of GPCR<sub>X</sub> to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of GPCR<sub>X</sub> to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent.

### Methods of Treatment

The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant GPCR<sub>X</sub> expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Osteodystrophy, and other diseases, disorders and conditions of the like.

These methods of treatment will be discussed more fully, below.

### Disease and Disorders

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (*i.e.*, reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs,



derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (*see, e.g.*, Capecchi, 1989. *Science* 244: 1288-1292); or (v) modulators (*i.e.*, inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (*e.g.*, by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (*e.g.*, Northern assays, dot blots, *in situ* hybridization, and the like).

## **Prophylactic Methods**

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant GPCR<sub>X</sub> expression or activity, by administering to the subject an agent that modulates GPCR<sub>X</sub> expression or at least one GPCR<sub>X</sub> activity. Subjects at risk for a disease that is caused or contributed to by aberrant GPCR<sub>X</sub> expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the GPCR<sub>X</sub> aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of GPCR<sub>X</sub> aberrancy, for example, an GPCR<sub>X</sub> agonist or GPCR<sub>X</sub> antagonist agent can be used for

treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

## 5 Therapeutic Methods

Another aspect of the invention pertains to methods of modulating GPCR<sub>X</sub> expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of GPCR<sub>X</sub> protein activity associated with the cell. An agent that modulates GPCR<sub>X</sub> protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of an GPCR<sub>X</sub> protein, a peptide, an GPCR<sub>X</sub> peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more GPCR<sub>X</sub> protein activity. Examples of such stimulatory agents include active GPCR<sub>X</sub> protein and a nucleic acid molecule encoding GPCR<sub>X</sub> that has been introduced into the cell. In another embodiment, the agent inhibits one or more GPCR<sub>X</sub> protein activity. Examples of such inhibitory agents include antisense GPCR<sub>X</sub> nucleic acid molecules and anti-GPCR<sub>X</sub> antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of an GPCR<sub>X</sub> protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) GPCR<sub>X</sub> expression or activity. In another embodiment, the method involves administering an GPCR<sub>X</sub> protein or nucleic acid molecule as therapy to compensate for reduced or aberrant GPCR<sub>X</sub> expression or activity.

Stimulation of GPCR<sub>X</sub> activity is desirable in situations in which GPCR<sub>X</sub> is abnormally downregulated and/or in which increased GPCR<sub>X</sub> activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).

### Determination of the Biological Effect of the Therapeutic

In various embodiments of the invention, suitable *in vitro* or *in vivo* assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

5 In various specific embodiments, *in vitro* assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for *in vivo* testing, any of the animal model system known in the art may be used prior to administration to human subjects.

### Prophylactic and Therapeutic Uses of the Compositions of the Invention

The GPCR<sub>X</sub> nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.

20 As an example, a cDNA encoding the GPCR<sub>X</sub> protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.

Both the novel nucleic acid encoding the GPCR<sub>X</sub> protein, and the GPCR<sub>X</sub> protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (*i.e.*, some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

## EQUIVALENTS

Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is

5 contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the  
10 embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims.

**WHAT IS CLAIMED IS:**

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
  - (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83;
  - (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
  - (c) an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83; and
  - (d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.
2. The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of a naturally-occurring allelic variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83.
3. The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38.
4. The polypeptide of claim 1, wherein the amino acid sequence of said variant comprises a conservative amino acid substitution.

5. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83;
  - (b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
  - (c) an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83;
  - (d) a variant of an amino acid sequence selected from the group consisting SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;
  - (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and
  - (f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).
6. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally-occurring allelic nucleic acid variant.
7. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of a naturally-occurring polypeptide variant.

8. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38.
9. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:
  - (a) a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38;
  - (b) a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, provided that no more than 20% of the nucleotides differ from said nucleotide sequence;
  - (c) a nucleic acid fragment of (a); and
  - (d) a nucleic acid fragment of (b).
10. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence chosen from the group consisting of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 16, 18, 20, 22, 24, 28, 30, 32, 34, 36, and 38, or a complement of said nucleotide sequence.
11. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:
  - (a) a first nucleotide sequence comprising a coding sequence differing by one or more nucleotide sequences from a coding sequence encoding said amino acid sequence, provided that no more than 20% of the nucleotides in the coding sequence in said first nucleotide sequence differ from said coding sequence;
  - (b) an isolated second polynucleotide that is a complement of the first polynucleotide; and
  - (c) a nucleic acid fragment of (a) or (b).
12. A vector comprising the nucleic acid molecule of claim 11.
13. The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.

14. A cell comprising the vector of claim 12.
15. An antibody that binds immunospecifically to the polypeptide of claim 1.
16. The antibody of claim 15, wherein said antibody is a monoclonal antibody.
17. The antibody of claim 15, wherein the antibody is a humanized antibody.
18. A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising:
  - (a) providing the sample;
  - (b) contacting the sample with an antibody that binds immunospecifically to the polypeptide; and
  - (c) determining the presence or amount of antibody bound to said polypeptide, thereby determining the presence or amount of polypeptide in said sample.
19. A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising:
  - (a) providing the sample;
  - (b) contacting the sample with a probe that binds to said nucleic acid molecule; and
  - (c) determining the presence or amount of the probe bound to said nucleic acid molecule, thereby determining the presence or amount of the nucleic acid molecule in said sample.
20. The method of claim 19 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.
21. The method of claim 20 wherein the cell or tissue type is cancerous.
22. A method of identifying an agent that binds to a polypeptide of claim 1, the method comprising:
  - (a) contacting said polypeptide with said agent; and
  - (b) determining whether said agent binds to said polypeptide.



23. The method of claim 22 wherein the agent is a cellular receptor or a downstream effector.
24. A method for identifying an agent that modulates the expression or activity of the polypeptide of claim 1, the method comprising:
- (a) providing a cell expressing said polypeptide;
  - (b) contacting the cell with said agent, and
  - (c) determining whether the agent modulates expression or activity of said polypeptide,
- whereby an alteration in expression or activity of said peptide indicates said agent modulates expression or activity of said polypeptide.
25. A method for modulating the activity of the polypeptide of claim 1, the method comprising contacting a cell sample expressing the polypeptide of said claim with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.
26. A method of treating or preventing a GPCR<sub>X</sub>-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the polypeptide of claim 1 in an amount sufficient to treat or prevent said GPCR<sub>X</sub>-associated disorder in said subject.
27. The method of claim 26 wherein the disorder is selected from the group consisting of cardiomyopathy and atherosclerosis.
28. The method of claim 26 wherein the disorder is related to cell signal processing and metabolic pathway modulation.
29. The method of claim 26, wherein said subject is a human.
30. A method of treating or preventing a GPCR<sub>X</sub>-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired

the nucleic acid of claim 5 in an amount sufficient to treat or prevent said GPCR<sub>X</sub>-associated disorder in said subject.

31. The method of claim 30 wherein the disorder is selected from the group consisting of cardiomyopathy and atherosclerosis.
32. The method of claim 30 wherein the disorder is related to cell signal processing and metabolic pathway modulation.
33. The method of claim 30, wherein said subject is a human.
34. A method of treating or preventing a GPCR<sub>X</sub>-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the antibody of claim 15 in an amount sufficient to treat or prevent said GPCR<sub>X</sub>-associated disorder in said subject.
35. The method of claim 34 wherein the disorder is diabetes.
36. The method of claim 34 wherein the disorder is related to cell signal processing and metabolic pathway modulation.
37. The method of claim 34, wherein the subject is a human.
38. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically-acceptable carrier.
39. A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically-acceptable carrier.
40. A pharmaceutical composition comprising the antibody of claim 15 and a pharmaceutically-acceptable carrier.
41. A kit comprising in one or more containers, the pharmaceutical composition of claim 38.

42. A kit comprising in one or more containers, the pharmaceutical composition of claim 39.
43. A kit comprising in one or more containers, the pharmaceutical composition of claim 40.
44. A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim 1 in a first mammalian subject, the method comprising:
- (a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and
  - (b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease;
- wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.
45. The method of claim 44 wherein the predisposition is to cancers.
46. A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 5 in a first mammalian subject, the method comprising:
- (a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and
  - (b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease;
- wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.
47. The method of claim 46 wherein the predisposition is to a cancer.

48. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising an amino acid sequence of at least one of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, or a biologically active fragment thereof.
49. A method of treating a pathological state in a mammal, the method comprising administering to the mammal the antibody of claim 15 in an amount sufficient to alleviate the pathological state.
50. A method for the screening of a candidate substance interacting with an olfactory receptor polypeptide selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, or fragments or variants thereof, comprises the following steps:
- a) providing a polypeptide selected from the group consisting of the sequences of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, or a peptide fragment or a variant thereof;
  - b) obtaining a candidate substance;
  - c) bringing into contact said polypeptide with said candidate substance; and
  - d) detecting the complexes formed between said polypeptide and said candidate substance.
51. A method for the screening of ligand molecules interacting with an olfactory receptor polypeptide selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, wherein said method comprises:

- a) providing a recombinant eukaryotic host cell containing a nucleic acid encoding a polypeptide selected from the group consisting of the polypeptides comprising the amino acid sequences SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83;
  - b) preparing membrane extracts of said recombinant eukaryotic host cell;
  - c) bringing into contact the membrane extracts prepared at step b) with a selected ligand molecule; and
  - d) detecting the production level of second messengers metabolites.
52. A method for the screening of ligand molecules interacting with an olfactory receptor polypeptide selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83, wherein said method comprises:
- a) providing an adenovirus containing a nucleic acid encoding a polypeptide selected from the group consisting of polypeptides comprising the amino acid sequences SEQ ID NOS:2, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 29, 31, 33, 35, 37, and 83;
  - b) infecting an olfactory epithelium with said adenovirus;
  - c) bringing into contact the olfactory epithelium b) with a selected ligand molecule; and
  - d) detecting the increase of the response to said ligand molecule.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number  
**WO 01/64879 A3**

(51) International Patent Classification<sup>7</sup>: **C12N 15/12**,  
C07K 14/705, 16/28, C12N 1/21, 5/10, G01N 33/68,  
C12Q 1/68, A61K 38/17, 31/70, 39/395

(21) International Application Number: **PCT/US01/06474**

(22) International Filing Date: 28 February 2001 (28.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/185,674	28 February 2000 (28.02.2000)	US
60/185,535	28 February 2000 (28.02.2000)	US
60/186,585	3 March 2000 (03.03.2000)	US
60/186,604	3 March 2000 (03.03.2000)	US
60/186,606	3 March 2000 (03.03.2000)	US
60/186,715	3 March 2000 (03.03.2000)	US
60/186,716	3 March 2000 (03.03.2000)	US
60/186,717	3 March 2000 (03.03.2000)	US
60/186,719	3 March 2000 (03.03.2000)	US
60/186,827	3 March 2000 (03.03.2000)	US
60/218,323	14 July 2000 (14.07.2000)	US
60/218,435	14 July 2000 (14.07.2000)	US
60/220,517	24 July 2000 (24.07.2000)	US
60/223,897	9 August 2000 (09.08.2000)	US
60/260,020	5 January 2001 (05.01.2001)	US
60/264,849	26 January 2001 (26.01.2001)	US
09/795,271	27 February 2001 (27.02.2001)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/185,674 (CIP)
Filed on	28 February 2000 (28.02.2000)
US	60/185,535 (CIP)
Filed on	28 February 2000 (28.02.2000)
US	60/186,585 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/186,604 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/186,606 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/186,715 (CIP)
Filed on	3 March 2000 (03.03.2000)

US	60/186,716 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/186,717 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/186,719 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/186,827 (CIP)
Filed on	3 March 2000 (03.03.2000)
US	60/218,323 (CIP)
Filed on	14 July 2000 (14.07.2000)
US	60/218,435 (CIP)
Filed on	14 July 2000 (14.07.2000)
US	60/220,517 (CIP)
Filed on	24 July 2000 (24.07.2000)
US	60/223,897 (CIP)
Filed on	9 August 2000 (09.08.2000)
US	60/260,020 (CIP)
Filed on	5 January 2001 (05.01.2001)
US	60/264,849 (CIP)
Filed on	26 January 2001 (26.01.2001)
US	Not furnished (CIP)
Filed on	27 February 2001 (27.02.2001)

(71) Applicant (for all designated States except US): **CURAGEN CORPORATION** [US/US]; 555 Long Wharf Drive, 11th floor, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **PADIGARU, Mur-  
ralidhara** [IN/US]; 1579 Rhinelander Avenue, Apartment  
6E, Bronx, NY 10561 (US). **MAJUMDER, Kumud**  
[IN/US]; 140 Silver Hill Lane, Stamford, CT 06905  
(US). **BURGESS, Catherine, E.** [US/US]; 90 Carriage  
Hill Drive, Wethersfield, CT 06109 (US). **VERNET,  
Corine, A., M.** [FR/US]; 4830 N.W. 43rd Street P#253,  
Gainesville, FL 32060 (US). **FERNANDES, Elma**  
[IN/US]; 77 Florence Road, #2, Branford, CT 06405 (US).  
**SHIMKETS, Richard, A.** [US/US]; 191 Leete Street,  
West Haven, CT 06516 (US). **TCHERNEV, Velizar, T.**  
[BG/US]; 1216 S.W. 2nd Avenue, Apt. 156, Gainesville,  
FL 32601 (US). **MISHRA, Vishnu** [IN/US]; 309 East  
Main Street, #306, Branford, CT 06405 (US). **CASMAN,  
Stacie** [US/US]; 155 Knollwood Drive, Wallingford, CT  
06492 (US). **SPYTEK, Kimberly, A.** [US/US]; 28 Court  
Street #1, New Haven, CT 06511 (US). **ZERHUSEN,  
Bryan** [US/US]; 45 Jefferson Road, Apartment #2-10,  
Branford, CT 06405 (US).

[Continued on next page]

(54) Title: G-PROTEINS COUPLED RECEPTOR RELATED POLYPEPTIDES

(57) Abstract: Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.



(74) Agent: ELRIFI, Iv r, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

(88) Date of publication of the international search report:

10 May 2002

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/06474

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 C07K16/28 C12N1/21 C12N5/10  
 G01N33/68 C12Q1/68 A61K38/17 A61K31/70 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, SEQUENCE SEARCH, EMBL, BIOSIS, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 867 508 A (SMITHKLINE BEECHAM CORP) 30 September 1998 (1998-09-30) the whole document --- -/--	1-24, 26-52

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

30 October 2001

Date of mailing of the international search report

31. 01. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tlx. 31 551 epo nl  
 Fax: (+31-70) 340-3016

Authorized officer

LE CORNEC N.D.R.

## INTERNATIONAL SEARCH REPORT

International Application No

PC1/US 01/06474

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL [Online]  MMU133427, accession number AJ133427,  9 September 1999 (1999-09-09)  J. STROTMAN ET AL: "Olfactory  receptor; or37d gene; pseudogene"  XP002181511  cited in the application  * 84,8% identity in 1021 nt overlap with  seq ID no.1 (5-1019:41-1056) *  * 85% identity in 1015 nt overlap with seq  ID no.3 (3-1011:47-1061) *  abstract  -&amp; J. STROTMAN ET AL: "Small subfamily of  olfactory receptor genes: Structural  features, expression pattern and genomic  organization"  GENE.,  vol. 236, 1999, pages 281-291, XP004178064  ELSEVIER BIOMEDICAL PRESS. AMSTERDAM., NL  ISSN: 0378-1119</p> <p>---</p>	1,5-7,9, 10,12,14
X	<p>DATABASE EMBL [Online]  MMU133428, accession number AJ133428,  9 September 1999 (1999-09-09)  J. STROTMAN: "Olfactory receptor or37e  gene"  XP002181512  * 79,7% identity in 902 nt overlap with  seq ID no.5 (108-1002:152-1047) *  abstract  -&amp; J. STROTMAN ET AL: "Small subfamily of  olfactory receptor genes: structural  features, expression pattern and genomic  organization"  GENE,  vol. 236, 1999, pages 281-291, XP004178064</p> <p>---</p>	1,5-7,9, 10,12,14
X	<p>DATABASE EMBL [Online]  AL135841, 21 December 1999 (1999-12-21)  N. CORBY: "human DNA sequence from clone  RP11-327L3 on chromosome9p13.1-13-3"  XP002181513  * 84,9% identity in 997 nt overlap with  seq ID no.1 (999-3:81731-82724) *  abstract</p> <p>---</p>	1,5-7,9, 10,12, 14,19
A	<p>ROUQUIER S ET AL: "Distribution of  olfactory receptor genes in the human  genome"  NATURE GENETICS, NEW YORK, NY, US,  vol. 18, no. 3, March 1998 (1998-03),  pages 243-250, XP002111208  ISSN: 1061-4036</p> <p>---</p> <p style="text-align: center;">-/--</p>	

Form PCT/ISA 210 (continuation of second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/06474

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE EMBL [Online] AL138834, accession number AL138834, 4 February 2000 (2000-02-04) D. LLOYD: "Human DNA sequence from clone RP11-113A10 on chromosome 9" XP002181514 * 99,9% identity in 1019 nt overlap with sequence ID no.1 (1019-1:27692-28709) * * 99,9% identity in 1003 bp overlap with seq ID no.5 (1003-1:16125-17126) * * 90,3% identity in 807 nt overlap with seq ID no.3 (1014-217:16121-16919)* abstract</p> <p>---</p>	5-11,14
E	<p>WO 01 27158 A (FUCHS TANIA ;GLUSMAN GUSTAVO (IL); LANCET DORON (IL); YEDA RES &amp; D) 19 April 2001 (2001-04-19) sequences ID no.733, 734, 735, 1665, 1666, 1667 and 1670 claims</p> <p>-----</p>	1-24, 26-52

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/06474

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 26-37 and 48-49 are directed to a method of treatment of the human/animal body (rule 39.1 IV PCT), the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 25  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-52 all partially

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 25

Claim 25 refers to a method for modulating the activity of the polypeptide GPCR using a compound that binds to said polypeptide without giving a true technical characterization. Moreover, no such compounds are disclosed in the application. In consequence, the scope of said claim is ambiguous and vague and its subject-matter is not sufficiently disclosed and supported (Art. 5/6 PCT).

no meaningful search can be carried out for such purely speculative claim whose wording is, in fact, a mere recitation of the result to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-52 all partially

Olfactory receptors GPCR1a, GPCR1b and GPCR1c represented respectively by the amino acid sequences ID no.2, 4 and 6 and their respective corresponding DNA sequences ID no.1, 3 and 5. Antibodies. Therapeutic and diagnostic uses.

2. Claims: 1-52 all partially

Olfactory receptor GPCR2 represented respectively by the amino acid sequences ID no.8 and its respective corresponding DNA sequence ID no.7. Antibodies. Therapeutic and diagnostic uses.

3. Claims: 1-52 all partially

Olfactory receptor GPCR3 represented respectively by the amino acid sequence ID no.10 and its respective corresponding DNA sequence ID no.9. Antibodies. Therapeutic and diagnostic uses.

4. Claims: 1-52 all partially

Olfactory receptors GPCR4a and GPCR4b represented respectively by the amino acid sequences ID no.12 and no.17 and their corresponding DNA sequences ID no.11, 13 and 16. Antibodies. Therapeutic and diagnostic uses.

5. Claims: 1-52 all partially

Olfactory receptors GPCR5a, GPCR5b and GPCR5c represented respectively by the amino acid sequences ID no.19, 21 and 23 and their respective corresponding DNA sequences ID no.18, 20 and 22. Antibodies. Therapeutic and diagnostic uses.

6. Claims: 1-52 all partially

Olfactory receptor GPCR6 represented by the amino acid sequence ID no.25 and its corresponding DNA sequence ID no. 24. Antibodies. Therapeutic and diagnostic uses.

7. Claims: 1-52 all partially

Olfactory receptor GPCR7 represented by the amino acid sequence ID no.29 and its corresponding DNA sequence ID no. 28. Antibodies. Therapeutic and diagnostic uses.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

8. Claims: 1-52 all partially

Olfactory receptor GPCR8 represented by the amino acid sequence ID no.31 and its corresponding DNA sequence ID no. 30. Antibodies. Therapeutic and diagnostic uses.

9. Claims: 1-52 all partially

Olfactory receptor GPCR9 represented by the amino acid sequence ID no.33 and its corresponding DNA sequence ID no. 32. Antibodies. Therapeutic and diagnostic uses.

10. Claims: 1-52 all partially

Olfactory receptor GPCR10a, GPCR10b and GPCR10c represented respectively by the amino acid sequences ID no.35, 37 and 83 and their respective corresponding DNA sequence ID no.34, 36 and 38. Antibodies. Therapeutic and diagnostic uses.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/06474

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0867508	A	30-09-1998	US 5874243 A	23-02-1999
			EP 0867508 A2	30-09-1998
			JP 11028094 A	02-02-1999
<hr/>				
WO 0127158	A	19-04-2001	AU 1326201 A	13-02-2001
			AU 2903701 A	23-04-2001
			AU 6118100 A	13-02-2001
			WO 0107093 A1	01-02-2001
			WO 0107094 A1	01-02-2001
			WO 0127158 A2	19-04-2001
<hr/>				

Form PCT/ISA/210 (patent family annex) (July 1992)